

UNIVERSITÀ
DEGLI STUDI
DI PADOVA

Università Degli Studi Di Padova
Dipartimento Di Biologia

Scuola Di Dottorato Di Ricerca In Bioscienze E Biotecnologie
Indirizzo Di Genetica E Biologia Molecolare Dello Sviluppo
Ciclo XXIV

MicroRNAs: from biogenesis to post-transcriptional regulatory networks

Direttore della Scuola: Ch.mo Prof. Giuseppe Zanotti

Supervisore: Dr.ssa Stefania Bortoluzzi

Dottorando: Marta Biasiolo

Contents

1. Abstract	1
2. Sommario	3
3. Background	5
3.1. miRNA biology.....	5
3.1.1. microRNAs biogenesis.....	5
3.1.2 miRNA genes genomic arrangement.....	7
3.2. microRNA detection and their interaction with mRNAs	9
3.2.1. MicroRNAs discovery and analysis	9
3.2.2. MicroRNA-mRNA interaction	10
3.2.3. MicroRNA targets prediction	12
3.3. miRNAs and diseases	14
3.4. MicroRNA–offset RNAs (moRNAs): by-product spectators or functional players?	15
3.4.1. moRNA discovery by massive sequencing of short RNAs	16
3.4.2. moRNAs biogenesis: by-product or co-product?	16
3.4.3. The functions of moRNAs are unknown at present.....	17
3.5. Regulatory network inference.....	18
4. Material and Methods.....	23
4.1. microRNAs and genes: sequences and genomic positions.....	23
4.2. Biological Datasets	23
4.2.1. Multiple Myeloma dataset.....	23
4.2.2. Acute Lymphoblastic Leukemia dataset.....	24
4.2.3. Normal and Alzheimer's parietal lobe cortex	24
4.2.4. Normal prostate and prostate cancer	25
4.2.5. Multiple cancers and normal tissues dataset.....	25
4.2.6. Colorectal cancer dataset.....	25
4.2.7. Adult T-cell leukemia lymphoma dataset.....	26

4.2.8. SET2 cells line dataset	27
4.3. Cluster analysis.....	27
4.4. miRNA and gene differential expression analysis	28
4.5. MicroRNA target predictions.....	28
4.5.1. miRanda	28
4.5.2. Pita	28
4.5.3. TargetScan.....	29
4.6. Regulatory network reconstruction.....	29
4.6.1. Transcriptional regulatory network	29
4.6.2. Integrative analysis.....	29
4.6.3. Post-transcriptional regulatory networks.....	30
4.6.4. Network critical components analysis	31
4.7. MAGIA web-based tool.....	35
4.7.1. Input files	36
4.7.2. Target predictions.....	37
4.7.3. Computation of interaction measure.....	38
4.7.4. Output and links to other database resources	40
4.7.5. Bi-partite networks visualizations	40
4.8. Analysis of sister miRNA pairs expression ratio.	41
4.9. Statistical analysis.....	41
4.10. New miRNA target prediction	41
5. Results.....	45
5.1. Identification of microRNA expression patterns and definition of a microRNA/mRNA regulatory network in distinct molecular groups of multiple myeloma	45
5.1.1. Global miRNA expression profiling in MM patients	45
5.1.2. Integrative analysis of miRNA/mRNA expression and reconstruction of a regulatory network in MM	49
5.1.3. Critical analysis of transcriptional and post-transcriptional regulatory networks	51

5.2. miRNAs modulation in colon cancer and metastasis development and its impact on regulatory networks and pathways.....	56
5.2.1. miRNA and genes expression in normal colon, colon carcinoma and liver metastasis samples	56
5.2.2. Informativity of miRNAs and genes for samples classification and variability in the N-T-M transitions.....	58
5.2.3. Differentially expressed miRNAs	60
5.2.4. RT-PCR miRNA expression validation.....	62
5.2.5. miRNA and genes expression profiles integration allows the identification of most probable miRNA targets.....	63
5.2.6. Regulatory networks modulated in tumor and metastasis development	63
5.2.7. miR-182 control ENTPD5.....	66
5.2.8 miRNAs modulated KEGG pathways	67
5.3. microRNA expression in HTLV-1 infection and adult T-cell leukemia/lymphoma	68
5.3.1. microRNAs with altered expression in ATLL cells	68
5.3.2. microRNA target prediction	70
5.4. MAGIA, a web-based tool for miRNA and Genes Integrated Analysis.....	73
5.4.1. MAGIA application and testing to a case study	73
5.5. Impact of host genes and strand selection on miRNA and miRNA* expression....	76
5.5.1. Microarray-based expression datasets analyses description	76
5.5.2. Expression of sister mature miRNA pairs belonging to the same hairpin	77
5.5.3. miRNA are hosted by long genes	83
5.5.4. Limited co-expression of intragenic miRNAs and host genes.....	83
5.5.5. Impact of host genes expression used as proxy for miRNAs on target selection.	84
5.6. Characterization and discovery of novel miRNAs and moRNAs in JAK2V617F mutated SET2 cell.....	87
5.6.1. Small RNA library	87
5.6.2. Known miRNAs and isomiRs expressed in SET2 cells	87
5.6.3. Novel miRNAs expressed in SET2 cells were discovered in known hairpin precursors.....	89

5.6.4. Sister miRNA expression prevalence	92
5.6.5. miRNA-offset RNAs (moRNAs) identification in known hairpin precursors	94
6. Discussion and Conclusions.....	95
6.1. Identification of microRNA expression patterns and definition of a transcriptional and post-transcriptional regulatory network in distinct molecular groups of multiple myeloma	95
6.2. miRNAs modulation in colon cancer and metastasis development and its impact on regulatory networks and pathways.....	100
6.3. microRNA expression in HTLV-1 infection and adult T-cell leukemia/lymphoma	104
6.4. MAGIA, a web-based tool for miRNA and Genes Integrated Analysis.....	106
6.5. Impact of host genes and strand selection on miRNA and miRNA* expression..	107
6.6. Characterization and discovery of novel miRNAs and moRNAs in JAK2V617F mutated SET2 cell.....	109
Reference List	113
Supplementary material.....	133

1. Abstract

The discovery of microRNA-based post-transcriptional regulation of gene expression added a novel level of genetic regulation to a wide range of biological processes. Dysregulation of miRNAs expression plays a critical role in the pathogenesis of genetic and multifactorial disorders and of most human cancers. To bypass limitations of computational predictions of miRNA–target relationships, we developed a method for integrated analysis of miRNA and gene expression profiles in combination with target prediction, allowing the identification and study of post-transcriptional regulatory networks in specific biological contexts. This methodology was also implemented in a web tool, MAGIA, that allows integrating target predictions and miRNA and gene expression profiles for the miRNA–mRNA bipartite networks reconstruction, gene functional enrichment and pathway annotations for results browsing. Network analysis has been applied to highlight the importance of some regulatory elements in the regulatory network reconstructed calculating the drop of network efficiency caused by node deactivation. Biologically relevant results, obtained by bioinformatic analyses in the frame of different projects, were the starting point for further experimental studies, which identified key miRNA–target relations in cancerogenesis. miRNAs biogenesis is not still completely understood. Thus with the integration of genomic information with sequence and expression data we studied the strand selection bias and the expression behavior of intragenic miRNAs and host genes. In contrast with classical biogenesis model, these analyses highlighted that 5' and 3' miRNA strands, the “major” and the “minor” forms, deriving from the same hairpin precursor may co-coordinately contribute to silencing of different sets of target genes. Indeed, the behaved tendency to co-expression of intragenic miRNAs and their “host” mRNA genes was confuted by expression profiles examination, suggesting that the expression profile of a given host gene can hardly be a good estimator of co-transcribed miRNA(s) for post-transcriptional regulatory networks inference. In the last year, short RNAs massive sequencing was exploited for a miRNOME analysis of myeloproliferative neoplasms (MPN). This analysis allowed the characterization of short RNAs (known and novel miRNAs, isomiRs and moRNAs) expressed by SET2 cells, a JAK2-mutated cell line model for MPN. moRNAs (microRNA-offset RNA) derived from extended hairpin stem sequences, probably by alternative nuclear and/or cytoplasmic processing. They seem to be conserved across species and the conservation extent correlates with expression level. This evidence suggests that moRNAs might be miRNA co-products, representing a distinct functional class of miRNA-related agents. In conclusion, our analyses were addressed to shed light on the complexity of microRNA-mediated gene regulation, pointing out the regulatory importance of post-transcriptional phases of miRNAs biogenesis, reinforcing the role of such layer of miRNA biogenesis in miRNA-based regulation of cell activities in physiology and in different diseases

2. Sommario

La scoperta della regolazione post-trascrizionale dei miRNA ha aggiunto un nuovo livello alla regolazione genetica in numerosi processi biologici. Alterazioni nell'espressione dei miRNA possono giocare un importante ruolo nell'insorgenza di svariate patologie ed in particolare in molte neoplasie. Per ovviare alle limitazioni presenti nelle relazioni miRNA-mRNA degli algoritmi di predizione computazionali, è stata sviluppata una metodologia per l'integrazione dei profili d'espressione di miRNA e mRNA con le predizioni dei bersagli biologici dei miRNA, che ha permesso l'identificazione di reti regolative post-trascrizionali in diversi contesti biologici. Questa metodologia è stata inoltre implementata in un "web-tool", soprannominato MAGIA. Per evidenziare l'importanza di alcuni elementi regolativi presenti nei circuiti biologici è stata applicata la teoria delle reti per l'identificazione di geni critici attraverso la loro de-attivazione nella rete. I frutti di queste analisi bioinformatiche, svolte nell'ambito di numerosi progetti, hanno rappresentato il punto di partenza per successivi studi sperimentali che hanno portato alla scoperta di rilevanti relazioni miRNA-target in specifici tumori. La biogenesi dei miRNA non è stata ancora completamente chiarita, perciò, integrando informazioni derivanti dalle sequenze genomiche e da dati d'espressione, sono stati approfonditi alcuni loro aspetti, quali la teoria di generazione dei miRNA maturi per selezione del filamento e la co-espressione dei miRNA intragenici e dei loro geni ospiti. Le suddette analisi hanno evidenziato che i miRNA generati dal 5' ed il 3', derivanti dallo stesso miRNA precursore, supportano solo parzialmente il modello classico della biogenesi dei miRNA, secondo il quale uno dei due miRNA maturi è scelto in modo deterministico e degradato. Entrambe le forme "major" e "minor", infatti, possono contribuire insieme al silenziamento di gruppi diversi di geni bersaglio. La tendenza alla co-espressione tra i miRNA intragenici e i loro geni ospiti, inoltre, è stata confutata dall'analisi dei loro profili d'espressione, dimostrando che i profili d'espressione dei geni ospite non possono essere usati come stimatori dell'espressione dei miRNA per l'inferenza di reti regolative post-trascrizionali. Nell'ultimo anno, il sequenziamento massivo di brevi RNA è stato sfruttato per l'analisi approfondita di miRNA nelle neoplasie mieloproliferative. Attraverso questo approccio è stato possibile scoprire e caratterizzare numerosi brevi RNA, quali miRNA noti e nuovi, isomiRNA e i moRNA, che sono espressi nelle cellule SET2, linee cellulari con mutazione del gene JAK2. I moRNA (microRNA-offset RNA) derivano dalle sequenze dei precursori dei miRNA, probabilmente da un processo alternativo del nucleo e/o citoplasmatico, e sembrano essere conservati in varie specie. Il loro grado di conservazione è correlato con i livelli d'espressione e si potrebbe dedurre che siano prodotti insieme ai miRNA, ma rappresentando una classe funzionale distinta da essi. In conclusione, le nostre analisi sono state indirizzate a far luce sulla complessità della regolazione dei geni da parte dei miRNA, in particolare sull'importanza delle fasi post-trascrizionali della biogenesi dei miRNA ed il loro ruolo nella regolazione delle attività cellulari fisiologiche ed in diverse patologie.

3. Background

In 1993 in a genetic screen in nematode worms two small RNA sequences, originating by lin-4 transcript, were identified. These small RNAs of approximately 22 and 61 nt had sequences complementary to a sequence in the 3' untranslated region (UTR) of lin-14 mRNA. This discovery led to hypothesize that lin-4 regulates lin-14 translation via an antisense RNA-RNA interaction for a post-transcriptional temporal regulation during *C. elegans* development (Lee et al., 1993; Wightman et al., 1993). From that moment small RNAs were observed to be involved in many biological processes range from heterochromatin formation to mRNA destabilization and transcriptional control. The number of small RNAs continues to substantially increase also thanks to the recent development of deep-sequencing technologies and computational prediction methods, able to discover also less abundant small RNAs. 'Small RNA' is a rather arbitrary term, because it was previously used for other non-coding RNAs, such as small nuclear RNAs (shrines) and transfer RNAs (tunas). What distinguishes and defines eukaryotic small RNAs in the RNA silencing pathway is their limited size (~20-30 nucleotides (nt)) and their association with Argonaut (Ago)-family proteins (Kim et al., 2009). At least three classes of small RNAs are encoded in our genome, based on their biogenesis mechanism and the type of Ago protein that they are associated with: microns (miRNAs), endogenous small interfering RNAs (endo-siRNAs or esiRNAs) and Piwi-interacting RNAs (piRNAs) (Kim et al., 2009). This thesis will focus on different aspects of microRNAs from biogenesis to the reconstruction of the post-transcriptional regulatory network.

3.1. miRNA biology

3.1.1. microRNAs biogenesis

miRNAs are single-stranded RNAs of ~22 nt in length that are transcribed in the nucleus by RNA polymerase II, originating primary transcripts (pri-miRNAs). Pri-miRNAs are usually several kilobases long and contain local stem-loop structures. The first step of miRNA maturation is cleavage at the stem of the hairpin structure by Drosha-DiGeorge syndrome critical region gene 8 (DGCR8) complex that generate ~65 nt hairpin, a pre-miRNA. Following nuclear processing, pre-miRNAs are exported to the cytoplasm by exportin 5 (EXP5) where they are cleaved again near the terminal loop by Dicer, releasing ~22-nt miRNA duplexes. Human Dicer seems to cooperate with two closely related protein,

TRBP (TAR RNA-binding protein) and PACT contributing to the formation of RNA-induced silencing complex (RISC). The resulting ~22-nt miRNA duplex is loaded on Ago protein so as to generate the effector complex, RISC. One strand of the duplex remains in Ago as a mature miRNA (the guide strand or miRNA), whereas the other strand (the passenger strand or miRNA*) is degraded (Kim et al., 2009) (Figure 1). This is the so-called miRNA strand selection theory. Often, two different mature miRNAs sequences can be derived from the same precursor hairpin: a major, the stable and prevalent form, and a minor, the unstable one, degraded. The two forms are associated to different sets of target genes, thus contributing in different ways to the regulation of cell activities; experiments conducted on selected miRNAs pairs demonstrated that they could be both functionally effective (Ro et al., 2007). To date, such asymmetry of the strand selection process is considered determined by differential thermodynamic stability of alternative sister miRNAs (“strand bias” theory, as in (Kim, 2005b; Winter et al., 2009a)), although additional features possibly acting as miRNA strand selection determinants in humans and flies were also investigated (Hu et al., 2010). In contrast, fragmentary but interesting evidences of regulated and tissue-dependent paired expression of sister miRNAs have been reported (Ro




Figure 1. Schematic representation of miRNA biogenesis and function. Transcription of miRNA genes is mediated by RNA polymerase II. The initial transcripts, termed “pri-miRNAs”, is cleaved by the RNase III endonuclease Drosha, along with its partner DGCR8 (DiGeorge syndrome critical region 8 gene; also known as Pasha). The pre-miRNA, is exported from the nucleus by Exportin 5 where Dicer cleaves it into a double-stranded mature miRNA incorporated into the RISC to repress mRNA translation or destabilize mRNA transcripts through cleavage or deadenylation (Cordes et al. 2010). Figure taken from Cordes et al., 2010.

et al., 2007).

To support this, a recent paper has been published reporting sequencing and characterization of bovine miRNAs (Jin et al., 2009), which underlined that only 60% of them displayed thermodynamic stability-dependent strand selection bias. These studies introduced innovative concepts and unraveled that i) both sister mature miRNAs may be accumulated in some tissues and cell types, and ii) the strand selection might not be deterministic but tissue-specific, so that a given strand could be guide strand in a specific cell type and passenger in another one. The crucial pathogenetic role of the passenger strand has been pointed out by a study on thyroid cancer (Jazdzewski et al., 2009). Moreover with the increase of the attention of miRNA biogenesis processes, always new details about new biological mechanisms about mature miRNA generation come out. In particular, production of mature miRNA from an endogenous hairpin RNA with 5' overhangs has also been reported. Ando et al. show that human recombinant DICER protein (rDICER) processes a hairpin RNA with 5' overhangs in vitro and generates an intermediate duplex with a 29 nt-5' strand and a 23 nt-3' strand, which was eventually cleaved into a canonical miRNA duplex via a two-step cleavage (Ando et al., 2011). The two-step cleavage of a hairpin RNA with 5' overhangs shows that DICER releases double-stranded RNAs after the first cleavage and binds them again in the inverse direction for a second cleavage. These findings may have consequences for how DICER may be able to interact with or process differing precursor structures (Ando et al., 2011).

3.1.2 miRNA genes genomic arrangement

Many studies improved notions about miRNA genes structure but their clear definition is still ongoing. The majority of miRNAs derive from stand-alone non-protein-coding loci distinct from known transcription units, identified as intergenic. These miRNAs can be monocistronic with their own promoters or polycistronic, where several miRNAs are transcribed as cluster of primary transcripts with a shared promoter (Axtell et al., 2011; Olena and Patton, 2010). A number of miRNA genes have also been discovered that reside within the TUs of other genes, both intronic and exonic. Approximately 50% of miRNAs are located on introns of annotated genes, both protein-coding and noncoding. Intronic miRNAs are thought to be transcribed from the same promoter as their host genes and processed from the introns of host genes but there is evidence of miRNA genes resided within the introns under control of their own promoters.

A special intronic miRNAs are mirtrons, that are generated from the termini of short intronic hairpins giving rise to pre-miRNA hairpins with 3' overhangs and subsequently to mature ~22 nt species, which function as typical miRNA-class regulatory RNAs (Westholm and Lai, 2011). Rarely, miRNAs are also found resided within the exons of annotated genes; in particular, they often overlap an exon and an intron of a noncoding genes. These

miRNAs are also thought to be transcribed by their host gene promoter and their maturation often excludes host genes function (Axtell et al., 2011; Olena and Patton, 2010) (Figure 2).

About 40% of miRNAs are found in clusters frequently containing miRNAs belonging to different families. This unrelated mature miRNAs generated from a given cluster can target multiple different mRNAs. The best and well-studied example of miRNA cluster is miR-17-19 cluster, a miRNA polycistron also known as oncomir-1, is among the most potent oncogenic miRNAs. Overexpression of mir-17-92 was both found in several human B-cell lymphomas, and its enforced expression exhibits strong tumorigenic activity in multiple mouse tumor models. mir-17-92 carries out pleiotropic functions during both normal development and malignant transformation, as it acts to promote proliferation, inhibit differentiation, increase angiogenesis, and sustain cell survival. Unlike most protein coding genes, mir-17-92 is a polycistronic miRNA cluster that contains multiple miRNA components, each of which has a potential to regulate hundreds of target mRNAs. This unique gene structure of mir-17-92 may underlie the molecular basis for its pleiotropic functions in a cell type- and context-dependent manner. These findings on mir-17-92




Figure 2. miRNA genes structure. Intergenic miRNAs derive from stand-alone non-protein-coding loci distinct from known transcription units. A number of miRNA genes have also been discovered that reside within the TUs of other genes, both intronic and exonic. About 40% of miRNAs are found in clusters frequently containing miRNAs belonging to different families. Figure taken from Olena and Patton, 2010.

indicate that miRNAs are integrated components of the molecular pathways that regulate tumor development and tumor maintenance and imply nuanced regulation by miRNAs than was perhaps expected (Olena and Patton, 2010; Olive et al., 2010). Moreover this cluster was found highly expressed (among the top 25% of expressed miRNAs) in SET2 cells (Bortoluzzi et al., 2012). Recent evidence support the contention that uncontrolled expression of both or either these two clusters results in the loss of physiologic control of cell cycle arrest and apoptosis by transforming growth factor- β contributing to oncogenesis.

3.2. microRNA detection and their interaction with mRNAs

3.2.1. MicroRNAs discovery and analysis

A still present challenge in biology is the efficient discovery of miRNAs. Initially, miRNAs was detected by large cloning and sequencing efforts, a methodology extremely time and labor demanding. Moreover, structural and physiological miRNA characteristics make difficult to detect their presence because also their low expression levels the main reason for their late discovery (Lhakhang and Chaudhry, 2011). Hybridization methods (Northern blotting and microarray technology) are very useful for miRNA detection. First these methods have a well established protocol set and are able to observed both pre-cursor and mature miRNA forms. This technique is quite laborious and time consuming, do not distinguish miRNAs with small sequence differences and cannot be used for stem cells and primary tumor analysis for the amount of RNA required for detecting miRNAs (5-10 micrograms of total RNA per gel lane). On the other hand, microarrays technology offers a high-throughput analysis to quantify miRNA abundance and copy number variations. Reverse transcriptase PCR-based methods were developed and optimized for miRNA detection, including real-time methods based upon reverse transcription (RT) reaction with stem-loop primer followed by a TaqMan PCR analysis. Microarray profiling and quantitative real-time RT-PCR (qRT-PCR) are the two common methods for miRNA expression evaluation, but results from microarray data and qRT-PCR do not always agree. This depends on the higher sensitivity of qRT-PCR compared with microarray technologies, which can only detect a 3-4 log of dynamic range rather than 7 log using qRT-PCR. Next-generation sequencing technologies allow today a quickly sequencing and profiling miRNA populations. This methodology provides measuring miRNAs sequence variations, isomiRs, and in-depth analysis of post-transcriptional miRNA editing. Moreover it gives the possibility to detect and measure expression of known miRNAs and to discover new miRNAs (Lhakhang and Chaudhry, 2011). Due to several gigabytes of sequence data generated in each single deep-sequencing experiment, the need to adapted bioinformatics tools is immediately emerged. Following some tools will be reported. miRanalyzer is a web server tool for the analysis of deep-sequencing experiments for small RNAs. The web server tool requires a simple input file containing a list of unique reads and its copy numbers (expression levels). Using these data, miRanalyzer (i) detects all known microRNA sequences annotated in miRBase, (ii) finds all perfect matches against other libraries of transcribed sequences and (iii) predicts new microRNAs with a machine learning approach (Hackenberg et al., 2009). Guan et al. developed mirExplorer, which is based on an integrated adaptive boosting method to de novo predict pre-miRNAs from genome, and to discover miRNAs from NGS data (Guan et al., 2011). Instead DARIO free web service allows to study short read data from small RNA-seq experiments providing a wide range of analysis features, including quality control, read normalization, ncRNA

quantification and prediction of putative ncRNA candidates (Fasold et al., 2011).

3.2.2. *MicroRNA-mRNA interaction*

Mature miRNAs can cause translation inhibition or mRNA cleavage, by base pairing with the 3' untranslated region (3'-UTR) of their target mRNAs, depending on the complementarity degree between the miRNA and its target sequence (Alexiou et al., 2009; Kuhn et al., 2008; Sethupathy et al., 2006). An individual miRNA is able to affect the translation of more than one target mRNAs and each mRNA may be regulated by multiple miRNAs. Many mRNAs have potential multiple sites for the same miRNA. It was reported that multiple sites enhance the degree of down-regulation and two sites of the same or different miRNAs located closely to each other could act synergistically (Witkos et al., 2011). The 5' region of miRNA ("seed" sequence) usually contributes more to the specificity and activity in binding targets according to experimental evidence. The interactions between miRNA and mRNA are usually restricted to the "seed" sequence near the 5' terminus in animals despite the fact that most plant miRNAs regulate their targets based on complete complementarity. The 6 to 8-nt "seed" sequence is highly conserved among species and is characterized by a strict Watson-Crick pairing between miRNA and its target site. Even a slight change in seed sequence may alter the spectrum of miRNA targets (Cai et al., 2009; Lim et al., 2003). In animal, miRNA-mRNA interactions presented regions of strict complementarity, bulges and mismatches. There is no single model that would depict all miRNA-mRNA interactions because of their relative heterogeneity. The classification of miRNA target sites is based on the complementarity within 5' (the seed region) and 3' part of miRNA and distinguishes three sites types (Figure 3): 1) canonical, 2) 3'-supplementary and 3) 3'-compensatory sites (Witkos et al., 2011).

Canonical sites have a complete pairing within the seed region. There are three major types of canonical sites: the 7mer1A that has an adenine in position 1 at the 5' end of miRNA, the 8mer having matched adenine in position 1 and an additional match in position 8 and the 7mer-m8 that has a match in position 8. A minor class of canonical sites are represented by 6-nt seed which modestly downregulate targeted mRNA. miRNA-mRNA bound by a canonical site at the 5' of miRNA can have an additional pairing also at the 3' with its corresponding mRNA, the so-called 3'-supplementary site. This site type usually has a less profound effect on target recognition and its efficiency. 3' compensatory sites required 3-4 nt consecutively paired in positions 13-16 of miRNA for enhancing the effectiveness of miRNA-mRNA interaction which facilitate target prediction and may compensate possible discontinuity of seed pairing (Witkos et al., 2011).




Figure 3. Types of miRNA-mRNA interactions. Different classes of miRNA target sites are presented in a schematic way. Vertical dashes represent single Watson-Crick pairing. Nucleotides involved in binding have been arbitrarily defined to depict positions of required complementarity between miRNA and mRNA. Seed regions of miRNAs are marked by red color and the adenine at binding position 1 by green. Interactions between mRNA and the 3' end of miRNA have not been shown because they are sequence-dependent and do not significantly contribute to the miRNA downregulation effect. In the case of 3'-supplementary and 3'-compensatory sites two regions of pairing (base pairs colored in blue) force middle mismatches to form a loop structure. Additionally, features of particular site types have been listed (Witkos et al., 2011). Figure taken from Witkos et al., 2011.

At the beginning, it was believed the extent of base pairing between the miRNA and mRNA might be an important determinant for the ultimate fate of the target mRNA. Usually perfect, or near perfect, base pair complementation results in mRNA decay. Translational silencing or blocking of the target mRNA, however, usually takes place by the imperfect base pairing between one or more miRNAs (same or different miRNAs) and the 3'UTR region of the target mRNA. The resulting translationally silenced target mRNAs are then thought to be sequestered by the miRNAs to cytoplasmic processing bodies (P-bodies, also known as GW bodies), where untranslated mRNAs are stored and, ultimately, sometimes degraded (Erson and Petty, 2008). Indeed, citing literally, “even if rules

involving Watson–Crick hybridization of microRNAs with mRNAs have generated great interest and researchers ardently seek simplifying principles, nature seems very uncooperative” (Jeffries et al., 2010). Furthermore, nowadays the relation between base-complementary and mode of action is controversial, and this vision is surpassed. Analysis of the miRNA target sites indicated that genes with longer 3' UTRs usually have higher density of miRNA-binding sites and are mainly involved in developmental modulations, whereas genes with shorter 3' UTRs usually have lower density of miRNA-binding sites and tend to be involved in basic cellular processes. This might be also related to shortening of 3'UTR in the oncogene in tumor to escape their repression (Mayr and Bartel, 2009). Some evidence show a small subset of miRNAs exert repression regulation by specifically targeting the 5' UTR of some mRNAs suggesting many miRNAs may contain significant interaction sites with mRNA 5'-UTR and 3'-UTR motifs through their 3'- and 5'-end sequences, respectively (Cai et al., 2009).

To date few miRNAs have been shown to be prone to RNA editing providing another layer of regulatory controls within the complex network of RNA-mediated gene functions. RNA editing can display a micro-regulatory role in controlling the miRNA-processing machinery since it contributes to the generation of different mature miRNAs from identical miRNA transcripts that may silence a set of genes different from those target by the unedited miRNA, potentially targeting a different set of genes due to RNA editing in different tissues (tissue-specific RNA editing) (Cai et al., 2009; Erson and Petty, 2008). Single nucleotide polymorphisms (SNP), created by changes in DNA sequences of miRNA-coding genes or in an miRNA-binding site in mRNAs, are recently emerged to affect the biogenesis and function of miRNA. Many miRNA polymorphisms are shown to be associated with disease because of a gain- or a loss-of function of miRNAs on mRNAs (Cai et al., 2009).

All these findings increase the complexity of mechanisms by which miRNA regulate gene expressions and highlight how much investigation are needed to illustrate the functional circuits that are critical to cellular processes.

3.2.3. MicroRNA targets prediction

Target mRNAs of miRNAs can be predicted by computational methods, developed according to our understanding of miRNA regulatory functions. Current target prediction programs depend on the information from sequence, structure associated free energy and evolutionary conservation to predict candidate mRNAs. Different computational miRNA finding strategies have been planned based on the conserved sequences present amongst the different species that can both fold into extended hairpins and are also present in intergenic locations. Availability of full genome databases of several organisms has further enabled in the development of better informatics based approaches. In recent years, a number of

programs and bioinformatics tools have been developed and used successfully for the identification and analysis of miRNAs and their targets (Shruti et al., 2011). These algorithms can be divided into two main classes established on the basis of the use or not of the target site conservation, influencing the output by narrowing the results. The algorithms based on conservation criteria are for example miRanda, Targetscan, Pictar, Diana-microT while PITA and rna22 belong to the algorithms using thermodynamic stability of miRNA:mRNA hybrid, seed complementarity, multiple target site, and free energy of binding sites(Witkos et al., 2011).

TargetScan, the most famous algorithm for the miRNA target prediction, predicts regulatory targets of vertebrate microRNAs by identifying mRNAs with conserved complementary to the seed (2-7 nt) of miRNA among orthologous 3' UTR of vertebrates(Lewis et al., 2005). It consists of a series of steps starting with the search of UTR for segment with perfect Watson-Crick complementary to bases 2-8 of the miRNA, then extends each seed match with additional base pairs to the miRNA, allowing G:U pairs, calculates a folding free energy G, and assign a Z score to each UTR considering only one with a good Z score(Lewis et al., 2003). Several feature of site boosting their efficiency contribute to final outcome score: AU-rich nucleotide composition near the site, proximity to sites for co-expressed miRNAs (which leads to cooperative action), proximity to residues pairing to miRNA nucleotides 13-16, positioning within the 3'UTR at least 15 nt from the stop codon, positioning away from the center of long UTRs, and conserved 3'-compensatory sites(Friedman et al., 2009; Grimson et al., 2007a). TargetScanS algorithm, a simplified version of TargetScan, predicts targets that have a conserved 6-nt seed match flanked by either a 7-nt match or 6-nt with A on the 3' terminus no considering free energy values(Lewis et al., 2005; Witkos et al., 2011).

MiRanda optimizes sequence complementarity using position-specific rules and relies on strict requirements of interspecies conservation. This is three-phase algorithm consist of: sequence-matching to assess first whether two sequences are complementary and possibly bind; free energy calculation (thermodynamics) to estimate the energetic of this physical interaction; and evolutionary conservation as an informational filter. The miRanda algorithm scans all available miRNA sequences for a given genome against 3' UTR with a dynamic programming approach to search for maximal local complementarity alignments, corresponding to a double-stranded antiparallel duplex(Enright et al., 2003b; John et al., 2004). miRanda-mirSVR is a refinement of miRanda algorithm based on a new machine learning method for ranking microRNA target sites by a down-regulation score. The algorithm trains a regression model on sequence and contextual features extracted from miRanda-predicted target sites. miRanda-mirSVR is able also to identify a significant number of experimentally determined non-canonical and non-conserved sites(Betel et al., 2010).

PITA focuses on site accessibility considered critical in microRNA-mRNA interaction. It

is a parameter-free model for microRNA-target interaction that computes the difference between the free energy gained from the formation of the microRNA-target duplex and the energetic cost of unpairing the target to make it accessible to the microRNA (Kertesz et al., 2007).

Comparative evaluations of different target prediction methods provided some kind of ranking of the sensitivity of different algorithm (Bagga et al., 2005; Lim et al., 2005; Wu and Belasco, 2008), but all available software produces a large fraction of false positive predictions. This might be due not only to the limited comprehension of the molecular basis and effect of miRNA-target pairing, but also to context dependency of post-transcriptional regulation. Thus, the integration of target predictions with miRNA and target mRNA expression profiles has been proposed to select functional miRNA-mRNA relationships, according to increasing experimental evidences which supported the miRNA mechanism of target degradation rather than translational repression.

3.3. miRNAs and diseases

miRNAs play important roles in many biological processes including cell differentiation, organogenesis, development and death. Dysregulation of miRNAs expression plays a critical role in the pathogenesis of genetic and multifactorial disorders (<http://www.mir2disease.org/>) and of most, if not all, human cancers. Cancer is a complex disease involving a variety of changes in gene expression that result in abnormal cell growth, migration and apoptosis. miRNAs are found aberrantly expressed in many cancer types involving chronic lymphoblastic leukemia, multiple myeloma, breast, colon, lung and prostate tumors. They can act either as tumor suppressor genes (TS-miRs), facilitating cancer cell death and/or to inhibit cancer cell growth, or as oncogenes (oncomiRs), promoting cancer cell proliferation. miR-15 and miR-16 are the first defined miRNAs with tumor suppressor functions. B-cell chronic lymphocytic leukemia (B-CLL) is associated with loss of chromosomal region 13q14 and miR-15 and miR-16 are located within a 30-kb region at chromosome 13q14, a region deleted in more than half of B-CLL (68%). miR-15- and miR-16-induced tumor suppression appears to be mediated through downregulating the anti-apoptotic protein Bcl2. Bcl2 is frequently over-expressed in CLL and the 3' UTR of the Bcl2 mRNA contains potential binding sites for miR-15 and miR-16. Expression of these miRNAs causes downregulation of Bcl2 and induces apoptosis in a leukemia cell line. Other examples include miR-29, which suppresses DNA methyltransferase (DNM vs T)-3A and -3B in lung cancer; let-7, which regulates the expression of *RAS* and other genes involved in cell cycle and cell division functions in lung cancer; and miR-34, which suppresses cell growth in ovarian cancer and colon cancer. miRNAs can also serve as oncogenes to promote cancer growth. miR-10b is shown to have the tumor-promoting

activity in cancer metastasis; it is over-expressed in metastatic breast cancer cells and promotes cell migration and invasion. The transcription of miR-10b is regulated by the transcription factor Twist, and the downstream targets of miR-10b include homeobox D10. The inhibition of homeobox D10 by miR-10b increases the expression of RHOC, a well-characterized pro-metastatic gene, leading to tumor cell invasion and metastasis. Other miRNAs as oncogenes include miR-17 clusters in B-cell lymphoma, miR-21 in glioblastoma, and miR-373 and miR-520c as metastasis-promoting miRNAs. miRNA clusters also are emerged implicated in many cancer type. A well-studied miRNA cluster, miR-17-92, consists of 7 individual miRNAs encoded from a frequently amplified locus at 13q31.3 in B-cell lymphomas. It was shown miRNAs of this cluster only altogether can enhance tumorigenesis by inhibition of apoptosis in tumors(Li et al., 2009).

Recently, miR-16 has been found to be involved in polycythemia vera development and functional experiments showed that miR-16 silencing is able to prevent erythroid colony formation in vitro and erythrocytosis in vivo(Guglielmelli et al., 2011).

miRNAs also participate in the regulation of differentiation and growth of cardiac cells, and it is hypothesize that miRNAs involved in cardiac hypertrophy and heart failure. Other evidence correlates miRNA dysfunction with metabolic, immune, and inflammatory disorders.

In conclusion, miRNAs are emerged as possible therapeutic targets for a large number of diseases and can use as a novel clinical method to monitor the progression, prognosis, diagnosis, and evaluation of treatment responses(Li et al., 2009; Wang, 2010; Zhang, 2008).

3.4. MicroRNA–offset RNAs (moRNAs): by-product spectators or functional players?

Recent studies have exponentially increased the number of known noncoding RNA categories and short RNA sequencing led to the discovery of a novel type of miRNA-related small RNA, miRNA–offset RNA (moRNA), whose function is currently unknown. MoRNAs were first reported in a simple chordate, the ascidian *Ciona intestinalis*, as ~20-nt-long RNAs derived from the ends of pre-miRNAs, possibly by RNase III-like processing. moRNAs can originate from either end of the pre-miRNA, but they are prevalently derived from the 5' arm, regardless of the major miRNA position. This suggests that moRNA and miRNA biogenesis might be linked but not interdependent. The expression levels of moRNAs seem to be regulated in different developmental stages of *Ciona*, and their abundance can exceed that of the corresponding mature miRNA(Bortoluzzi et al., 2011).

3.4.1. *moRNA discovery by massive sequencing of short RNAs*

For both intragenic and intergenic (single or clustered) miRNAs, primary miRNAs are transcribed, edited and cleaved in the nucleus to generate hairpin precursors that are exported to the cytoplasm, where maturation takes place (Winter et al., 2009b). Dicer cleaves the pre-miRNA hairpin to produce an miRNA duplex (~22 nt), which is incorporated into the RNA-induced silencing complex (RISC). The RISC recognizes the duplex, unwinds it, selects the guide miRNA strand (while degrading the passenger strand) and mediates recognition of target RNAs. In some cases, both miRNAs are expressed and can differentially contribute to the regulation of cellular activities.

The application of deep sequencing technologies (RNAseq) to short RNAs facilitated the identification and expression quantification of known miRNAs, as well as the discovery of new miRNAs; the number of miRNAs identified increased by at least 50% in the last year (Kozomara and Griffiths-Jones, 2011). In addition, short RNA sequencing led to the discovery of moRNAs, which were first reported in a simple chordate, the ascidian *Ciona intestinalis* (Shi et al., 2009), as ~20-nt-long RNAs derived from the ends of pre-miRNAs, possibly by RNase III-like processing (Figure 4). moRNAs can originate from either end of the pre-miRNA, but they are prevalently derived from the 5' arm, regardless of the major miRNA position. This suggests that moRNA and miRNA biogenesis might be linked but not interdependent. The expression levels of moRNAs seem to be regulated in different developmental stages of *Ciona*, and their abundance can exceed that of the corresponding mature miRNA.




Figure 4. moRNAs. Two miRNAs and two moRNAs can be produced by transcription and processing of a single miRNA locus.

3.4.2. *moRNAs biogenesis: by-product or co-product?*

Initially, moRNAs were considered as by-products of potentially atypical miRNA processing (Shi et al., 2009). Later, moRNAs were also found in human cells by deep sequencing data analysis. Langerberger et al. reported that moRNAs from 78 genomic loci are weakly expressed in the prefrontal cortex (Langerberger et al., 2009). They also observed that some moRNAs are as conserved as miRNAs, and that miRNA precursors that also contain moRNAs are typically old from an evolutionary perspective (Langerberger et al., 2009). Furthermore, some weakly expressed moRNAs

have been found in solid tumors, together with other small RNAs(Meiri et al., 2010). Subsequently, moRNAs that lie immediately 5' or 3' of a viral miRNA were discovered by small RNA sequencing in the B cell line BC-3 infected with Kaposi's sarcoma-associated herpes virus(Umbach and Cullen, 2010) and in rhadinovirus-infected tumor samples from rhesus macaques. A study investigating different types of tiny RNAs localized in nuclear or cytoplasmic RNA fractions of THP-1 cells (a human acute monocytic leukemia cell line) showed that moRNAs are 18-fold enriched in the nucleus and are predominantly derived from the 5' arm of the precursor(Taft et al., 2010). Recently, *Drosophila melanogaster* miRNAs were deeply annotated using more than 1 billion reads from 187 short RNA libraries(Berezikov et al., 2011b). In this way, five-phased miRNA loci were identified (e.g. the locus *dme-mir-277* produces the following: 5' moR, miR-277, expressed loop, miR-277 and 3' moR).

moRNAs are generally included in the miRNA hairpin precursor, and in some cases the moRNA overlaps the miRNA position by a few nucleotides(Langenberger et al., 2009). Other moRNAs that overhang the miRNA hairpin can be produced by non-canonical Drosha processing(Berezikov et al., 2011b). Thus, it is not clear how the two ends of moRNAs arise and if or how Drosha and Dicer are involved. moRNAs seem to be conserved across species, the conservation extent correlates with expression level (Shi et al., 2009) and expression levels of certain moRNAs are greater than for their corresponding miRNA(Umbach et al., 2010). In addition, moRNAs are prevalently produced by the 5' arm of the precursor, independent of which arm produces the most expressed mature miRNA (Langenberger et al., 2009) and (Umbach et al., 2010). This evidence suggests that moRNAs might be miRNA co-products, representing a distinct functional class of miRNA-related agents (Berezikov et al., 2011a).

3.4.3. The functions of moRNAs are unknown at present

The hypothesis that moRNAs are a new class of functional regulators whose qualitative alteration and/or expression dysregulation might impact on human diseases is intriguing, but evidence regarding possible moRNA functions is still fragmentary. Umbach and colleagues used a luciferase-based indicator assay to demonstrate that a viral moRNA (moR-rR1-3-5p) has moderate inhibitory activity against an artificial mRNA bearing a perfect target site (Langenberger et al., 2009). In this case, an moRNA might guide RISC to complementary target mRNAs, acting as an miRNA. Nevertheless, moRNA enrichment observed in the nucleus (Taft et al., 2010) might indicate that some moRNAs play a different role specifically related to nuclear processes. It is known that specific miRNAs, such as miR-29b, are re-imported into the nucleus where they might be transcriptional regulators(Winter et al., 2009a). Similarly, other nuclear tiny RNAs are associated with transcript initiation and splice sites(Taft et al., 2010).

It is believed that the great majority of the transcriptional output of eukaryotic genomes is long and short ncRNAs (Brosnan and Voinnet, 2009) and some authors have pointed to a compelling need for disruption experiments of transcribed loci to determine the impact of ncRNAs on phenotype (Ponting and Belgard, 2010). In accordance with this view, both functional characterization of moRNAs and elucidation of their biogenesis are highly relevant for future research. The importance of assigning functions to these short RNA sequences provides us with another example of the power of deep sequencing data analysis in enhancing biological knowledge and hypothesis generation.

3.5. Regulatory network inference

Systems biology elevates the study from the single entity level (e.g., genes, proteins) to higher hierarchies, such as entire genomic regions, groups of co-expressed genes, functional modules, and networks of interactions. The functioning and development of a living organism is controlled by the networks of relations among its genes (as well as proteins and small molecules) and the signals regulating each gene (or set of genes), therefore understanding how elementary biological objects act together and interact in the general context of a genome is fundamental to the advancement of science.

Microarray experiments have been extensively used to detect patterns in gene expression that stem from regulatory interactions.

Network analysis has emerged as a powerful approach to understand complex phenomena and organization in social, technological and biological systems (Dorogovtsev and Mendes, 2003; Strogatz, 2001; Wasserman S., 1994). In particular, it is increasingly recognized the role played by the topology of cellular networks, the intricate web of interactions among genes, proteins and other molecules regulating cell activity, in unveiling the function and the evolution of living organisms (Jeong et al., 2000; Jeong et al., 2001; Maslov and Sneppen, 2002; Milo et al., 2002; Wagner and Fell, 2001). Gene networks, in this respect, present a unique opportunity to employ this new type of approach (Sharan and Ideker, 2006; Vazquez et al., 2004). A gene regulatory network (GRN) aims to capture the dependencies between these molecular entities and is often modeled as a network composed of nodes (representing genes, proteins and/or metabolites) and edges (representing molecular interactions such as protein–DNA and protein–protein interactions or rather indirect relationships between genes).

Algorithms to infer the structure of gene-gene relationships take as primary input the data from a set of microarrays measuring the mRNA expression levels in different physiological states and use either classical statistics (e.g., Pearson correlation), concepts from the information theory (i.e., the mutual information as in ARACNe (Algorithm for the Reconstruction of Accurate Cellular Networks (Basso et al., 2005a)) and CLR

algorithms (Faith et al., 2007) or probabilistic models (as in the Bayesian networks) to reconstruct the network of transcriptional interactions.

Many GRN inference approaches solely consider transcript levels and aim to identify regulatory influences between RNA transcripts. Such approaches employ an ‘influential’ GRN, i.e. a GRN where the nodes consist of genes and edges represent direct as well as indirect relationships between genes (Figure 5). This approximation leads to ‘influence’ network models that are intended to implicitly capture regulatory events at the proteomic and metabolomic level, which sometimes makes them difficult to interpret in physical terms.




Figure 5. Schematic view of a simple gene regulatory network. Gene A regulates its own expression and those of gene B. Thereby, gene A might exert its regulatory influence directly (if it encodes a TF) or indirectly (if it controls the activity of another TF possibly via a signaling cascade). When reconstructing the GRN, one often aims to infer an ‘influence’ network model as shown at the bottom (Hecker et al., 2009). Figure taken from Hecker et al., 2009.

The modeling (reconstruction) of a GRN based on experimental data is also called reverse engineering or network inference. Reverse engineering GRNs is a challenging task as the problem itself is of a combinatorial nature (find the right combination of regulators) and available data are often few and inaccurate. Therefore, it is beneficial to integrate system-wide genomic, transcriptomic, proteomic and metabolomic measurements as well as prior biological knowledge (e.g. from the scientific literature) into a single modeling process (Hecker et al., 2009).

Using computational support to adequately manage, structure and employ heterogeneous types of information in order to obtain a more detailed insight into biological network mechanisms represents a major challenge in GRN inference today. The number of computational methods that are being developed to reconstruct TRNs from genome-wide expression data is rapidly increasing (De Smet and Marchal, 2010). Recently a number of different model architectures for reverse engineering GRNs from gene expression data have been proposed using mathematical, Boolean, and statistics approaches.

Main models comprise (Hecker et al., 2009):

- *Information Theory Models*: correlation coefficients, Euclidean distances and information theoretic scores, such as the mutual information, were applied to detect gene regulatory dependencies. Two genes are predicted to interact if the correlation coefficient of their expression levels is above some set threshold. The higher the threshold is set, the sparser is the inferred GRN. Principle network inference algorithms are RELNET (RELevance NETworks (Butte and Kohane, 2000)), ARACNE (Algorithm for the Reverse engineering of Accurate Cellular Networks (Basso et al., 2005a)) and CLR (Context Likelihood of Relatedness (Faith et al., 2007)). Simplicity and low computational costs are the major advantages of information theory models. In comparison to other formalisms, a drawback of such models is that they do not take into account that multiple genes can participate in the regulation. A further disadvantage is that they are static.
- *Boolean Networks*: boolean networks are discrete dynamical networks. They use binary variables $x_i \in \{0, 1\}$ that define the state of a gene i represented by a network node as ‘off’ or ‘on’ (inactive or active). Hence, before inferring a Boolean network, continuous gene expression signals have to be transformed to binary data. Boolean networks can be represented as a directed graph, where the edges are represented by Boolean functions made up of simple Boolean operations, e.g. AND, OR, NOT. Various algorithms exist for the inference of Boolean networks, e.g. REVEAL (REVerse Engineering Algorithm (Liang et al., 1998)). Boolean networks can be used to simulate gene regulatory events because they are dynamics.
- *Differential and Difference Equations*: differential equations describe gene expression changes as a function of the expression of other genes and environmental factors. Thus, they are adequate to model the dynamic behavior of GRNs in a more quantitative manner. Their flexibility allows describing even complex relations among components. A modeling of the gene expression dynamics may apply ordinary differential equations (ODEs):

$$\frac{\partial x}{\partial t} = f(x, p, u, t) \quad (1)$$

where $x(t) = (x_1(t), \dots, x_n(t))$ is the gene expression vector of the genes $1, \dots, n$ at time t , f is the function that describes the rate of change of the state variables x_i in dependence on the model parameter set p , and the externally given perturbation signals u . In this case, network inference means the identification of function f and parameters p from measured signals x , u and t . Commonly, there are multiple solutions. Thus, the identification of model structure and model parameters requires specifications of the function f and constraints representing prior knowledge, simplifications or approximations. Regulatory processes are characterized by complex

non-linear dynamics, but mainly GRN inference approaches based on differential equations consider linear models or are limited to very specific types of non-linear functions.

- *Linear Differential Equations*: a linear model

$$\frac{dx_i}{dt} = \sum_{j=1}^N w_{i,j} \cdot x_j + b_i \cdot u_i \quad i = 1, \dots, N \quad (2)$$

can be applied to describe the gene expression kinetics $x_i(t)$ of N genes by $N \times (N + 1)$ parameters for (i) the N^2 components $w_{i,j}$ of the interaction matrix W and (ii) N parameters b_i quantifying, for example, the impact of the perturbation u on gene expression. In general, the simplification obtained by linearization is still not sufficient to identify large-scale GRNs from gene expression data unequivocally. Differential equations can be approximated by difference equations (discrete-time models). Thereby, the linear differential Eq. (2) becomes the linear difference Eq. (3):

$$\frac{x_i[t + \Delta t] - x_i[t]}{\Delta t} = \sum_{j=1}^N w_{i,j} \cdot x_j[t] + b_i \cdot u \quad i = 1, \dots, N \quad (3)$$

In this way one obtains a linear algebraic equation system that can be solved by well-established methods of linear algebra. Main inference algorithms based on this approach are LASSO (Least Absolute Shrinkage and Selection Operator, provides a robust estimation of a network with limited connectivity and low model prediction error), NIR (Network Identification by multiple Regression), M vs NI (Microarray Network Identification) and TSNI (Time-Series Network Identification).

- *Non-linear Differential Equations*: Complex dynamic behaviors such as the emergence of multiple steady states (e.g. healthy or disease states) or stable oscillatory states (e.g. calcium oscillations and circadian rhythms) cannot be explained by simple linear systems. The identification of non-linear models is not only limited by mathematical difficulties and computational efforts for numerical ODE solution and parameter identification, but also mainly by the fact that the sample size M is usually too small for the reliable identification of non-linear interactions. Thus, the search space for non-linear model structure identification has to be stringently restricted. Inference of non-linear systems employ predefined functions that reflect available knowledge. The data insufficiency still limits the practical relevance of non-linear models.
- *Bayesian Networks*: Bayesian networks (BNs) reflect the stochastic nature of gene regulation and make use of the Bayes' rule. Here, the assumption is that gene expression values can be described by random variables, which follow probability distributions. As they represent regulatory relations by probability, BNs are thought to model randomness and noise as inherent features of gene regulatory processes. Most importantly, BNs provide a very flexible framework for combining different types of

data and prior knowledge in the process of GRN inference to derive a suitable network structure. Besides, BNs have a number of features that make them attractive candidates for GRN modeling, such as their ability to avoid over-fitting a model to training data and to handle incomplete noisy data as well as hidden variables (e.g. TF activities). BNs can be learned based on discrete (often Boolean) and continuous expression levels.

The discovery of small RNAs adding a novel level of post-transcriptional gene regulation of different biological processes and systematic integration of various high-throughput datasets was proposed to analyze the transcriptional activity of microRNAs.

Cheng et al. (Cheng et al., 2011) planned the reconstruction of an integrated regulatory network, using three major types of regulation: TF→gene, TF→miRNA and miRNA→gene. They identified the target genes and target miRNAs for a set of TFs based on the ChIP-Seq binding profiles, the predicted targets of miRNAs using annotated 3'UTR sequences and conservation information. Schmeier et al. combined several sources of interaction and association data to analyse and place miRNAs within regulatory pathways that influence human ovarian cancer (OC) suggesting a major role of miRNAs in OC (Schmeier et al., 2011). Another example is GenMiR++, a Bayesian data analysis algorithm that uses paired expression profiles of miRNAs and mRNAs expression data to identify functional miRNA-target relationships and directed research in this area is of utmost importance to enhance our understanding of the molecular mechanisms underlying biological systems.

4. Material and Methods

4.1. microRNAs and genes: sequences and genomic positions

The complete set of hairpin precursors of human microRNA sequences was downloaded from miRBase version 14, thus obtaining a set of 721 pre-miRNA hairpin sequences and 904 mature miRNAs, 185 of which are tagged as “minor”, according to miRBase annotation (i.e. hsa-miR-30e*). We obtained 49,506 human genes and 132,056 transcripts sequences from ENSEMBL (version 56) each associated to a unique chromosomal position. Hairpin miRNA sequences were aligned with the version 37.1 of the human genome to establish their genomic positions as start and end coordinates of the aligned region in a specific chromosome and strand. Alignments associated to at least 95% sequence identities, calculated over the hairpin sequence length, have been considered for miRNA genome position definition. As genomic localization is referred to hairpin sequences whereas miRNA microarray platforms measure expression profiles of mature miRNAs, mature miRNAs to hairpin correspondence info was used for data integration. miRNA hairpins localizations were compared with those of protein-coding genes to identify intragenic miRNAs, putatively transcribed from the coding gene promoter. To define the miRNA-host gene relationships considered in further analyses, only miRNAs fully included in genes spanned regions were considered as intragenic. Specifically, 367 miRNAs were categorized as intergenic and thus excluded, whereas 309 intragenic miRNAs, were associated with 279 protein-coding human host genes. Among these, 23 (8.5%) include at least two miRNAs.

4.2. Biological Datasets

4.2.1. *Multiple Myeloma dataset*

Multiple Myeloma dataset (MM) dataset consists of matched miRNAs and genes expression profiles from purified plasma cells of thirty-nine human samples, including 33 patients with multiple myeloma (MM), 2 with plasma cell leukemia (PCLs) and 4 normal control samples (NCs) from healthy donors. The miRNA expression was profiled on the Agilent Human miRNA Microarray V2 (Lionetti et al., 2009). The human miRNAs data were reannotated on Sanger Release 12.0 and normalized using the Aroma Light package for Bioconductor. To overcome scaling biases resulting from background subtraction, the data were converted to obtain positive values throughout the dataset, at a minimum value of 1.

The raw and normalized microRNA data are available through GEO accession number GSE17498. The gene expression was profiled on Affymetrix GeneChip® Human Gene 1.0 ST Array. The raw intensity signals of genes were extracted from CEL files and normalized using robust multi-array average (RMA) normalization method, which consists of three steps: background correction, quantile normalization (each performed at the individual probe level), and robust linear model fit using log-transformed intensities (at the probeset level) implemented in the affy package for Bioconductor and re-annotated using Manhong Dai custom cdf, HuGene10stv1_Hs_ENSG (available at <http://brainarray.mbni.med.umich.edu/Brainarray/Database/CustomCDF/12.1.0/ensg.asp>). To the reconstruction of the transcriptional regulatory network a bigger dataset of gene expression (hereafter denoted as MM158GE) comprising 5 normal, 11 monoclonal gammopathies of unknown significance (MGUS), 133 MM, and 9 plasma cell leukemia (PCL) for a total of 158 samples was collected and were quantified using RMA (affy Bioconductor package) and the GeneAnnot custom Chip Definition Files.

4.2.2. Acute Lymphoblastic Leukemia dataset

Acute Lymphoblastic Leukemia dataset (ALL) dataset consists of matched miRNA and genes expression profiles in nineteen adult Acute Lymphoblastic Leukemia (ALL) cases, including T-lineage and B-lineage cells, harboring specific molecular lesions (Fulci et al., 2009)(GEO accession GSE14834). Human miRNA data obtained by Lc Sciences Human 470 miRHuman 9.0 microarray were background subtracted, quantile-normalized between the intra-array replicates, and summarized for each microRNA as the average of its seven repeating spots on the array. The background value was set for each array as quantified by the service provider. Processed miRNA intensity values were normalized between-array by quantile normalization. Quantile normalization was performed using function *normalize.quantiles* from R package *preprocessCore*. Gene expression was profiled on Affymetrix GeneChip® Human Genome U133 Plus 2.0 Array. The raw intensity signals of genes were extracted from CEL files and normalized using RMA algorithm of affy package for Bioconductor and re-annotated using Manhong Dai custom cdf, HGU133Plus2_Hs_ENSG (available at <http://brainarray.mbni.med.umich.edu/Brainarray/Database/CustomCDF/12.1.0/ensg.asp>).

4.2.3. Normal and Alzheimer's parietal lobe cortex

Normal and Alzheimer's parietal lobe cortex (ALZ) dataset consists of 16 matched miRNA and gene expression experiments, obtained by USC/XJZ Human 0.9 K miRNA-940-v1.0 and Affymetrix Human Genome U133 Plus 2.0 Array, in parietal lobe tissue from 4 Alzheimer Disease patients and 4 age-matched controls (GSE16759)(Nunez-Iglesias et

al., 2010). The raw intensity signals of genes were extracted from CEL files, normalized using RMA algorithm of affy package for Bioconductor, and re-annotated using Manhong Dai custom cdf, HGU133Plus2_Hs_ENSG. Human miRNA data were processed using the same approach of gene expression reconstruction.

4.2.4. Normal prostate and prostate cancer

Normal prostate and prostate cancer (PRO) dataset consists of the subset of 140 matched miRNA and gene expression experiments, obtained respectively by Agilent-019118 Human miRNA Microarray 2.0 and Affymetrix Human Exon 1.0 ST, of the prostate data reported in (Taylor et al., 2010)(GEO accession GSE21032) regarding primary and metastatic prostate cancer samples and control normal adjacent benign prostate. Human miRNA data were processed using the same approach suggested by the original paper. Gene expression profiles was obtain using RMAExpress, a standalone GUI program to compute gene expression summary values for Affymetrix Genechip data using the Robust Multichip Average expression summary and to carry out quality assessment using probe-level metrics.

4.2.5. Multiple cancers and normal tissues dataset

Multiple cancers and normal tissues dataset (MCN) dataset includes miRNAs expression profiles in 32 samples from 14 different patients and 8 different tumor types, with tumor cells and normal cells counterpart for each patient (GEO accession GSE14985). Tissue samples were from various embryonic lineages: one pair from breast, lymphoma and prostate; two from liver, ovary, testes and lung and three from colon: two technical replicates are included for ovary and testes samples. MiRNA expression was profiled using Agilent Human miRNA Microarray 2.0. Agilent's Feature Extraction software version 9.5.3.1 was used to generate GeneView files. These files contain the processed signals for each of the 799 miRNAs on the array. For each miRNA, expression values (gTotalGeneSignal) below the noise level (gTotalGeneError) were replaced by the value of the corresponding total gene error. All samples were then normalized to have the same 75th percentile value(Navon et al., 2009).

4.2.6. Colorectal cancer dataset

From the institutional colorectal database, 55 patients with colorectal cancer, who underwent primary surgery at University of Padova, were selected. Tissue samples were obtained from the patients during the surgical procedure. Colorectal cancer dataset includes 78 and 80 miRNA and gene expression experiments, respectively.

MiRNA expression was profiled using GeneChip miRNA 1.0 Array. We used free miRNA QC tool software from Affymetrix to normalize data and perform preliminary quality control procedures for all miRNA experiments. miRNA expression measures were reconstructed from .cel files by using the Robust Multichip Average (RMA) method. miRNAs resulting detected in less than 20 samples were discarded. In this way we obtained 309 miRNAs with expression profiles in the considered set of tissue samples, which were considered for the following analyses.

GeneChip Human Exon 1.0 ST (Affymetrix) has been used to obtain high quality gene expression quantification. Raw data were processed by RMAExpress, a GUI program to compute gene expression summary values for Affymetrix Genechip® data using the Robust Multichip Average expression summary and to carry out quality assessment using probe-level metrics. Gene expression profiles were obtained from exon data by RMA using EntrezGene-based custom CDF (<http://brainarray.mbni.med.umich.edu/Brainarray>). Using Shannon entropy calculated on expression profiles as variability measure, 30% of genes with less variable expression profile across considered samples were filtered out. Quality control of miRNA and gene chips was grounded on two main PLM-based quality statistics, Normalized Unscaled Standard Error (NUSE) and Relative Log Expression (RLE), to assess the global quality of signals in each array, on the basis of distribution of standard errors and of relative log of expression of the single probeset. MA plots before and after RMA were evaluated to identify biases associated to specific classes of signal intensity. IQR Limits option was used to visualize control limits ($1.5 \cdot \text{IQR}$ above the upper quartile and $1.5 \cdot \text{IQR}$ below the lower quartile) derived based on normal boxplot outlier identification rules.

4.2.7. Adult T-cell leukemia lymphoma dataset

Adult T-cell leukemia lymphoma dataset (ATLL) consists of 15 matched miRNA and gene expression experiments deriving from peripheral blood mononuclear cells (PBMC) of 7 ATLL patients (6 with leukemia, 1 with lymphoma) and from 4 resting and 4 stimulated CD4+ cells. miRNA expressions were quantified using Agilent microRNA microarrays (V1). Signal intensities were normalized using quantile-quantile normalization after substituting negative values with the lowest positive value obtained for the arrays. The distribution of signal intensities was then plotted to filter out microRNAs with weak signals having probably no biological relevance. This procedure yielded 137 microRNAs with at least two samples in the upper 75th percentile (corresponding to a signal intensity of >5.91). Gene expression data for resting and stimulated CD4+ cells (sample sets A, B, D, P) were obtained using Affymetrix hgu133plus2 arrays. ATLL samples were analyzed using Affymetrix hgu133a2 arrays as described (Pise-Masison et al., 2009). Data were extracted from CEL files and normalized using the RMA package for Bioconductor and

custom Gene-Annot-based Chip Annotation Files, Version 2.0.1 (CDF)(Ferrari et al., 2007). Total RNA was subjected to reverse transcription and quantitative PCR to detect known microRNAs using Applied Biosystems Taqman microRNA assays and 7900HT Fast Real-Time PCR System according the manufacturer's protocol. Results were analyzed by relative quantification using total RNA from freshly isolated PBMC (pooled from 3 donors) as a calibrator and RNU44 as an endogenous control.

4.2.8. SET2 cells line dataset

SET2 cells line dataset comprises a small RNA library generated from exponentially growing SET2 cells (DSMZ, Braunschweig, Germany) and sequenced on Illumina GAIIX. Raw sequencing reads were obtained using Illumina's Pipeline v1.5 software following analysis of sequencing image by Pipeline Firecrest Module and base-calling by Pipeline Bustard Module. Library construction and sequencing were performed at LC Sciences (Houston, Tx; www.lcsciences.com).

4.3. Cluster analysis

Hierarchical cluster analysis on microarray data was performed on gene and miRNA expression data to arrange gene or miRNA according to similarity in pattern of gene expression, or arrange biological sample according to similarity in different biological conditions or tissue types. Average-linkage method was used for clustering correlation microarray expression matrices. The object of this algorithm is to compute a dendrogram that assembles all elements into a single tree. For any set of n genes or miRNAs (similar processes was computed for microarray sample), an upper-diagonal similarity matrix is computed by using the metric described above, which contains similarity scores for all pairs of genes. The matrix is scanned to identify the highest value (representing the most similar pair of genes). A node is created joining these two genes, and a gene expression profile is computed for the node by averaging observation for the joined elements (missing values are omitted and the two joined elements are weighted by the number of genes they contain). The similarity matrix is updated with this new node replacing the two joined elements, and the process is repeated $n-1$ times until only a single element remains. Clustering expression data were used to see how much considered biological microarray samples groups together efficiently the same tissue type in the same biological condition or simply similar biological condition, such as normal and tumor samples(Eisen et al., 1998).

4.4. miRNA and gene differential expression analysis

A Significance analysis of microarrays (SAM) was performed to identify significant genes in a set of microarray experiments. The input to SAM is gene expression measurements from a set of microarray experiments, as well as a response variable from each experiment. The response variable may be a grouping like untreated, treated (either unpaired or paired), a multiclass grouping (like breast cancer, lymphoma, colon cancer, etc...), a quantitative variable (like blood pressure) or a possibly censored survival time. SAM computes a statistic for each gene, measuring the strength of the relationship between gene expression and the response variable. It uses repeated permutations of the data to determine if the expression of any genes is significantly related to the response. The cutoff for significance is determined by a tuning parameter delta, chosen by the user based on the false positive rate. One can also choose a fold change parameter, to ensure that called genes change at least a pre-specified amount (Tusher et al., 2001). The cutoff for significance is determined by a tuning parameter delta, chosen based on the false positive rate (FDR). We considered significant a FDR lower than to 0.01.

4.5. MicroRNA target predictions

4.5.1. miRanda

miRNA targets have been predicted applying miRanda algorithm (Enright et al., 2003a; John et al., 2004) on human miRNA and transcript sequences of miRBase Release 123 and ENSEMBL Release 52, respectively. The score threshold of miRanda, associated with each predicted miRNA-transcript targeting relationship and depending on the sequence alignment and thermodynamic stability of the RNA duplex, has been set at 160. Finally, the correspondence between ENSEMBL_transcript and EntrezGene_ID was defined.

4.5.2. Pita

PITA algorithm was used to compute miRNA target predictions over up-to-date versions 56 and 38 of ENSEMBL and RefSeq transcript sequences, respectively. The miRNA sequences were downloaded from mirBase version 14. Based on known transcript to gene correspondences, gene-centered predictions were then derived combining transcript-based results into a single group for each gene. In this way a gene is predicted target of a given miRNA if at least one of its transcripts carries predicted target site(s) (Kertesz et al., 2007).

4.5.3. TargetScan

TargetScan predictions (versions 5.0 or 5.1) were downloaded from <http://www.targetscan.org>. The set of microRNA-target predictions comprises both conserved and non conserved sites that match the seed region of each miRNA (Friedman et al., 2009).

4.6. Regulatory network reconstruction

4.6.1. Transcriptional regulatory network

The transcriptional regulatory network was reconstructed using ARACNe and gene expression signals. ARACNe utilizes information and data transmission concepts (i.e., mutual information and data processing inequality) to identify statistically significant co-regulations among genes from microarray expression profiles. Mutual information and data processing inequality allow reconstructing gene-gene relationships which most likely represent either direct regulatory interactions or interactions mediated by post-transcriptional modifiers. Briefly, the algorithm first uses the expression data to calculate pair wise Mutual Information (MI) through a computationally efficient Gaussian kernel estimator. ARACNe calculates the kernel width depending on the size and statistics of the dataset. The second step is the elimination of the interactions that are not statistically significant according to a p-value or a MI threshold and returns a series of irreducible statistical dependencies. The post-processing step eliminates interactions that are likely to be indirect. The Data Processing Inequality (DPI) theorem removes indirect regulatory influences that appear as direct because of a high MI score due to the presence of a common neighbor. An additional parameter, called DPI tolerance, can be used to compensate for errors in the MI estimate that might affect DPI application (Basso et al., 2005a). The parameters of the kernel width and the Mutual Information threshold were calculated using MATLAB scripts. The p-value to determine the MI threshold was set at $1e^{-7}$, while the DPI tolerance was set equal to 10%. A list of Transcription Factors (TF) for the platform HG-U133A was also imputed as a parameter to prevent the DPI from removing transcriptional interactions in favor of non-transcriptional ones (interactions between two non-TFs).

4.6.2. Integrative analysis

The integrative analysis of miRNAs and target genes expression profiles is based on the assumption that, at least for miRNAs acting at post-transcriptional level on mRNAs stability, for a given miRNA, true targets expression profiles are expected to be anti-

correlated with that of the miRNA (Figure 6). The assumption is corroborated by the findings of different proteomics studies (Baek et al., 2008). It was shown that most targets with significantly reduced protein level also experienced detectable reduction in mRNA levels, indicating that changes in mRNA




Figure 6. Assumption of integrative analysis. miRNAs act at post-transcriptional level on mRNAs stability. Thus for a given miRNA, true targets expression profiles are expected to be anti-correlated with that of the miRNA. As can be seen from the schema, only miRNA₁ have an opposite behavior with gene_i, so miRNA₁-gene_i is considered a regulatory relation supported by expression data.

predicted relationships associated to most negative Pearson coefficients. Different percentile-based cutoffs were applied, to define the groups of supported regulatory interactions.

4.6.3. Post-transcriptional regulatory networks

The posttranscriptional regulatory network of miRNA and genes in MM has been defined as a directed, bipartite graph in which miRNA-mRNA relationships are supported by both targeting predictions and expression data. Specifically, the network reconstruction required to:

levels, indicating that changes in mRNA expression are reasonable indicators for microRNA regulation.

This analysis combines target predictions with miRNAs and gene expression data correlation-based analysis to identify, among predicted target genes for each considered miRNA, those regulatory relationships significantly supported by expression data.

In details, the procedure comprises the identification of miRNA target genes by computational predictions and compilation of the adjacency matrix of targeting relationships, and the computation of pair-wise relatedness of miRNAs and targets from matched expression matrices, to identify relationships supported by expression data, which could be used for post-transcriptional regulatory networks reconstruction and study. The set of microRNA-target relations were defined using a prediction algorithm as TargetScan, miRanda and Pita. The pair-wise Pearson correlation coefficient between miRNA and target genes expression profiles in exactly the same samples was calculated. We then selected as reliable and potentially functional the subset of

- i) identify the miRNA target genes basing on computational predictions;
- ii) compute the integrative analysis;
- iii)reconstruct the post-transcriptional regulatory network from the regulatory relations supported by miRNA and mRNA expression levels obtained by integrative analysis.

Computational prediction of miRNA targets presents significant challenges due to the lack of a sufficiently large group of known miRNA targets to be used as training set. As such, most computational algorithms for target prediction (miRanda, TargetScan, PicTar, PITA, RNAhybrid) result in a significant proportion of false positives, i.e. in the prediction of not-functional miRNA-mRNA interactions. The integrative analysis can be performed using a variational Bayesian model(Huang et al., 2007c) or, as in this case, through a non-heuristic methodology based on the anti-correlation between miRNA and mRNA matched expression profiles(Gennarino et al., 2009; Xin et al., 2009). Genes were considered genuine miRNA targets only if included within the top 3% of all anti-correlated pairs. This selection gave rise to a final adjacency matrix S of regulatory relations supported by expression levels. The adjacency matrix S defined a bipartite directed network with two types of nodes (miRNAs and mRNAs) connected by directed edges, each representing a probably functional regulatory effect of a miRNA on a target gene. The same matrix S was used to derive a gene-only network in which genes (nodes) are connected by undirected weighted links and the edge weight quantifies the number of shared miRNAs regulating each gene pair.

4.6.4. Network critical components analysis

The topological structure of a network can be used to identify the components (nodes or links) that are critical for the functioning of the system (*critical components*). Network critical components analysis has been successfully applied in different fields as communication or transportation. For instance, critical analysis is used to identify nodes that must be protected from terrorist attacks in communication networks, in social networks finding critical nodes can be fundamental to reduce the spreading of viruses, and in biological systems, this analysis can be extremely helpful to understand complex phenomena and to find more powerful ways to defend the system from a disease. Nodes and links can be removed using various techniques and different networks exhibit different levels of resilience to such disturbances. Networks can be perturbed simulating the deletion of node/links chosen at random (*error removal* or *failure*) or targeting a specific class of nodes/links (removal through intentional *attacks*). Attacks can be addressed sorting and removing progressively the nodes in descending order of degree or betweenness or the links in descending order of betweenness or range(Albert et al., 2004; Holme et al., 2002; Motter and Lai, 2002). The network robustness is usually measured by the size of the largest connected component and by the average node-node distance as a function of the

percentage of nodes/links removed. The method used here to identify the critical components of gene regulatory networks is based on an *ad-hoc* definition of network performance, rather than on local node information such as the number of ingoing or outgoing links. Specifically, the importance of a node is measured by the drop in the network efficiency caused by the removal of that node, where the network efficiency $E(G)$ quantifies how efficiently the nodes of the network exchange information (Latora and Marchiori, 2001). The definition of $E(G)$ requires recalling some formalism from the graph theory. A network can be modeled by a graph G of nodes that are tied by one or more specific type of interdependency. Formally, an *undirected* graph $G=(N, L)$ consists of two sets N and L such that $N \neq \emptyset$ and L is a set of unordered pairs of element of N . The elements of $N=\{n_1, n_2, \dots, n_M\}$ are the nodes of the graph G while the elements of $L=\{l_1, l_2, \dots, l_K\}$ are the edges. Two nodes joined by an edge are referred to as *adjacent* or *neighboring*. A graph is *weighted* when exists a function $w: L \rightarrow R$ from edges to real numbers, such that each edge has associated a number that represents the strength of the connection. A graph is called *m-partite* if N admits a partition into m classes such that every edge has its ends in different classes: vertices in the same partition class must not be adjacent. When $m=2$, the graph is called *bipartite*. A *walk* from node i to node j is an alternating sequence of nodes and edges that begins with i and ends with j . If no node is visited more than once, the walk is called a *path*. A graph G is said to be *connected* if, for every pair of distinct nodes i and j , there is a path from i to j in G . The *degree* or *connectivity* k_i of a node i is the number of edges incident with the node, i.e. the number of neighbors of that node. One of the most relevant topological characterizations of a graph G can be obtained from the degree distribution $P(k)$, which is normally represented plotting the number of nodes having degree of connectivity k against k in a loglog scale. A decreasing linear dependency in this plot indicates that the network has a *scale-free* structure, associated with a corresponding power-law $n(k) \propto k^{-\gamma}$ (Figure 7).




Figure 7. Effect of node removal through error and attack in scale free (A., solid lines) and in random (B., dotted lines) networks. In a scale-free network (solid lines), the random removal (error) of even a large fraction of vertices impacts the overall connectedness of the network very little (black line), while targeted attack (red line) destroys the connectedness very quickly, causing a rapid drop in efficiency. On the contrary, in random graphs, removal of nodes through either error or attack has the same effect on the network performance.

Graphs can be further classified as *assortative* if $k_{nn}(k)$, i.e., the average degree of the neighbors of degree k , is an increasing function of k ; otherwise they are referred to as *disassortative*. In assortative networks the nodes tend to connect to their connectivity peers, while in disassortative networks nodes with low degree are more likely connected with highly connected ones. The efficiency of G relies on the calculation of the shortest path lengths d_{ij} between two generic nodes i and j . In a weighted graph d_{ij} is defined as the smallest sum of the physical distances throughout all the possible paths in the graph from i to j , while in an un-weighted graph d_{ij} reduces to the minimum number of edges traversed to get from i to j . The maximum value of d_{ij} is called the *diameter* of the graph and the average shortest path length L is quantified as follows:

$$L = \frac{1}{n(n-1)} \sum_{i,j \in N, i \neq j} d_{ij} \quad (4)$$

Supposing that every node sends information along the network, through its links, the

efficiency ε_{ij} in the communication between node i and node j is assumed to be inversely proportional to their shortest distance, i.e. $\varepsilon_{ij} = 1/d_{ij} \forall i, j$. It's worthwhile noting that the assumption that efficiency and distance are inversely proportional is a reasonable approximation although sometimes other relationships might be used, especially if justified by a more specific knowledge of the system. By assuming $\varepsilon_{ij} = 1/d_{ij}$, when there is no path in the graph between i and j , $d_{ij} = +\infty$ and consistently. Consequently, the average efficiency $E(G)$ of the graph G can be defined as:

$$E(G) = \frac{1}{M(M-1)} \sum_{i,j \in N, i \neq j} \varepsilon_{ij} = \frac{1}{M(M-1)} \sum_{i,j \in N, i \neq j} \frac{1}{d_{ij}} \quad (5)$$

The definition of $E(G)$ according to Eq.(5) avoids the divergence of L in case of disconnected components thus allowing the analysis of the entire network and not only of the biggest connected sub-graph. Since $E(G)$ varies in the range $[0, \infty)$, it would be more practical to normalize $E(G)$ in the interval $[0, 1]$. The most natural way to normalize $E(G)$ is with respect to the efficiency of a network G^{ideal} composed of all the $M(M-1)/2$ possible edges:

$$E(G) = \frac{1}{M(M-1)} \quad (6)$$

Though the maximum value $E(G)=1$ is reached only when there is a link between each pair of nodes, real networks can nevertheless assume high values of E . This definition is valid for both un-weighted and weighted graphs and can also be applied to disconnected graphs. The efficiency can be evaluated on any *sub-graph* $G'=(N', L')$ of $G=(N, L)$, where G' of G is a graph such that $N' \subseteq N$ and $L' \subseteq L$. The sub-graph of the neighbors of a given node i , denoted as G_i , is the sub-graph induced by N_i , i.e., the set of nodes adjacent to i . Given c_i the node cardinality of G_i , the local efficiency E_{loc} is defined as the average of the sub-graph efficiencies $E(G_i)$ normalized with respect to the ideal sub-graphs in which all the $c_i(c_i-1)/2$ edges are present:

$$E_{loc} = \frac{1}{M} \sum_{i \in G} \frac{E(G_i)}{E(G_i^{ideal})} \quad (7)$$

Since $i \in G_i$, the local efficiency E_{loc} quantifies the efficiency of the system in tolerating faults, i.e., how efficient is the communication between the first neighbors of i when i is removed. Graphs that have high value of E_{glob} and E_{loc} , i.e., that are very efficient both in their global and local communication, are defined as *small-worlds networks*. Given the

definition of $E(G)$ and assuming that the efficiency is an appropriate quantity to characterize the average properties of a network, critical components can be identified considering the efficiency drop, caused by the deactivation of a component, as a measure of the centrality of that component. Therefore, the topological importance of a node α in a graph is quantified by the *network relevance* r_α :

$$r_\alpha = \frac{E(G) - E(G_\alpha)}{E(G)} = \frac{\Delta E_\alpha}{E} \quad (8)$$

where G_α is the graph obtained by removing node α from G , for each $\alpha = 1, \dots, M$. The most critical nodes are those whose removal causes the largest drop in efficiency, i.e., those with the highest r_α (Figure 7). Although here the focus is on the determination of the critical nodes, the method is of general applicability to any subset (nodes, links and combination of nodes and links) of G (Crucitti et al., 2004).

4.7. MAGIA web-based tool

MAGIA is a novel web-based tool that allows:

- to retrieve and browse updated miRNA target predictions for human miRNAs, based on a number of different algorithms (PITA, miRanda and TargetScan), with the possibility of combining them with Boolean operators,
- the direct integration through different functional measures (parametric and non-parametric correlation indexes, a variational Bayesian model, mutual information and a meta-analysis approach based on P-value combination) of mRNA and miRNA expression data
- the construction of bipartite regulatory networks of the best miRNAs and mRNA putative interaction and finally and
- to retrieve information available in several public databases of genes, miRNAs and diseases and via scientific literature text-mining. Step-by-step tutorial pages and sample data sets are provided to the user to easily introduce him to the use of the tool.

MAGIA is divided into two separate sections: the query and the analyses frameworks. The query section of MAGIA allows the user to search for target predictions of specific miRNAs obtained through PITA, miRanda or TargetScan or combinations thereof, setting cutoffs on prediction scores. Target prediction algorithms have been selected according to their different strategies: sequence similarity (miRanda), sequence similarity with conservation (TargetScan) and sequence similarity with free energy minimization (PITA). We run each of these algorithms on our servers to update predictions every 6 months. The

query output is a table including, for all considered miRNAs, the list of predicted target genes or transcripts with the different prediction scores according to the method(s) chosen by the user. The same information may be downloaded as a text file for processing and further elaboration.

The analysis pipeline is composed by three different steps through which MAGIA refines target predictions using miRNA and mRNA gene expression data (Figure 8):

- selection of the gene or transcript annotation (EntrezGene, RefSeq, ENSEMBL gene or transcript) and of the integration method or the relatedness measure;
- choice of target prediction algorithms, their score cut-offs and Boolean combinations;
- upload of two matrices representing mRNA and miRNA normalized expression profiles.

MAGIA takes into account two different experimental designs:

- mRNA and miRNA data collected on different biological samples, resulting in different sample sizes (hereafter called non-matched case)
- mRNA and miRNA expression data obtained from the same biological samples (the matched case).

The tool employs a meta-analysis approach based on a P-value combination in the first case, while one of four different measures of relatedness can be adopted for the analysis of matched profiles: Spearman and Pearson correlation, mutual information, and a variational Bayesian model. Computational intensive calculations of MAGIA analyses are carried out by a multicore cluster.

4.7.1. Input files

MAGIA analysis pipeline takes as input two expression matrices (in the tab-delimited format) with genes and miRNAs on the rows and samples on the columns. When profiles are matched, the names of the columns of mRNA and miRNA data sets should correspond exactly, while in the non-matched-case the columns labels should represent sample classes: samples belonging to the same class should have the same label. The first column of both matrices should represent miRNA and gene IDs. MAGIA allows EntrezGene or Ensembl IDs for genes and RefSeq or Ensembl IDs for transcripts, while miRNA IDs must represent miRBase-compliant mature miRNA identifiers. Expression matrices should be pre-processed and a filtering procedure for the removal of invariable ('flat') expression profiles is highly recommended. A series of quality checks are performed during the upload.

Sample files for miRNA and gene expression, fully compliant with the user choices of steps 1 and 2, are also provided in this step for tutorial purposes. These sample files

derive from expression data publicly available at GEO database (GSE14834) (Fulci et al., 2009).




Figure 8. Work flow diagram of the three main steps of analysis pipeline performed by MAGIA web tool.

4.7.2. Target predictions

We have used the miRanda and PITA algorithms to compute miRNA target predictions over up-to-date versions 56 and 38 of ENSEMBL and RefSeq transcript sequences, respectively. The miRNA sequences were downloaded from mirBase version 14. Based

on known transcript to gene correspondences, gene-centered predictions were then derived combining transcript-based results into a single group for each gene. In this way a gene is predicted target of a given miRNA if at least one of its transcripts carries predicted target site(s). TargetScan predictions (version 5.0) were downloaded from <http://www.targetscan.org>.

4.7.3. Computation of interaction measure

Pearson and Spearman correlations. Correlation indicates the strength and direction of a linear relationship between two random variables. Parametric (Pearson) or non-parametric (Spearman) correlation coefficients are computed in the case of matched samples between gene/transcript and miRNA data. Pearson's correlation coefficient between two variables is defined as the covariance of the two variables (X, Y) divided by the product of their standard deviations:

$$\rho_{X,Y} = \frac{\text{cov}(X,Y)}{\sigma_X \sigma_Y} = \frac{E[(X - \mu_X) \cdot (Y - \mu_Y)]}{\sigma_X \sigma_Y} \quad (9)$$

The Spearman correlation coefficient is defined as the Pearson correlation coefficient between the ranked variables. The n raw scores X_i, Y_i are converted to ranks x_i, y_i , and ρ is computed from these:

$$\rho_{X,Y} = \frac{\sum_i (x_i - \bar{x}) \cdot (y_i - \bar{y})}{\sqrt{\sum_i (x_i - \bar{x})^2 \cdot \sum_i (y_i - \bar{y})^2}} \quad (10)$$

Tied values are assigned a rank equal to the average of their positions in the ascending order of the values.

In general, non-parametric statistic has different expected values from the Pearson correlation coefficient, even for large samples. Since they estimate different population parameters, they cannot be directly compared: they generally should be viewed as alternative measures of association. The non-parametric coefficient should be chosen in case of outliers or with small number of measures; otherwise a parametric approach may be more appropriate. Moreover, Pearson coefficient testing requires that both variables derive from a bivariate normal distribution, an assumption not necessary for the Spearman coefficient testing. The tool computes correlation coefficients for all the predicted miRNA–target interactions and also provides a false discovery rate (FDR, following Benjamini and Hochberg estimation method) for each one.

Mutual information. Mutual information is a measure of the mutual dependence of two variables. The mutual information of two discrete random variable X and Y can be formally defined as:

$$I(X, Y) = \sum_{y \in \mathcal{Y}} \sum_{x \in \mathcal{X}} p(x, y) \cdot \log \left(\frac{p(x, y)}{p(x) \cdot p(y)} \right) \quad (11)$$

Intuitively, it captures the information that a variable X (a gene expression profile) and a variable Y (a miRNA expression profile) share: how much the knowledge of one of these variables reduces our uncertainty about the other. Thus, the mutual information can be interpreted as a generalized measure of correlation, analogous to the Pearson correlation, but sensitive to any functional relationship, not just to linear dependencies. There are several possible strategies for the reliable estimation of the mutual information in case of finite data, each of them characterized by a systematic error due to the finite size sample [see (Steuer et al., 2002) for a review]. In particular, following the Kraskov and colleagues (2003) approach (Kraskov et al., 2004), MAGIA calculates mutual information based on nearest neighbor distances with $k = 5$. Mutual information, identifying any functional relationship between miRNA and gene expression profiles, does not allow the identification of the sign of such relationship.

GenMir++. The variational Bayesian model, called GenMiR++ (Huang et al., 2007c) uses as prior information target predictions derived from one of the previous mentioned algorithms (e.g. PITA) and updates such information using expression matrices. It combines predictions with miRNA and mRNA expression profiles, under the assumption of anti-correlation. Under a complex model, the posterior probability of miRNA–gene interactions (S) is calculated, known the target predictions (C), expression matrices (X and Z), by integrating over nuisance variables gamma (Γ , tissue scaling) and lambda (Λ , regulatory weights) and other parameters in the equation,

$$p(X, S, \Gamma, \Lambda | C, Z, \Theta) = p(S | C, \Theta) p(\Gamma | \Theta) p(\Lambda | \Theta) \prod_g p(x_g | Z, S, \Gamma, \Lambda, \Theta) \quad (12)$$

An estimate of such posterior probability is calculated through an EM algorithm. Thus GenMir++ could have convergence problems, particularly in case of non-sparse incidence matrices.

Meta-analysis. The meta-analysis approach is suggested only in the case of non-matched biological samples. Given the diverse nature and number of samples between miRNA and gene profiles, neither correlation coefficients nor mutual information or posterior probabilities can be computed. MAGIA adopts in their place a meta-analyses approach based on P-value combination allowing, unlike other web tools, the presence of more than two groups. Empirical Bayes test (Smyth, 2004) (as implemented in *limma* package in R) is separately performed on miRNA and mRNA expression levels and lists of differentially miRNAs and genes are stored. Then, only for predicted miRNA–mRNA interactions (based on the target prediction algorithms the user has chosen) the inverse Chi-squared approach (Moreau et al., 2003) is used to combine miRNAs and genes P-values. In particular, in the case of a two classes experimental design, P-values of over-expressed

miRNAs (e.g. under-expressed in Class 1 versus Class 2) are combined with those of under-expressed genes (Class 1 versus Class 2) and vice versa. In the case of more than two classes the tool combines P-values derived from miRNAs, genes and from the test on Spearman correlation coefficient computed between vectors representing the average expression values of miRNAs and genes within each class. Only the interactions with small P-values (<0.1) will be considered as functional.

4.7.4. Output and links to other database resources

MAGIA reports results in a web page containing different sections. For the top 250 most probable functional miRNA–mRNA interactions according to the association measure selected by the user, the interactive bipartite regulatory network obtained through the analysis is reported along with the corresponding browsable table of relationships. It gives a hyperlink allowing the functional enrichment analysis by the DAVID web tool (Huang da et al., 2009) on the desired number of target genes. The tool also provides the complete list of the predicted interactions, ranked by statistical significance computed from the integrated expression data analysis. Such information is given as HTML tables and as two (Cytoscape-compliant) flat files for network reconstruction. Each mRNA, miRNA or miRNA–mRNA interaction can be further investigated by the user and used for different queries. In particular, each gene is linked to EntrezGene (Maglott et al., 2005), and ArrayExpress Atlas (Parkinson et al., 2009) databases, each miRNA is linked to miRNA2disease (Jiang et al., 2009) and miRecords (Xiao et al., 2009b). Furthermore, to allow efficient and systematic retrieval of statements from Medline, MAGIA directly links results to PubFocus (Plikus et al., 2006) and EbiMED (Rebholz-Schuhmann et al., 2007) for a text-mining search using genes and miRNAs as keywords.

4.7.5. Bi-partite networks visualizations

The miRNA and gene bipartite network is rendered using Graphviz (<http://www.graphviz.org/>) open source graph visualization software. Each node of the network can be selected and the user is directly linked to the corresponding miRNA/gene full interactions results. Thus the user is allowed to ‘walk through the network’ following miRNA and gene interactions. The complete list of significant interactions can be downloaded as a tab-delimited text file that can be imported into Excel or Cytoscape, to allow further processing.

4.8. Analysis of sister miRNA pairs expression ratio.

For each sister miRNA pair represented in at least one of the five considered datasets, we calculated the per sample $\log_2(\text{ratio})$ between expression values of sister miRNAs (e.g. miR-X/miR-X*, miR-X-5p/miR-X-3p according to miRBase annotation). Matrix values were standardized and used for cluster analysis of samples and of miRNA pairs, using Euclidean distance and average clustering. Then, for each dataset we considered not expressed in a given sample those miRNAs associated to expression values lower than the median of the dataset expression matrix (i.e. low values were set to 0). We calculated the per sample $\log_2(\text{ratio})$ between expression values of sister miRNAs as indicated before, but miRNA pairs expressed in alternative way in a given sample were associated to extreme values. When only one out of two sister miRNAs was expressed over the threshold, $\log_2(\text{ratio})$ values (generating $\pm\infty$) were artificially set to $\max\text{Log}(\text{ratio})+0.1$, if only the first miR is expressed, or to $\min\text{Log}(\text{ratio})-0.1$ in the opposite case. Values of $\log_2(\text{ratio})$ of samples in which both miRNAs of the pair are not expressed were not considered for the clustering analyses.

4.9. Statistical analysis

Conventional statistical procedures were applied, where appropriated using standard packages for R software. Wilcoxon rank-sum tests was used to evaluate the length of host gene in comparison with all human genes. This is a non-parametric statistical hypothesis test for assessing whether one of two distribution samples of independent observations tends to have larger values than the other. Student's t-test was applied with independent samples having a standard normal distribution. In particular this was performed for test the difference between the expression level of new and novel miRNAs and moRNAs in SET2 cells. Shannon Entropy was used for filter out invariant miRNAs or genes in the expression datasets. Entropy is a measure of the uncertainty associated with a random variable and in particular Shannon entropy quantifies the expected value of the information contained in different type of data.

4.10. New miRNA target prediction

The prediction of target genes of novel miRNAs, discovered by small RNA deep sequencing constitutes one of the final parts of a complex analysis employing for data handling and analysis summary in a flow-chart outline of study procedures (Figure 9).




Figure 9. Computational pipeline. A computational pipeline was set up using the Scons build tool (<http://www.scons.org/>) as skeleton. It includes third party libraries and programs and in house developed code and aims to analyze in a reproducible way short RNA sequencing data using up to date metadata from human genome sequence and miRBase (<http://www.mirbase.org/>). As shown in Figure S1, the pipeline includes raw data pre-processing, different filtering steps before and after mapping to reference sequences, as well as methods for known miRNAs quantification, isomiR characterization, and for miRNA and other short RNA discovery.

Genes target of new miRNAs were predicted by using TargetScan run locally using as input new miRNA sequences and the set of 3'UTR sequences of all human transcripts and orthologs in 23 species (TargetScan database v5.2). TargetScan groups miRNAs (intra- and inter species) in a family if they have conserved 8mer and 7mer sites representing the seed

region, required by the prediction algorithm. For each novel miRNA, a family was created aggregating to all known miRNAs the novel miRNA satisfying a custom similarity condition. Specifically, for each novel miRNA we performed a pair-wise alignment with all known miRNAs, using ClustalW2 algorithm, from above-mentioned species set. If the number of matches between the 5' regions of miRNA pairs exceeded the half-length of the shorter miRNA minus 3, the novel and the known miRNAs were included in a custom family. The process was repeated iteratively. Then for each custom family we performed a multiple alignment with ClustalW2 to find the common substring of 7nt in the 5' of all miRNAs sequences, which was used as seed sequence for target predictions.

5. Results

5.1. Identification of microRNA expression patterns and definition of a microRNA/mRNA regulatory network in distinct molecular groups of multiple myeloma

Multiple myeloma (MM) is a malignant proliferation of bone marrow (BM) plasma cells (PCLs), characterized by a profound genomic instability involving both numerical and structural chromosomal aberrations of potential prognostic relevance.¹ Nearly half of MM tumors are hyperdiploid (HD) with multiple trisomies of nonrandom odd-numbered chromosomes and a low prevalence of chromosomal translocations involving the immunoglobulin heavy chain (IGH) locus at 14q32 and chromosome 13 deletion¹; the others are nonhyperdiploid (NHD) tumors often showing chromosome 13 deletion, 1q gain, and IGH translocations with the most frequent partners being 11q13, 4p16, 16q23, 20q11, and 6p21. The deregulation of at least one of the cyclin D genes is observed in almost all MM cases and, in combination with recurrent IGH translocations, has been proposed for a molecular classification of MM called translocation/cyclin (TC) classification. The occurrence of specific transcriptional patterns associated with the molecular subgroups and major genetic lesions of MM has been extensively described in several studies by us and others (Biasiolo et al., 2010; Lionetti et al., 2009).

5.1.1. Global miRNA expression profiling in MM patients

MiRNA profiles were analyzed by high-density microarrays, specific for 723 human miRNAs, in 40 patients representative of the 5 TC groups (supplemental Table S 1), and in PCLs from 3 NCs. To determine whether global miRNA profiling could distinguish the molecular groups, we performed an unsupervised analysis using conventional hierarchical agglomerative clustering: the 43 samples were described by 74 miRNAs whose average change in expression levels varied at least 2-fold from the mean across the dataset. The most striking finding was that all of the TC4 patients were tightly clustered (Figure 10, gray cluster, $P < .001$), as were 4 of 5 TC5 cases (red cluster, $P < .001$). The TC2 cases were partially grouped (blue cluster, $P < 0.005$), whereas the TC1 and TC3 samples were scattered along the dendrogram. The NCs were clearly grouped in a distinct sub-branch.




Figure 10. Unsupervised analysis of miRNA expression profiles. Hierarchical clustering of the samples using the 74 most variable miRNAs (patients in columns, miRNAs in rows). The color scale bar represents the relative miRNA expression changes normalized by the standard deviation. The patients' molecular characteristics are shown above the matrix; n indicates unavailable information. Specific characteristics are enriched in colored sub-branches.

Next, multiclass analysis allowed identifying a set of 26 miRNAs showing highly significant differential expression (at q value = 0) across the 5 TC groups (Table 1).

Table 1. List of the 26 differentially expressed miRNAs identified by a high stringent supervised multiclass analysis between TC1, TC2, TC3, TC4, and TC5 MM groups (SAM, q-value 0). The chromosome cytoband at which the corresponding miRNA gene/s is/are localized is indicated. miRNAs are ordered according to the SAM *score(d)*. The *contrast* value for each miRNA in each class is also shown (positive score means positive correlation)

miRNA	miRNA gene/s localization	Score(d)	contrast-score 1	contrast-score 2	contrast-score 3	contrast-score 4	contrast-score 5
miR-125a-5p	19q13.33 [§]	0.7472	-1.4968	-1.8431	-1.7395	8.1205	-1.8574
let-7e	19q13.33 [§]	0.6708	-1.2939	-1.4103	-1.5334	6.4867	-1.1717
miR-99b	19q13.33 [§]	0.4704	-1.3015	-1.2546	-1.2724	5.8095	-0.9912
miR-150	19q13.33	0.3609	-0.7045	-0.6055	-0.4235	-0.5503	4.0117
miR-133b	6p12.2	0.2887	-0.5039	-0.3723	-0.5199	-0.5128	3.3054
miR-99a	21q21.1 [§]	0.2812	0.1671	-1.2936	-0.7954	0.9321	2.4131
miR-133a	18q11.2/20q13.33 [§]	0.2756	-0.7064	0.2715	-0.9625	-0.6040	3.3067
miR-222	Xp11.3 [§]	0.2625	-1.1590	1.0105	-0.4665	1.5522	-1.2681
miR-361-3p	Xq21.2	0.2482	1.7843	-1.0305	-0.9277	0.2793	0.1283
miR-221	Xp11.3 [§]	0.2441	-1.0911	0.5539	-0.2468	1.7780	-1.1887
miR-155	21q21.3	0.2423	-0.3002	-0.3749	-0.3554	-0.5491	2.6985
miR-221*	Xp11.3 [§]	0.2394	-0.9400	0.8958	-0.6144	1.5611	-1.1791
miR-874	5q31.2	0.2340	-0.8797	1.6302	0.1426	-0.8693	-0.7167
miR-125b	11q24.1/21q21.1 [§]	0.2267	-0.1313	-1.0237	-0.4915	0.8975	1.9118
miR-582-5p	5q12.1	0.2163	1.8273	-0.7122	-0.6474	-0.4508	-0.0684
let-7c	21q21.1 [§]	0.2155	0.1471	-0.9872	-0.6295	0.7477	1.7960
miR-1	20q13.33 [§] /18q11.2	0.2124	-0.4974	-0.1322	-0.6193	-0.5520	3.0473
miR-155*	21q21.3	0.2004	-0.1358	-0.4634	-0.4272	-0.3900	2.4862
miR-365	16p13.12/17q11.2	0.1996	0.2296	-1.0822	-0.4609	1.2668	0.8072
miR-1237	11q13.1	0.1968	-0.4815	1.4353	-0.6621	-0.6048	0.0346
miR-512-3p	19q13.41	0.1950	-0.3898	1.4555	0.1524	-0.6234	-1.6107
miR-940	16p13.3	0.1943	-0.7961	1.3778	-0.2156	-0.3388	-0.4601
miR-30e*	1p34.2	0.1943	1.5317	-0.9238	-0.3565	-0.2639	0.1017
miR-34b*	11q23.1	0.1921	-0.3151	-0.2336	-0.3820	-0.3134	2.1606
miR-933	2q31.1	0.1897	-0.4687	1.4930	-0.5137	-0.6568	-0.2981
miR-1226*	3p21.31	0.1883	-0.9248	1.0605	0.7737	-0.9275	-0.5508

As shown in Figure 11A, all of the TC groups except TC3 were characterized by the up-regulation of specific miRNAs. In particular, 10 (38%) miRNAs (miR-150, miR-133b, miR-99a, miR-133a, miR-155, miR-125b, let-7c, miR-1, miR-155*, and miR-34b*) were expressed at higher levels in TC5 than in the other classes, 7 (27%) in TC4 (miR-125a-5p, let-7e, miR-99b, miR-222, miR-221, miR-221*, and miR-365), 6 (23%) in TC2 (miR-874, miR-1237, miR-512-3p, miR-940, miR-933, and miR-1226*), and 3 (11%) in TC1 (miR-361-3p, miR-582-5p, and miR-30e*). Notably, miR-125a-5p, let-7e, and miR-99b, which were associated with the highest scores in the supervised analysis and

overexpressed specifically in the TC4 samples, belong to a cluster at 19q13.33, whereas mir-99a, let-7c, and mir-125b-2, highly expressed in the TC5 cases, belong to a paralogous cluster at 21q21.1. Figure 11B shows the 40 MM samples clustered according to the expression profiles of the 26 miRNAs, suggesting their capacity to drive TC distribution into separate branches. To test the correctness of the obtained signature and its capability to discriminate the 5 TC groups, we additionally tested the predictive power of the 26 miRNAs using linear discriminant analysis for classification of multivariate observations. The procedure led to confirm the accuracy of the identified signature, at a percentage of an overall classification rate of 89.3%: specifically, all TC1, TC4, and TC5 samples were classified correctly, whereas TC2 and TC3 cases showed a misclassification error of 32.8% and 11.1%, respectively.




Figure 11. Identification of miRNA signatures characterizing TC classes. (A) Heatmap of the differentially expressed miRNAs in MM patients stratified into the 5 TC groups. (B) Dendrogram of the 40 MM samples clustered according to the expression profiles of the 26 miRNAs.

We also investigated the differential miRNA expression on the basis of the occurrence of other recurrent chromosomal alterations, such as 1q gain and 13q and 17p deletions, and identified several differentially expressed miRNAs, none of which was located in the involved chromosomal region. Similarly, comparison of the HD and NHD cases revealed a set of up-regulated miRNAs only in the latter. Some of the miRNAs identified in these analyses were the same as those found in IGH-translocated patients, in all likelihood because of their representativeness within 1q gain, del(13), del(17), and NHD cases (Figure 12).




Figure 12. Identification of miRNA signatures characterizing distinct MM genetic subgroups. Supervised analyses identifying the miRNAs that are differentially expressed in MM patients harboring: (A) gain/amplification of the 1q arm, (B) del(13q14), (C) deletion of 17p, and (D) hyperdiploidy.

5.1.2. Integrative analysis of miRNA/mRNA expression and reconstruction of a regulatory network in MM

The integrative analysis of miRNA/mRNA expression profiles allows reconstructing a network of functional interactions occurring in MM from the panel of potential regulatory relationships predicted from sequence information. Our integrative approach assumes that the final effect of a truly functional interaction between a miRNA and its predicted mRNA targets can be seen as a pair of anticorrelated expression profiles. Thus, the set of MiRanda predicted targeting relationships was refined selecting those more strongly supported by the miRNA and mRNA expression data. The entire procedure led to the identification of 23 729 regulatory relationships, namely, anticorrelation, involving 628 miRNAs and 6435 predicted target genes, as approximately 47% of the genes associated

with an expression profile were not targets of any of the considered miRNAs and 93 miRNAs (13%) were not significantly anticorrelated with any target gene. The data from the integrative analysis were used to reconstruct a bipartite direct miRNAs/mRNAs regulatory network. The number of target genes per miRNA ranged from 1 to 440 (average, 34; mean, 3.7 miRNAs per gene). Various subnetworks can be derived from the global identified network, as those accounting for the targeting relationships of specific miRNA signatures associated with distinct TC groups.




Figure 13 Probably functional regulatory effects (represented by direct edges) of miRNAs up-regulated in t(4;14) cases (green nodes) to their target genes (orange nodes). The network-based frame allows visualization of possible post-transcriptional co-regulated groups of genes and of groups of miRNAs sharing one or more target genes.

Figure 13 reports the subnetwork of the t(4;14) miRNA signature, i.e., one of the most consistent and specific subgroups of our dataset. The network of t(4;14) consists of 7 miRNAs and 289 anticorrelated targets, with the number of targets per miRNA ranging from 1 to 113, and approximately 29% of the genes being targeted by at least 2 miRNAs. Interestingly, 3 genes are commonly regulated by 5 miRNAs (CBFA2T2, core-binding factor, runt domain, α subunit 2, translocated to, 2; PPP1R16B, protein phosphatase 1,

regulatory inhibitor subunit 16B; and GOSR2, Golgi SNAP receptor complex member 2). Functional enrichment analysis of anticorrelated targets revealed various overrepresented biologic processes, including chromosome segregation, protein polyubiquitination, cell cycle regulation, and unfolded protein response. Interestingly, a comparison between the identified supported miRNA target genes and mRNAs down-regulated in the t(4;14) cases (as identified in a larger proprietary dataset of 132 MMs, data not shown) highlighted that the miRNA targets were significantly enriched in down-regulated genes ($P < 0.001$). Similarly, subnetworks were derived considering the sets of miRNAs differentially expressed in TC5 and TC1 groups (supplemental Table S 2).

5.1.3. Critical analysis of transcriptional and post-transcriptional regulatory networks

Network analysis has emerged as a powerful approach to understand complex phenomena and organization in social, technological and biological systems. In particular, it is increasingly recognized the role played by the topology of cellular networks, the intricate web of interactions among genes, proteins and other molecules regulating cell activity, in unveiling the biological mechanisms underlying the physiological states of living organisms. Critical analysis of network components has been applied to inspect the transcriptional and post-transcriptional regulatory networks reconstructed from mRNA and microRNA expression data of multiple myeloma (MM) samples. Specifically, the importance of a gene as a putative regulatory element has been assessed calculating the drop in the network performance caused by its deactivation instead of quantifying its degree of connectivity.

ARACNe inferred a transcriptional network with 9666 nodes (i.e. genes) and 86846 edges (i.e. interactions) from the MM158GE dataset. The topological characteristics of the network are reported in Table 2, in terms of number of nodes, number of edges, maximum k_{max} and average k_{mean} connectivity (k being the degree of a node, i.e. the number of its interactions), diameter (representing the maximum value of d_{ij}) and global and local efficiencies.

Table 2. Metrics of transcriptional and post-transcriptional networks

NETWORK TYPE	Nodes (M)	Edges (K)	k_{max}	k_{mean}	Diameter	E_{glob}	E_{loc}
Transcriptional	9666	86846	219	17.96	8	0.279	0.150
Post-transcriptional	6435	909324	1811	282.62	8	0.611	0.866

The connectivity distribution shows a power-law tail suggesting that the underlying structure of the network is scale-free (Figure 14A). At low connectivity values ($k < 11$), the degree distribution loses its linear progression probably as a consequence of the limited number of genes. The relationship between the average connectivity k_{nn} of the neighbors of a node and the node connectivity suggests an assortative behavior of the network, i.e., the nodes tend to connect with nodes with a similar connectivity thus partly implying a hierarchical structure of the network (Figure 14B). Ranking the nodes according to their connectivity allowed identifying 27 hubs, i.e. genes with more than 100 interactions (data not shown). The miRNA-mRNA integrated analysis resulted in a post-transcriptional gene network with 6435 nodes (genes) and 909324 weighted edges. The network was reconstructed first refining the predicted targeting relationships of MiRanda through the selection of those predictions more supported by miRNA-mRNA expression data (the 3% most highly anti-correlated miRNA-gene pairs). This corresponded to 23729 regulatory relations involving 692 miRNAs and 6,435 target genes. It's worth noting that about 48% of genes associated to an expression profile resulted not to be real target of any considered miRNA and 9 miRNAs were not detected as sufficiently active on any target gene. Then, the remaining 692 miRNAs and 6,435 target genes were employed to reconstruct a bipartite directed miRNAs-mRNAs regulatory network, representing the probably functional regulatory effects of all these miRNA to their targets in MM. The number of target genes per miRNA ranges from 1 to 440 (average 33.3 with a mean value of 3.7 miRNAs per gene). Finally, a weighted post-transcriptional network of 6435 genes was extracted from the bipartite miRNA-mRNA regulatory network with the weight of an edge representing the number of functional interactions with microRNAs shared by the couple of connected genes. The topological characteristics of the network are reported in Table 1. Similarly to the transcriptional network, the connectivity distribution and the relationship between average connectivity k_{nn} of the neighbors of a node and the node connectivity suggest a scale free, assortative structure (Figure 14C and Figure 14D).

The critical nodes of both the transcriptional and post-transcriptional regulatory networks have been determined by the static analysis of error and attack tolerance. The drop in the network efficiency caused by the node removal (i.e., the node relevance r_α as defined in Eq. (8)) has been used as the criteria to determine the importance of a node. The critical analysis has been applied to the transcriptional network, to the post-transcriptional one, and, for testing the robustness of results, to a random graph (Crucitti et al., 2003). The random network has been constructed starting from an initial condition of M nodes and no edges and then adding K edges between pairs of randomly selected nodes, where M and K were the same as in the transcriptional network.




Figure 14. Connectivity properties of transcriptional (A. and B.) and post-transcriptional (C. and D.) networks. A. Connectivity distribution $P(k)$ of nodes with a specific number of incident edges (degree of connectivity k) in the transcriptional network. The connectivity distribution shows a power-law tail suggesting a scale-free structure of the network. B. Relationship between the average connectivity $\langle k_{nn} \rangle$ of the neighbors of a node and the node connectivity k . The linear trend suggests an assortative behavior of the transcriptional network. C. Same as A. for the posttranscriptional network. D. Same as B. for the post-transcriptional network.

Figure 15A and Figure 15B show the global efficiency for the transcriptional scale-free network and for the random graph (both with $M=9666$ nodes and $K=86846$ edges) as functions of the number of removed nodes through efficiency-based attacks (i.e., attacks performed removing nodes with the highest efficiency; red line) and random removals (errors; black line). The true transcriptional network shows a different behavior with respect to attacks and errors (Figure 15A). The removal of $\sim 30\%$ of nodes in a targeted way (attack) reduces the network efficiency to about half the initial value and removing $\sim 60\%$ of the nodes destroys completely the system. Instead, when removing nodes randomly (error), the drop of the network global efficiency shows a linear dependency with the number of removed nodes and even for high value of removals ($>60\%$) the system maintains a considerable efficiency (Figure 15C). The fact that removing specific nodes causes a rapid drop in the capability of the system to communicate further supports the scale-free structure of the regulatory graphs and proves the existence of a discrete number of critical components, i.e. of nodes responsible for the specific structure of the network. As far as the random graph is concerned (Figure 15B and Figure 15C), differences of

tolerance to attacks and to errors are much less pronounced. In this case, in fact, there is no substantial variability in the efficiency and the removal of a node in a targeted or in a random way produces similar, though not equal, behaviors.




Figure 15. Global efficiency $E(G)$ as a function of the number of removed nodes. In both the cases, the graphs were composed of $M=9666$ nodes and $K=86846$ edges and the node removal simulated by errors (black line) and efficiency-based attacks (red line). A. Transcriptional network generated by ARACNe using gene expression data from the MM158GE dataset. B. Random graph. C. Difference of tolerance to attacks and to errors (i.e., difference between the drop in efficiency caused by efficiency-based attacks and error node removals) for true transcriptional (unbroken line) and the randomly generated networks (broken line).




Figure 16. Comparison between the rank according to node degree k (rank degree) and the rank given by criticality r_c (rank criticality) for the nodes of A. random, B. transcriptional, and C. post-transcriptional networks.

The analysis of critical components revealed that, in the transcriptional and post-transcriptional networks, critical nodes are not limited to hub genes and that also genes with a limited number of connections can be critical for the structure of the network. Figure 16 reports the comparison between the node rankings calculated according to node degree (k) and node criticality (r_c) in the random, transcriptional, and post-transcriptional networks.

As expected, this comparison indicates that i) in random network there is no significant

difference between node degree and node criticality (Figure 16A) and ii) the vast majority of hub genes are critical nodes, i.e., the nodes whose removal causes a large drop in global efficiency correspond to the most connected genes (Figure 16B and Figure 16C). Nevertheless, there exist a fraction of nodes that are characterized by a higher criticality value than expectable according to their degree. These nodes, even if characterized by a low node degree, are indeed critical and would have been disregarded as putative regulatory targets due to their limited number of connections. For instance, in the MM transcriptional network, the B cell linker gene (BLNK) emerged as one of the most critical genes although being connected to only 34 other nodes (as compared to hubs characterized by >100 links). BLNK is known to be involved in normal B-cell development and deficiency in this protein has been shown in some cases of pre-B acute lymphoblastic leukemia, suggesting its putative role as a tumor suppressor gene. A search in the network for putative targets of BLNK allowed identifying 8 genes that, once ranked according to the mutual information, indicated CDKN1B (cyclin dependent kinase inhibitor, p27 kip1) as the most strongly connected target. This interaction was confirmed by the same analysis conducted on another MM dataset (Chng et al., 2007); data not shown) and by recent experimental evidences, which reported p27 kip1 induction by BLNK through JAK3 (Nakayama et al., 2009). Unfortunately, JAK3 was not present in the datasets used for the network reconstruction and thus this evidence could not be further confirmed. To integrate the results of the critical analyses, a list of 5145 non redundant genes/nodes represented in both transcriptional and post-transcriptional networks was compiled and used to select, in each network, the top 1% critical nodes and the top 1% most connected nodes (hubs). The intersections of such lists could help clarifying the role of nodes, which are critical in terms of network efficiency, although being not highly connected (Figure 17). In particular, when comparing the lists of top 1% critical genes for the two networks, 2 genes emerged as critical for both transcriptional and post-transcriptional regulation, i.e. CHRNA4 (cholinergic receptor, nicotinic, alpha 4) and TMX4 (thioredoxin-related transmembrane protein 4), both known to be expressed in B cells and the latter involved in B cells activation and in cancer. Interestingly, CHRNA4 shares, as post-transcriptional regulators supported by expression data, two miRNAs (i.e., hsa-miR-15a* and hsa-miR-30c-1*) that regulate also ELAVL3 and MLXIPL, two genes which are hubs and critical in the transcriptional and post-transcriptional network, respectively. Both miR-15a and miR-30c are differentially expressed in peripheral blood cells (Merkerova et al., 2008) and the presence of a MYB/miR-15a auto-regulatory feedback loop is of potential importance in human hematopoiesis (Zhao et al., 2009). In particular, miR-15a expression inversely correlates with MYB expression in cells undergoing erythroid differentiation and the overexpression of miR-15a blocks both erythroid and myeloid colony formation in-vitro.




Figure 17. Venn diagram of critical and hub nodes in transcriptional and post-transcriptional networks. Venn diagram showing the intersections of four sets: CR TR (top 1% critical nodes in the transcriptional regulatory network), HUB TR (1% most connected nodes, hubs, in the transcriptional regulatory network), CR PTR (top 1% critical nodes in the post-transcriptional regulatory network) and HUB PTR (1% most connected nodes, in the post-transcriptional regulatory network).

5.2. miRNAs modulation in colon cancer and metastasis development and its impact on regulatory networks and pathways

The association between abnormal expression levels of miRNAs colon cancer has been mainly demonstrated in primary tumors. More recently ability of specific miRNA to promote or inhibit metastasis has been reported. Non-overlapping sets of oncomirs, tumor suppressor miRs and metasta-miRs have been found or proposed by different studies.

5.2.1. miRNA and genes expression in normal colon, colon carcinoma and liver metastasis samples

Out of 55 patients, evaluable samples from 46 patients, whose characteristics are described in Table 3, was obtained. For each patient, colon primary tumor (T), adjacent normal tissue (N), and tissue from liver metastases (M) were collected and used for exon and miRNA chips hybridization, respectively.

After quality control analyses, a total of 78 and 80 samples constituted the final miRNA array datasets for miRNA and gene respectively

miRNA dataset comprise 23 N, 31 T, 24 M, including 24 samples pertaining to 8 cases with three samples per patient (primitive tumor, metastasis and normal mucosa from the same patient). Thus we obtained expression profiles of 847 miRNAs in 78 samples (normal colon, colon carcinoma and liver metastasis samples). Only miRNAs detected in

more than 20 samples were considered for the following analyses obtained a total of 309 miRNA considered for the following analyses.

Gene dataset comprise 23 N, 30 T, 27 M, including 27 samples pertaining to 9 cases with three matched samples (primitive tumor, metastasis and normal mucosa from the same patient). Out of 22,517 genes expression profiles obtained in 80 samples only a subset was selected, according to expression level and informativity. Therefore by filtering out 30% of genes with poor expression profile variability, calculated using Shannon entropy as a variability measure, 15,761 genes with moderately to highly variable expression profile were considered for subsequent analyses.

Considering miRNAs and genes expression experiments, we obtained a set of 77 samples (23N, 29T, 25M) with miRNAs and genes expression data from the same biological sample.

Table 3. Patient data.

CHARACTERISTICS	
No of patients (n)	46
Age (years, mean \pm s.d.)	60,7 \pm 10,2
Sex	
Female	17
Male	29
Localization of tumor	
Cecum	3
colon ascendens	8
colon transversum	2
splenic flexura	1
colon descendens	3
colon sigmoideum	17
Rectum	9
Colon	3
Stage	IV
Metastasis	
Synchronous	39
Metachronous	7

Table 4. Sample set description for miRNA and gene array datasets. Both for miRNA and gene array samples, column three indicates the number of patients for which we obtained paired data for different tissue types combinations; last column reports the total number of samples for each tissue type.

Array	Match type	Number of patients	Tissue type	Number of samples
miRNA	N-T-M	8	N	23
	N-T	7		
	T-M	8	T	31
	M-N	2		
	N	6	M	24
	T	8		
	M	6		
	Total	45	Total	78
Genes	N-T-M	9	N	23
	N-T	5		
	T-M	8	T	30
	M-N	3		
	N	6	M	27
	T	8		
	M	7		
	Total	46	Total	80

5.2.2. Informativity of miRNAs and genes for samples classification and variability in the N-T-M transitions

Heatmap and samples dendrograms in Figure 18 show the results of unsupervised hierarchical cluster analysis performed in parallel using selected microRNAs and genes, respectively.

According to both miRNAs and genes expression data, normal samples cluster together and are relatively well separated from tumor/metastatic samples. miRNA profiling has a higher capability to separate T and M, that partially mix in both cases. We also evaluated the distance of samples belonging to the same patient. The color-coding used for heatmap columns annotation refers to samples matching per patient: triples and couples of samples from the same patient are shown in the same color. Apparently, a considerable per-patient pairing of T and M samples is observed in both dendrograms, which is more evident when samples are classified according to gene expression data. (20% and 28% of per-patient sample pairing, in miRNA and gene heatmap respectively). In other words, in 25% of patients, the M tends to be more similar to the T from which it derives, rather than to the M samples of other patients. Besides, the few N samples cluster together with T and M samples derived from the same patient.




Figure 18 Sample classification and heatmap based on 309 miRNAs (top panel) and 15,761 genes (bottom panel) expression profiles. In both panels, color-coding of samples reported in three different lines refers to different information. First line indicates tissue type (normal colon, primary tumor and metastasis) as shown in the legend. The two lines below indicate the per-patient matching of samples, separately for triples (upper line) and couples (lower line) of samples from the same patient (i.e. samples from the same patient are in the same color).

To further explore miRNA expression variability in the two transitions from normal tissue (N) to primary tumor (T), and from tumor to metastasis (M), we considered the number of miRNAs and of genes resulting up-, down-modulated or invariable, using a simple fold-change 1 criterion, per each contrast, applied to mean values per miRNA (per gene) calculated on all available data, for the three sample classes.

Figure 19 shows two alternative patterns of miRNA and gene expression variation in the N-T-M progression: i. miRNAs/genes that are up- or down-modulated in the N-T transition and then remain basically stable in the T-M transition; ii. miRNAs/genes invariant in the N-T transition, but modulated in the T-M transition. This suggests that most expression variation takes place in the N vs T transition. Almost 100% of miRNAs modulated in the N-T transition are not modulated after metastasis development, where 4% of invariant miRNAs in the N-T transition are modulated in the metastasis phase. 93% of genes modulated in the first transition remain invariant in the second, so a not-negligible fraction of genes is modulated in both transitions. On the other hand, the percentage of genes modulated only in the T-M transition is 0.2%.




Figure 19. miRNA and gene expression variation in the N-T-M progression. Figure shows two patterns of miRNA and gene expression variation in the N-T-M progression: i. miRNAs/genes that are up- or down-modulated in the N-T transition and then remain basically stable in the T-M transition; ii. miRNAs/genes invariant in the N-T transition, but modulated in the T-M transition.

5.2.3. Differentially expressed miRNAs

Differentially expressed miRNAs (DEMs) were identified in two different types of pairwise group comparisons. First two-class unpaired test was performed to identify differences in miRNA expression between groups of normal mucosa (N), primary colon tumor (T) and liver metastases (M) samples (Table S 3). The cutoff for significance is determined by a

tuning parameter delta, chosen based on the false positive rate (FDR). We considered significant a FDR lower than to 0.01. Second two-class paired test compares groups of samples matched per patient (e.g. N vs T samples matched per patient) with FDR threshold lower 0.01 (Table S 4). The size of considered datasets in the two types of comparisons is considerably different. The whole set of samples with miRNA expression data is considered in unpaired tests (e.g. all N vs all T samples), while different samples subsets matched by patient are used for different paired comparisons (e.g. the subset of N vs T samples, with N and T coming from the same patient).

Respectively 62, 63 and 11 DEMs were identified in T vs N, M vs N and M vs T comparisons, using the unpaired but large dataset. Besides, 34, 38 and 5 DEMs were found respectively in T vs N, M vs N and M vs T comparisons, using paired but smaller datasets. Figure 20 top panels summarize, both for paired and unpaired design, the numbers of DEM per contrast, and intersections thereof.




Figure 20. Venn diagrams of intersections among DEM obtained in different contrast and with different methods.

The significantly (about six times) lower number of DEMs observed in the M vs T unpaired contrast, as compared with corresponding T vs N and M vs N contrasts, indirectly indicates the similarity between tumor and metastatic tissue. Nevertheless, considering paired M vs T dataset, at least five miRNAs expression is significantly different between primitive tumor and the corresponding liver metastasis of the same patient. The upper part of Figure 3 shows DEM common paired and unpaired design, for the three contrasts. It is worth note that the comparison of paired and unpaired contrasts between the same tissue types is

mainly descriptive, since a direct comparison of absolute DEM numbers is challenged by different sample sizes, affecting calculations of differential expression p- and q-values of. However, the majority of miRNAs resulting DEM according to the paired test were found also with unpaired test conducted on the larger dataset. A group of 53 miRNAs were common in at least two comparisons. Among them, 25 were under- and 26 over-expressed. Two miRNAs do not follow the same trend in the comparisons: miR-100 and mir-99a, both putative tumor suppressors, are under-expressed in T vs N comparison, and over- expressed in M vs T comparison. miR-10b, that is DEM in the three comparisons, decreases gradually

in the N, T and M series.

5.2.4. RT-PCR miRNA expression validation

A key issue for evaluating results robustness is the agreement of expression estimations obtained by array and qRT-PCR techniques. The goodness of array-based results was tested with two strategies using: i. qRT-PCR on the same RNA samples and ii. on an independent set of patients. Quantitative RT-PCR analysis was performed using TaqMan MicroRNA Assays (Applied Biosystems Technologies, Milan, IT) in all 78 samples constituted the final miRNA array dataset three times in triplicate. We used Shannon entropy, a measure of the information content of expression profiles (i.e. of profile variability) and identified miR-200c as a trustable control with minimum entropy and detectable expression used for normalize miRNA expression results obtained by qRT-PCR.

So the expression measure of 5 miRNA, three down-regulated miRNA (has-miR-150, hsa-miR-10b, hsa-miR-146a) and two up-regulated (has-miR-210 and has-miR-122).

miR-150 is the most down-regulated miRNAs in T vs N comparison, whereas miR-10b since it is DEM in all the three contrasts. miRNA-122 and miRNA-146a are DEM in comparison M vs T. miR-122, highly liver-specific and important in hepatitis C virus infection, cholesterol metabolism and hepatocellular carcinoma (Filipowicz and Grosshans, 2011), appeared to be strongly up-regulated in M vs T. Instead miR-146a is the most down-regulated miRNA in the same comparison. miR-210 was selected because up-regulated in M vs T and M vs N comparisons and a robust target of hypoxia-inducible factor, and its overexpression has been detected in a variety of cardiovascular diseases and solid tumors. High levels of miR-210 have been linked to an in vivo hypoxic signature and associated with adverse prognosis in cancer patients (Huang et al., 2010).

For the first strategy, we correlated the qRT-PCR data ($2^{-\Delta Ct}$ as expression estimation) for each miRNA with the corresponding expression level measured by microarray experiments using Spearman rank correlation, that is robust against outliers. The correlation coefficients were all significantly positive and significant ($P < 0.01$).

Furthermore, miR-150 and miR-146a were also tested in an independent set of 7 patients which matched tissue and the results confirmed data obtained with microarray data.

The expression level of miR-122, a highly liver-specific miRNA, was significantly different between primary and liver metastatic tumors (7.9 Fold Change) suggesting the effect from normal hepatocyte contamination. In order to verify this hypothesis, miR-122 expression was evaluated in samples where normal colon and liver tissue had been mixed in different proportions. Results obtained in RT-PCR confirmed the contamination effect, since a combination including more than 80% of colon tissue still revealed the expression of miR-122.

5.2.5. miRNA and genes expression profiles integration allows the identification of most probable miRNA targets

The combined analysis of target prediction and of expression profiles in the same set of samples of 305 miRNAs and 12,748 genes, with variable expression profile, allowed us to reconstruct post-transcriptional regulatory networks describing most probable regulatory interactions and circuits active in transitions characterizing tumor origin and progression. With the selected FDR threshold, 3,078 miRNA/target relations, predicted by mirSVR, resulted to be supported by expression data analysis, i.e. by significant anticorrelation of miRNAs and predicted target genes expression profiles. These supported relations were 3,078 and involved 117 miRNA and 1,423 target genes (corresponding to about 1% of top anticorrelated miRNA-target predicted pairs). Among supported relationships, 2,690 resulted to be based on predicted target sites that are conserved across species. The number of supported target genes per miRNAs ranges from 1 to 216 (hsa-miR-195), with an average value of 26.3. About one half of genes are supported target of only one specific miRNAs, whereas other genes appear to be putatively regulated by up to 10 different miRNAs.

Moreover, it should be noticed that the whole group of supported target genes includes different subsets of DEGs, i.e. genes resulting significantly expressed in at least one of the considered contrasts.

5.2.6. Regulatory networks modulated in tumor and metastasis development

The intersection between the post-transcriptional network and miRNA differential expression analysis results induced different subnetworks, describing post-transcriptional regulatory circuits involving those miRNAs whose expression variation may be important for tumor development and evolution. As previously said, only 5 miRNAs appeared significantly modulated in the transition from tumor to metastasis, whereas the number of DEMs observed when comparing normal tissue with primary tumor and with metastasis was large. We reasoned that, in these cases, those DEM being moderately highly expressed in considered samples would be responsible for the majority of target repression. Moreover, for each the T vs N and M vs N a contrasts, we focused on those supported regulatory interactions involving DEM up- and down-regulated in each comparison with a $FC > 3$.

Post-transcriptional regulatory networks were reconstructed with miRNAs differentially expressed in the normal vs primary tumor comparison and their supported relations with target genes. In particular two networks were generated involving respectively 6 up-regulated (

Figure 21) and 17 down-regulated (Figure 22) miRNAs and all their target genes. The network relating 6 up-regulated miRNAs is smaller and a large fraction of genes appear to be regulated by hsa-miR-182.




Figure 21. Post transcriptional regulatory network of miRNAs up-modulated in T vs N contrast (FC>3). The bipartite network represents DEM up-modulated in the T vs N comparison (red triangles), supported target genes (circles) and their relations (gray dotted lines). Target genes being differentially expressed in the T vs N contrast are colored in blue, whereas other genes are shown in grey. The pink solid line outlines an experimentally validated relation.

The networks obtained by 17 down-regulated DEMs seems to regulate a number of targets in average about two times bigger than that observed for the whole set of considered miRNAs. As shown in the Figure22, a considerable fraction of supported target genes resulted significantly differentially expressed (DEG). This is more evident of the component involving up-regulated miRNAs, in which 62 down-regulated DEGs are supported target of up-regulated DEM (27% of supported targets). Few genes are supported target of more than one up-regulated miRNA.




Figure22. Post transcriptional regulatory network of miRNAs down-modulated in TvsN contrast (FC>3). The bipartite network represents DEM down-modulated in the TvsN comparison (green triangles), supported target genes (circles) and their relations (gray dotted lines). Target genes being differentially expressed in the TvsN contrast are colored in orange, whereas other genes are shown in grey. The pink solid line outline an experimentally validated relation.




Figure 23. Post transcriptional regulatory network of miRNAs modulated in MvsT contrast. The bipartite network represents DEM up- and down-modulated (red and green triangles, respectively) in the MvsT comparison, supported target genes (circles) and their relations (gray dotted lines).

Figure 23 represents the network involving five DEM observed in the M vs T contrast and their supported target genes. This network is small and consists of five unconnected components. No differentially expressed genes were observed among the supported targets on miRNAs differentially expressed in the tumor to metastasis transition.

5.2.7. *miR-182 control ENTPD5*

Among the interactions between miRNA and target genes detected in our regulatory network, miR-145–c-Myc and miR-182–ENTPD5 relationships were experimentally validated using RT-PCR.

Data from expression arrays indicated that c-Myc mRNA is up-regulated in T vs N samples anti-correlating with down-regulation observed for miR-145. We examined this expression profile by qRT-PCR confirming the miR-mRNA modulation in the transition from normal to primary tumor and metastasis. As in literature, even in our series miR-145 is down-modulated in primary tumor and in metastases, while c-Myc is up-modulated (Figure S 1).

ENTPD5, known also as PCPH proto-oncogene, belongs to the family of ectonucleoside triphosphate diphosphohydrolase enzymes that hydrolyze extracellular tri- and diphosphonucleosides and are components of cellular purinergic signaling.

The importance of the interplay between miR-182 and ENTPD5, is supported by their expression behavior that was investigated by qRT-PCR in a panel of 5 tumor cell lines of colon cancer. As shown in Figure 24B, higher expression of miR-182 and lower expression of ENTPD5 were observed in all tumor cell lines as compared to normal colon mucosa. This result not only confirms the microarray profiling data but also suggests a role of the anti-correlated relationship in conferring some advantageous property to the tumor cells. The functional relationship was further validated by Luciferase reporter assay in HEK293T cells transfected with construct containing the firefly luciferase gene fused to the 3'-UTR of ENTPD5 (pMIR-ENTPD5). When cells were co-transfected with hsa-miR-182, we observed a 50% reduction in luciferase expression as compared to cells transfected with a control plasmid ($P < 0.05$) (Figure 24A).




Figure 24. Luciferase reporter assay of the 3'UTR region of ENTPD5. The average relative light units (RLU) of six biological replicates are compared between control (HEK293T pMIR-ENTPD5), non-target siRNA (HEK293T pMIR-ENTPD5 non-target siRNA) and miR-182 overexpression (HEK293T pMIR-ENTPD5 miR-182). * $P < 0.05$.

5.2.8 miRNAs modulated KEGG pathways

For each considered contrast, KEGG pathways enriched in genes resulting supported target of differentially expressed miRNAs were identified. Significantly perturbed KEGG pathways ($p\text{-value} < 0.05$) were identified using two parallel strategies, implemented with the statistical procedure GAGE (Luo et al., 2009) for gene-set enrichment analysis, which takes into account gene expression variations in both directions. For the NT contrast we first identified those pathways enriched in genes target of DEMs whose expression change in considered comparisons. Then we identified those pathways enriched only taking into account DEGs target of DEMs. Results are partially but not totally overlapping. Some very interesting pathways, as “Cell cycle”, “Purine metabolism” and “pathways in cancer” are

found in both cases, whereas other as “P53 signaling” is identified by the first, less conservative strategy. On the other hand, “Wnt signaling” and “Colorectal cancer” pathways are found specifically enriched in DEGs target of DEMs (Table S 5).

5.3. microRNA expression in HTLV-1 infection and adult T-cell leukemia/lymphoma

Human T-cell leukemia virus type 1 (HTLV-1) infects approximately 20 million people worldwide. About 5% of infected individuals develop an aggressive malignancy of mature CD4+ T-cells termed adult T-cell leukemia/lymphoma (ATLL) or a progressive neurological disease termed tropical spastic paraparesis/HTLV-associated myelopathy (TSP/HAM)(Goncalves et al., 2010). The transforming potential of HTLV-1 is attributable primarily to the viral protein Tax, which, in addition to transactivating the viral promoter, affects the expression and function of cellular genes controlling cell turnover and chromosome stability(Saggiaro et al., 2009).

5.3.1. microRNAs with altered expression in ATLL cells

Expression of microRNAs in 7 ATLL samples was examined using microRNA-microarrays

Table 5.

Table 5. ATLL patient samples

Patient	Gender/age (years)	Diagnosis	WBC (cells/ μ l)	CD4+CD25+ (cells/ μ l)	% CD4+CD25+	Therapy
ATL1	M/48	Leukemia	40,500	31,646	78	RIT
ATL3	M/53	Leukemia	39,700	30,211	76	Zenapax
ATL5a	F/50	Leukemia	49,300	40,640	82	CHOP
ATL12	M/41	Leukemia	10,500	4,958	47	CVP
ATL14	M/34	Leukemia	90,600	84,715	94	None
ATL24	F/36	Lymphoma	6,680	1,486	22	CHOP
ATL32	M/54	Leukemia	34,400	26,595	77	None

Controls consisted of 4 sets of resting and stimulated CD4+ cells. Only miRNA with signal intensities in the upper 3 quartiles in at least 2 samples, corresponding to an expression value of 5.91, was selected, giving rise to a subset of 137 microRNAs. Unsupervised cluster analysis was performed on this dataset using SPSS software, with

Pearson correlation as metric and average clustering as linking method. Hierarchical cluster analysis performed using expression data for the 137 microRNAs indicated high heterogeneity among the ATLL patients, although all samples except PT 1 were more similar to resting CD4+ cells than to their stimulated counterparts (Figure 25).

microRNAs with a significant difference in expression in ATLL samples versus normal resting CD4+ cells, and in resting vs. in vitro-stimulated normal CD4+ cells were identified using the *samr* package for R software from Bioconductor, considering a false discovery rate threshold of 0.05; the lymphoma sample (#24) was omitted from this analysis. Statistical analysis revealed 21 downregulated microRNAs and 6 upregulated microRNAs in ATLL samples compared to resting CD4+ cells (

Figure 26).

Comparison of vitro-stimulated and resting CD4+ controls revealed 6 upregulated microRNAs and 6 downregulated microRNAs. Three of the downregulated microRNAs (miR-99a, miR-192 and miR-194) were also downregulated in ATLL cells compared to resting CD4+ cells.

qRT-PCR to detect miR-34a, found down-regulated in several solid tumors, in 10 ATLL samples and 11 resting CD4+ confirmed a 100-fold upregulation of miR-34a in ATLL samples. To our knowledge, this is the first description of upregulated miR-34a expression in a T-cell malignancy.




Figure 25. Cluster analysis of microRNA expression in ATLL samples and control CD4+ cells. Unsupervised cluster analysis was performed on ATLL samples (PT) and CD4+ controls [A,B,D,P; resting and in vitro-stimulated (S)] using microRNA expression data and SPSS software, with Pearson correlation as metric and average clustering as linking method.




Figure 26. Differentially expressed microRNA. microRNAs with a significant difference in expression in ATLL samples versus normal resting CD4+ cells, and in resting vs. *in vitro*-stimulated normal CD4+ cells. The analysis was performed on data from samples reported in panel A (excluding #24, a lymphoma) using the *samr* package for R software from Bioconductor, considering a false discovery rate threshold of 0.05.

5.3.2. microRNA target prediction

Integrative analysis, performed on TargetScan predictions (release 5.2), yielded a total of 755 supported anticorrelated relationships between gene and microRNAs, differentially expressed in ATLL cells, selected in those anti-correlated relations falling in the top 10% among all negative Pearson correlation coefficients. Restriction of the analysis to genes whose expression differed significantly in ATLL cells compared to resting CD4+ controls yielded a total of 465 genes regulated by 13 microRNAs. Within the network, only five differential expressed genes were anticorrelated with 2 upregulated microRNAs (miR-146a and miR-15b); the remaining 460 genes were anticorrelated with 11 downregulated microRNAs (let-7g, miR-101, miR-142-5p, miR-192, miR-193b, miR-194, miR-212, miR-26a, miR-29c, miR-30b, miR-31) (Figure 28). miR-193b and miR-31 had the highest numbers of potential targets (108 and 190, respectively).




Figure 27. Piechar of the mapping of enriched BP terms to respectively 20 main functional classes of GO biological process terms. Figure shows the mapping of enriched BP terms to respectively 20 main functional classes.

Enrichment analysis performed using GOSTATS R packages highlighted 109 genes (out of 460 present in the network) belong to the GO term “developmental processes”, enriched with a P-value of 0.0036. twenty-one genes belong to GO Term “growth” and 11 to “regulation of cell growth” (see Table S 6). Figure 27 shows the result of enriched GO terms group in the respectively 20 main functional classes of biological process GO terms. Moreover the most represented pathways according to KEGG (Kyoto Encyclopedia of Genes and Genomes) analysis of pathways (<http://www.genome.jp/kegg/>) using DAVID are “pathways in cancer”, “Wnt signaling pathway” and again “cell cycle”.




Figure 28. Post-transcriptional regulatory network involved differentially expressed miRNAs between ATLL and resting CD4+. Figure shows a total of 755 supported miRNA-gene relations. Blue and orange nodes represent down- and up-regulated miRNAs, respectively. Green and red nodes represent gene down- and up-regulated, respectively. Grey nodes are genes not differentially expressed in the considered comparison.

5.4. MAGIA, a web-based tool for miRNA and Genes Integrated Analysis

miRNAs can have multiple targets and that each protein-coding gene can be targeted by multiple miRNAs, it has been suggested that more than one third of human genes could be regulated by miRNAs. In this perspective, the networks of post-transcriptional regulatory relationships tend to have a highly complex nature. All computational approaches applied to predict miRNA targets are plagued by a significant fraction of false positives. This is caused not only by the limited comprehension of the molecular basis of miRNA–target pairing, but also by the context-dependency of post-transcriptional regulation. According to the increasing experimental evidences supporting the miRNA mechanism of target degradation rather than translational repression, the integration of target predictions with miRNA and gene expression profiles has been proposed to improve the detection of functional miRNA–mRNA relationships. Since miRNAs tend to down-regulate target mRNAs (Bagga et al., 2005; Lim et al., 2005; Wu and Belasco, 2008), the expression profiles of genuinely interacting pairs are expected to be anti-correlated. Integrative analysis can be performed adopting a variational Bayesian model (Huang et al., 2007b; Huang et al., 2007c), or by using a non-heuristic methodology based on the anti-correlation between miRNA and mRNA expression profiles.

Unfortunately, the combination of large-scale target prediction results obtained with different algorithms is not straightforward for most experimental researchers, whereas the integrative analysis of miRNA and gene expression profiles is complicated by the many-to-many nature of predicted relationships and target annotations to be considered.

Then MAGIA (miRNA and genes integrated analysis, freely available at <http://gencomp.bio.unipd.it/magia>) will be presented. This novel web tool allows integrating target predictions and gene expression profiles using different relatedness measures either for matched or un-matched expression profiles, using miRNA–mRNA bipartite networks reconstruction, gene functional enrichment and pathway annotations for results browsing (Sales et al., 2010).

5.4.1. MAGIA application and testing to a case study

As a benchmark case study we used the mRNA and miRNA expression profiles published by Fulci et al. (Fulci et al., 2009). In this study, the Authors investigated miRNA and gene expression profiles in a series of adult Acute Lymphoblastic Leukemia (ALL) cases. ALL is a heterogeneous disease comprising several subentities that differ for both immunophenotypic and molecular characteristics. In particular, T-lineage and B-lineage harboring specific molecular lesions have been considered by expression analyses.

In this example, we choose EntrezGene IDs, Pearson correlation measure and the intersection of TargetScan and PITA target prediction algorithms. A total number of 468 miRNA–mRNA interactions with absolute correlations >0.25 have been identified, 249 of these show negative while 219 show positive correlation coefficients. Among the 468 putative interactions 23 have an FDR value <0.1 .

Figure 29 shows, for the top 250 miRNA–target relationships most supported by expression data, the bipartite network and the corresponding list with hyperlinks to mirBase, EntrezGene, PubFocus, EbiMed and mir2disease, whereas for all predicted interactions, a link to an html table and to a tab delimited flat file Cytoscape compliant are given, as well as the link to the DAVID annotation tool for a number of interactions that can be defined by the user (default is set to 250).

In this example, the top 250 interactions include a total number of 81 different miRNAs and of 197 different genes. Pathways enrichment analysis, conducted on target genes and aiming at clarifying the role of miRNAs in terms of cell activities under post-transcriptional regulation, leads to highly relevant and interesting results: chronic myeloid leukemia is the KEGG most enriched pathway according to DAVID, followed by Wnt-signaling pathway, pancreatic cancer and ubiquitin mediated proteolysis. Chronic myelogenous leukemia is a biphasic disease, initiated by expression of the BCR/ABL fusion gene product in self-renewing, hematopoietic stem cells; among the 43 B-ALL patients used in the expression analysis 17 had a BCR/ABL rearrangement. On the other hand, the Wnt family of secreted glycoproteins regulates early B cell growth and survival (Qiang et al., 2003) and aberrant activation of the Wnt-signaling pathway has major oncogenic effects (Peifer and Polakis, 2000). Finally, the ubiquitin pathway plays a central role in the regulation of cell growth and cell proliferation controlling the abundance of key cell-cycle proteins. Increasing evidence indicates that unscheduled proteolysis of many cell-cycle regulators contributes significantly to tumorigenesis and is indeed found in many types of human cancers (Bashir and Pagano, 2003).

Among the top miRNA–gene anti-correlated interactions we found RALB (v-ral simian leukemia viral oncogene homolog B), a gene encoding a GTP-binding protein that belongs to the small GTPase superfamily and Ras family of proteins, highly associated to either let-7d ($r = -0.82$) and let-7c ($r = -0.71$). Recently RALA and RALB have shown to collaborate to maintain tumorigenicity through regulation of both proliferation and survival (Chien and White, 2003) while both let-7d and let-7c have been shown to be involved in the human acute promyelocytic leukemia (Garzon et al., 2007).




Figure 29. Screenshot of the MAGIA analysis results summary page, obtained with the ALL data case study analysis. The summary page reports the regulatory network corresponding to the 250 relations most supported by expression data and the corresponding details, as genes and miRNAs involved, with links to databases and text-mining tools. This is also the entry point to reach gene- or miRNA-centered pages, to carry out functional enrichment analysis and to download complete results.

hsa-miR-222 and let-7e have been recently found to be two of the most discriminant miRNAs markers between ALL and AML (Mi et al., 2007) and in our analysis have been found highly anti-correlated with respectively ETS1 (v-ets erythroblastosis virus E26 oncogene homolog 1) ($r = -0.58$) recently found to be involved in tumor development and progression (Hahne et al., 2009) and with p53 ($r = -0.51$) whose oncogenic role has been extensively studied in the last years(Hrstka et al., 2009).

Several other interactions have been reported by MAGIA, most of them including miRNAs and/or genes involved in tumor development and progression. Indeed, repeating the sample analysis with the same expression data and settings indicated above, but only for the 12 miRNAs reportedly differentially expressed across samples (Fulci et al., 2009) an interaction biologically relevant and validated (according to Diana Tarbase and miRecords), regarding hsa-let-7e and HMGA2 (high mobility group AT-hook 2 gene) is indicated by MAGIA at the first ranked position. While a complete investigation of biological relevance of all interactions reported by MAGIA is beyond the scope of this work, they validate the MAGIA integrative approach, the usefulness of the display of results and the discovery power of data analysis with this tool.

5.5. Impact of host genes and strand selection on miRNA and miRNA* expression

Dysregulation of miRNAs expression plays a critical role in the pathogenesis of genetic, multifactorial disorders and in human cancers. We exploited sequence, genomic and expression information to investigate two main aspects of post-transcriptional regulation in miRNA biogenesis, namely strand selection regulation and expression relationships between intragenic miRNAs and host genes(Biasiolo et al., 2011).

5.5.1. Microarray-based expression datasets analyses description

Table 6 shows details about microarray-based expression datasets considered for each different analysis performed in this study. An amount of five dataset was collected to obtain expression profiles of large numbers of known miRNAs, measured in many samples, representing fairly different biological contexts. They comprise four microarray-based datasets including matched miRNA and gene expression profiles, two regard blood cells (Multiple Myeloma and normal plasma cells samples (MM), Acute Lymphoblastic Leukemia samples (ALL)) whereas the other two regard parietal lobe cortex (normal and with in Alzheimer's disease, ALZ) and prostate (normal and cancer), and a fifth dataset, include miRNA only expression profiles in 8 different cancer types and corresponding normal tissues samples (MCN). The number of miRNAs represented in each expression

dataset is also indicated in Table 6.

We considered all mature miRNAs in miRBase, where 676 (corresponding to 869 mature sequences) were assigned to unique genomic locations whereas the remaining were discarded, since unmapped or corresponding to more than one different localization per miRNA.

Table 6. Schema of expression datasets used for different levels of analyses in this study. Among five expression datasets obtained by microarray technology, four comprise matched miRNA and gene expression, whereas one includes only miRNA expression data.

		DATASETS					
		Matched miRNA and genes expression data				miRNA-only expression data	
		MM	ALL	ALZ	PRO	MCN	
Total number of miRNAs in the original series matrix		722	470	462	373	722	
ANALYSES	sister miRNA pairs	√	√	√	√	√	
	Intragenic miRNA/host gene	Co-expression	√	√	√	√	
		Real/Proxy for network reconstruction	√	√	√	√	

5.5.2. Expression of sister mature miRNA pairs belonging to the same hairpin

Two different mature miRNA sequences (miRNA/miRNA*) are generated from a fraction of precursor hairpins and are associated to different sets of target genes and regulated cell activities. We considered expression profiles of mature miRNAs, obtained by microarray platforms specifically designed to measure mature forms.

Part of miRNA hairpin sequences is represented, in each dataset, by two different mature miRNAs, each one associated to an individual expression profile. After removing redundancy due to existence of identical mature pairs derived from hairpins belonging to different genomic localizations, a set of 237 couples of sister mature miRNAs from the same hairpin represented in the MCN, MM datasets was considered. In ALL, ALZ and PRO datasets we found respectively 32, 37 and 95 sister miRNA pairs.

The investigation of expression relationships between sister miRNA pairs provided interesting clues for a better understanding of the regulation of the strand selection bias. We were willing to comprehend if one miRNA in the pair is more expressed than the other in all tissues/cell types/conditions or if the strand selection bias may be cell/tissue-specific.

The cluster analysis of samples and of miRNAs pairs according to standardized per sample $\log_2(\text{ratio})$ between expression values of sister miRNAs provides a general picture of expression prevalence among sister miRNA pairs. Only five miRNA pairs are represented in all considered datasets (Figure 30).




Figure 30. Variability of strand selection bias across samples among all considered datasets. Figure shows patterns prevalence for a set of 5 sister miRNA pairs obtained by the combination of all considered datasets.

The heatmap in Figure 31 shows patterns of prevalence for a set of 95 sister miRNAs in 211 samples deriving from the combination of three datasets giving rise to the maximum number of miRNA pairs (MM, PRO and MCN). It is worth notice that heatmap in Figure 30 and Figure 31 are not quantitative results derived from expression data meta-analysis, but rather they provide qualitative information about the prevalence among sister miRNA pairs.




Figure 31. Variability of strand selection bias across samples. The heatmap evidences patterns prevalence for a set of 95 sister miRNA pairs obtained by the combination of three out of five considered datasets giving rise to the maximum number of represented miRNA pairs (MM, PRO and MCN). The group includes 211 samples representing normal and malignant B cells plus two sets of solid tumors and corresponding normal tissues. Lines and columns of the heatmap respectively represent miRNA pairs and samples ordered by hierarchical cluster analysis of standardized per sample expression values $\log_2(\text{ratio})$ of sister miRNA pairs. Samples are tagged according to cell or tissue type and to normal or cancer state, to facilitate the interpretation of sample clustering. The red-blue color scale indicates the extent of prevalence of one or another miR in the pair according to miRBase miRNA annotation. A positive (red) value indicates that, in a given sample, the first miRNA of the pair is more expressed than the second, negative (blue) values indicates the opposite case and comparable expression values between sister miRNAs are indicated by $\log_2(\text{ratio})$ values around 0 and are shown in white or pale colors. The heatmap shows clearly the existence of pairs in which only one miRNA is prevalent across the majority of samples, but also pairs showing variable strand selection bias in different sample groups, representing different tissue types. Moreover, sample clustering based on standardized per sample $\log_2(\text{ratio})$ of sister miRNAs expression values is able to fairly well classify different tissues, and in case of MM, to distinguish normal and malignant B cells.

We found that the standardized $\log_2(\text{ratio})$ of expression values between two sister miRNAs, is able to fairly well separate different samples/tissue types. Even if a laboratory/study effects cannot be excluded, normal and malignant B cells, derived from the same dataset (MM) are correctly separated, suggesting that standardized $\log_2(\text{ratio})$ of expression values may help distinguish normal and tumor samples. **Figure 31** shows that, for

a considerable fraction of the pairs, the same miRNA is the most expressed in the majority of considered samples. Among pairs expressed at comparable level in part of considered samples, only minority are associated to standardized $\log_2(\text{ratio})$ of expression values close to zero in all considered samples. We can conclude that for the large majority of pairs the strand selection bias may be tissue/cell specific. Indeed, the heatmap shows lines in which positive and negative values are mixed, corresponding to sister miRNA pairs showing a not deterministic strand selection bias. At least two sets of miRNAs seem to be expressed in B cells with inverse ratio respectively to other tissues. For instance, 22 pairs shows mean values of expression $\log_2(\text{ratio})$ in the two sample sets of opposite sign, and 16 miRNA pairs shows mean values of expression $\log_2(\text{ratio})$ in MM and in all the other samples differing at least one point in the scale of standardized values.

Many mature miRNAs are characterized by low expression values, slightly over background, and possibly associated to miRNA cellular concentrations insufficient to guarantee the biological activity. Thus, as explained in Methods, mature miRNAs were tagged as “expressed” in a given sample whenever the expression level was higher than the median of all expression values in the matrix. Then, sister miRNA pairs may be alternatively (i.e. only one out of two sister miRNAs is present) or concurrently expressed (both miRNA and miRNA* are present) in a given sample. Therefore, for each of the five considered datasets, miRNA pairs fall in one of the following categories (

Figure 32, Table 7):

- A: alternatively expressed, with concurrent expression never occurring in considered samples;
- C: concurrently expressed pairs in the same set of samples (expressed concurrently whenever expressed);
- AC: miRNAs pairs resulting alternatively expressed in some samples and concurrently expressed in others.

According to microarray data, the majority of miRNA pairs ($60\% \pm 25\%$, mean and standard deviation across datasets) belong to the AC class, whereas a more or less negligible percentage results always concurrently expressed ($11\% \pm 10\%$, maximum 27%). Pairs showing pure “alternative” behavior, according to the classical biogenesis model, represent less than one quarter of total expressed pairs, in average ($23\% \pm 7\%$). When two mature forms are expressed in the same sample, we considered the comparability between their expression levels, as per sample expression ratios distribution among C pairs expression levels, in those samples showing concurrent expression. We considered that two expression levels are comparable when their absolute value of expression $\log_2(\text{ratio})$ not exceeds 1. Excluding the PRO dataset, in which only one C pair was recorded, in the remaining datasets in average $17\% \pm 13\%$ of miRNA pairs have comparable expression levels. Moreover, the distribution of $\log_2(\text{ratio})$ among expression levels of AC class miRNA pairs shows that about one third of them ($34\% \pm 28\%$), are expressed at comparable level.




Figure 32. miRNA sister pairs categories. miRNA sister pairs were classified according to their tendency of being concurrently or alternatively expressed in those samples in which at least one of the pairs is expressed over the threshold (median of all expression values). Left panels show the criteria for classification, using example expression profiles in four theoretical samples (S1-4) for a general miRNA pair (miR/miR*). Single miRNAs are considered expressed in those samples with signal intensity over the threshold (black dotted line). A sister pair may result alternatively (A) or concurrently (C) expressed, in a given sample. Then, considering expression in all samples, a sister pair will be: alternatively expressed (A; the two miRNAs of the pair are never expressed together in considered samples); alternatively expressed in some samples and concurrently expressed in others (AC); always concurrently expressed in the same set of samples (C). For each category, right panels show example expression profiles in MM samples of specific miRNA pairs belonging to the category.

Table 7. miRNA sister pairs classification. Categories of miRNAs pairs derived from the same precursor were classified according to their expression characteristics, for each dataset, in: alternatively expressed (A); concurrently expressed (C) or alternatively expressed in some samples and concurrently expressed in others (AC).

	PRO		MM		ALZ		ALL		MCN	
	#	%	#	%	#	%	#	%	#	%
C	1	1.1	13	5.5	10	27	4	12.5	25	10.5
AC	75	78.9	197	83.1	7	18.9	19	59.4	144	60.8
A	19	20	26	11	10	27	9	28.1	65	27.4
Total expressed	95	100	236	99.6	27	73	32	100	234	98.7
Both not expressed	0	0	1	0.4	10	27	0	0	3	1.3

The heatmap in Figure 33 reports, for sister miRNA pairs and datasets considered in Figure 1, patterns of prevalence recalculated according the above reported miRNA pairs classification and considerations.




Figure 33. Variability of strand selection bias across samples considering miRNA pair classification. Figure reports patterns prevalence for a set of 95 sister miRNA pairs obtained by the combination of three out of five considered datasets giving rise to the maximum number of represented miRNA pairs (MM, PRO and MCN). As detailed in Methods, miRNA pairs concurrently or alternatively expressed were associated respectively to the per sample standardized $\log_2(\text{ratio})$ and to extreme values derived from observed distribution. Cluster analysis performed with these values, produce an heatmap showing both the regulation of the strand selection bias and alternative expression occurrence in different samples.

5.5.3. miRNA are hosted by long genes

A few studies considered miRNAs host genes genomic length/organization and their possible regulatory role. In particular, Golan and colleagues (Golan et al., 2010) observed that miRNA genes are hosted within introns of short genes and hypothesized that miRNA integration into short genes might be evolutionary favorable due to interaction with the pre-mRNA splicing mechanism. Here, we evaluated the length of the 279 host genes in comparison with all human genes. The average gene span of the 279 host genes (180867 nt; Wilcoxon rank sum test p-value 2.2×10^{-16} , Figure 34) is significantly longer (on average 6 times) than that of remaining 49, 506 human genes (29, 945 nt).




Figure 34. Host genes are relatively long. The back-to-back histogram compares the length distribution of host genes with that of all human genes. Host genes are longer than expected by chance and the difference is highly significant.

5.5.4. Limited co-expression of intragenic miRNAs and host genes

We considered the pair-wise expression correlations of respectively 309, 147, 148 and 170 mature miRNA/host gene pairs in the MM, ALL, ALZ and PRO datasets (Table 8). In all datasets, more than one half of miRNA/host pairs (63 ± 13 , average and standard deviation across datasets) were positively correlated, with slightly positive value for the median correlation per dataset. However using a criterion of $FDR < 0.01$, no pairs meet a correlation significance in the ALZ dataset, whereas in the remaining datasets from the 5% to the 36% of correlations result significant. Overall, our data indicated that in all four different datasets a large majority of miRNA/host gene expression profiles are not significantly positively correlated and are instead poorly correlated or even anti-correlated, in contrast with the notion that intragenic miRNAs are co-expressed with host genes.

Table 8. Intragenic miRNAs and host genes correlations. The correlation between intragenic miRNA and host genes expression profiles tends to be slightly positive, but with prevalently low percentages of significantly positively correlated pairs.

		MM		ALL		ALZ		PRO	
miRNA-host gene correlation	Total	309	%	147	%	148	%	170	%
	Positive	199	64	81	55	77	52	138	81
	>0.25	78	25	53	36	47	31	56	33
	>0.5	33	11	20	13	21	14	13	8
	FDR<0.01	34	11	8	5	0	0	60	36

We reasoned that about 20% considered host genes is associated each to two mature miRNA forms, derived from the same hairpin whereas the remaining host genes are associated to only one mature miRNA. Since sister miRNA expression profiles may not be considered independent, we carried out again, for each of the four expression datasets, the above reported analysis of co-expression between intragenic miRNAs and host genes, but considering, for host genes including two mature miRNAs, only the mature miRNA of the pair with the highest miRNA-host correlation. Considering only the highest miRNA-host gene correlation, when a pre-miRNA hosted in a gene produces two mature forms, may give an overestimation of general miRNA-host co-expression tendency. Anyway, the percentages of miRNA-host correlations being positive, >0.25 and >0.5, for each dataset (data not shown), resulted to be almost equal to that reported in Table 8 and showed limited co-expression of intragenic miRNAs with host genes.

5.5.5. Impact of host genes expression used as proxy for miRNAs on target selection.

These observations discouraged the usage of host gene expression profiles as a proxy to monitor the expression of its embedded miRNA. Thus, we tested whether such procedure affected the results of an integrated analysis of target prediction with miRNA and target expression profiles, using datasets in which real and not inferred miRNAs expression data are available. In particular, for each of the four miRNA and genes matched datasets, a comparative evaluation of results was obtained, by contrasting two integrated analyses, the first (REAL) was conducted on real miRNA and gene expression profiles, whereas the second one (PROXY) was conducted on host genes expression profiles, used as proxy for miRNAs, and gene expression profiles. For each dataset, different numbers of miRNA and genes were considered for target prediction, using TargetScan, after filtering out those miRNAs with almost invariable profile (25% with lower Shannon entropy) and/or weakly expressed (25% with lowest average values). For each dataset, both for the REAL and PROXY analysis, the sets of predicted relationships mostly supported by expression

profiles anti-correlation analysis were identified according to different percentile cut-offs on miRNA-target expression profiles anti-correlation values. It is worth notice that in different studies cutoffs around 1-3% were considered adequately stringent for a selection of candidate functional miRNA-target relationships.

A set of 2, 848 validated miRNA-target interactions, resulting from Diana Tarbase (Papadopoulos et al., 2009b) and/or miRecords (Xiao et al., 2009a) was collected to provide an independent, also if narrow, true solution for comparative evaluation. In total, 756 validated miRNA-target relations were represented in the considered set of predicted relations, with different small subsets represented for different expression datasets. The average of total numbers of predicted relations associated to negative correlation values in different datasets (representing the group from which we selected most supported relations according to anti-correlation ranking cutoffs) was about 81,500. For each dataset and each threshold, we evaluated the number of validated relations included in the selected set of supported relations, according to the REAL and the PROXY analysis, as compared with the expected number of validated relations. The ratio between observed and expected numbers of validated relations included in a selected set of supported relations defines an “enrichment score”, measuring the helpfulness of expression profiles anti-correlation analysis to identify functional regulatory interactions among simply predicted relations. Figure 35 reports the variation of enrichment score, against stringency of anti-correlation-based percentile threshold, for each considered expression dataset. Plainly, the REAL analysis is able to enrich in validated relations, when it focuses on anti-correlated miRNA-target subsets defined with high stringency (from 1% to 5%), but loses its power, as expected, at lower stringency. Besides, the REAL analysis results outperform those of the PROXY, which seems to find, almost in all datasets, proportions of validated (over supported) relations comparable or even lower than expected by chance, almost independently from the applied stringency on anti-correlation. We observed also that, for each considered expression dataset, the groups of validated relations detected by the REAL and PROXY methods are almost completely disjointed.




Figure 35. Enrichment in validated miRNA-target relations obtained by REAL and PROXY analyses of different datasets. Comparative evaluation of integrated analysis results was performed using real miRNA and gene expression profiles (REAL) and host genes expression profiles, as proxy for miRNAs, and gene expression profiles (PROXY). For each dataset, first we filtered out miRNAs with almost invariable or weak expression, then we identified the miRNA and genes target prediction set using TargetScan. Both for the REAL and PROXY analysis, the groups of predicted relationships most supported by expression profiles anti-correlation analysis were identified according to different percentile of anti-correlation cut-offs. A subset of miRNA-gene validated relations, from Diana Tarbase and/or miRecords, provided an independent true solution for comparative evaluation. The figure shows the variation of “enrichment score” (ratio between the observed number of validated relations, included in the selected set of supported relations, and the expected number of validated relations, based on proportions) against stringency of anti-correlation-based percentile cutoff. Each dataset is considered separately to compare REAL and PROXY analysis methods. The REAL method is able to enrich in validated relations, outperforming the PROXY, when it focuses on anti-correlated miRNA-target subsets defined with high stringency. Also the REAL method loses any power, as expected, at low stringency.

5.6. Characterization and discovery of novel miRNAs and moRNAs in JAK2V617F mutated SET2 cell

The JAK2V617F mutation, that occurs in most patients with polycythemia vera (PV) and about 60% of those with essential thrombocythemia (ET) and primary myelofibrosis (PMF)1, is considered integral to the pathogenesis of myeloproliferative neoplasms (MPN), although additional, antecedent mutations are required for a MPN to develop. The disease can be reproduced in mice expressing the JAK2V617F allele 5. Cells harboring the JAK2V617F mutation display autonomous activation of several cell signaling pathways, particularly JAK/STAT, and proliferate and mature in a cytokine-independent manner. Recent information highlighted that deranged epigenetic gene regulation(Vannucchi et al., 2009) and abnormal expression of microRNAs(Bruchova et al., 2007; Bruchova et al., 2008; Guglielmelli et al., 2007) also contribute to the pathogenesis of MPN(Bortoluzzi et al., 2012).

5.6.1. Small RNA library

The Illumina GAIIx sequencing of the small RNA library from SET-2 cells produced 32,760,003 reads which, after extensive preprocessing and quality control, were reduced to 27,906,609 reads, representing about 85% of sequenced reads. A first mapping phase aimed at discarding contaminations and repeats, yet tolerating for possibly unknown miRNA loci, produced 22,167,999 reads (68% of raw data). These were accurately mapped to “extended hairpins” in order to identify and quantify known miRNAs and for discovery and characterization of novel isomiRs and other miRNA-associated expressed RNAs. In total, 1,421 known hairpin precursors, corresponding to 1,731 known mature miRNA sequences.

5.6.2. Known miRNAs and isomiRs expressed in SET2 cells

A total of 652 known miRNAs were found expressed in SET2 cells with expression levels ranged from 10 to 2,268,333 (mean 29,830, median 613), with 300 and 124 miRNAs presenting read counts of at least 10^3 and 10^4 , respectively. Only 21 highly expressed miRNAs accounted for 70% of known miRNAs expression (Table 9) and are thus predicted to account for most of miRNA-mediated gene repression in SET2 cells. KEGG pathway enrichment for known miRNAs was obtained using DIANA-miRPath web-tool (Papadopoulos et al., 2009a) based on TargetScan5 miRNA target predictions. mirPath is a software to identify molecular pathways potentially altered by the expression of single or multiple microRNAs. Most relevant KEGG pathways significantly enriched in genes predicted target of 21 most expressed miRNAs are the MAPK signaling pathway, TGF-

beta signaling pathway, mTOR signaling pathway, and Wnt signaling pathway, pathways having functional relevance for MPN-associated cellular abnormalities.

Table 9. Twenty-one miRNAs highly expressed account for 70% of total known miRNAs expression in SET2 cells.

miRNA	Expression level	Cumulative % of total known miRNAs expression
hsa-miR-21	2268333	12
hsa-miR-148a	1737364	21
hsa-miR-146b-5p	1632959	29
hsa-miR-101	1293074	36
hsa-miR-142-3p	1037658	41
hsa-miR-19b	1025647	46
hsa-miR-378	561770	49
hsa-miR-92a	538422	52
hsa-miR-191	416870	54
hsa-miR-425	391247	56
hsa-miR-126	349719	58
hsa-miR-17	314388	59
hsa-miR-181b	310800	61
hsa-miR-181a	301902	63
hsa-miR-93	223220	64
hsa-miR-126*	216687	65
hsa-miR-30e	201602	66
hsa-miR-99b	200438	67
hsa-let-7f	196921	68
hsa-miR-25	191693	69
hsa-miR-20a	186436	70

The majority of expressed mature miRNAs were not represented by a unique sequence corresponding to that annotated in miRBase. The whole group of reads belonging to each miRNA, including the “classic” mature sequence annotated in miRBase (“exact” alignment) as well as those reads perfectly matching the precursor but overlapping the mature position by 3nt (longer/shorter), those presenting 1 mismatch (1-Mismatch), and those presenting two mismatches, both at the 3’ end (2-3’-Mismatches) was evaluated.

Considering the whole set of variants presenting at least 10 reads each, 636 miRNAs were identified, 232 of which (36%) appeared “invariant” whereas the remaining 404 (64%) represented a mixture of 2 to 6 sequence variants (Figure 36).




Figure 36. miRNAs variants. Figure shows the number of isomiRs observed per miRNA by considering those sequence variants with a read count of at least 10 reads or those accounting each for at least the 10% of the total count of the miRNA.

But the most important sequence variation is represented by 5’ and 3’ length variability, possibly occurring as a consequence of alternative, non- canonical, regulated processing of the precursor sequence.

5.6.3. Novel miRNAs expressed in SET2 cells were discovered in known hairpin precursors

For novel miRNA discovery, we operationally defined as “expressed RNA elements” (ERE) those discrete hairpin regions covered by overlapping reads with a minimum count of 10 and with a start position within 4 nt each from the following one. We found that a discrete number of regions located outside known mature miRNAs were expressed from detectable to high level; among them, we identified a number of ERE able to pair with known miRNAs in the most probable duplex produced by Dicer processing of the hairpin structure. Specifically, we considered 943 hairpins associated

to only one annotated mature miRNA, whereas an additional 478 included two known sister mature miRNAs.

The analysis of known hairpin precursors associated to only one known miRNA produced a set of 78 novel miRNAs expressed in SET2 cells (Table S 7).




Figure 37. Examples of new miRNAs discovered. Plots show the number of reads per nt position mapping in extended hairpin loci for hsa-mir-1307, hsa-mir-376a-2, hsa-mir-382 and hsa-mir-539, expressing both known and new miRNAs. Known miRNA positions respective to the extended hairpins indicated in the plot. In the upper part of panel, the sequence of mature miRNAs is shown (known miRNA in red, new miRNA in pink).

Plots in Figure 37 show, for the four most expressed new miRNAs (hsa-miR-1307*, hsa-miR-376a-2*, hsa-miR-382* and hsa-miR-539*), the number of reads aligned per nucleotide position. This information was integrated with hairpin sequence and folding

data to define new miRNA sequences. Table 10 reports name, sequence and expression level of novel miRNAs having a read count of at least 500.

Table 10. Novel miRNA expressions. Name and predicted sequence of 15 new miRNAs with read count greater than 500. Seven new miRNAs associated to read counts over 10^3 are shown in bold.

New miRNA	Sequence	Expression
hsa-miR-1307*	CTCGACCGGACCTCGACCGGCTCGT	72670
hsa-miR-376a-2*	GGTAGATTTTCCTTCTATGGTTA	14296
hsa-miR-382*	CGAATCATTACGGACAACACTTTTT	8296
hsa-miR-539*	AATCATACAAGGACAATTTCTTTTTGA	3332
hsa-miR-181b-1*	CTCACTGAACAATGAATGCAACT	1542
hsa-miR-561*	ATCAAGGATCTTAAACTTTGCC	1315
hsa-let-7c*	CTGTACAACCTTCTAGCTTTCCT	1195
hsa-miR-652*	ACAACCCTAGGAGAGGGTGCCATTCA	982
hsa-miR-301a*	GCTCTGACTTTATTGCACTACT	880
hsa-miR-487a*	GTGGTTATCCCTGCTGTGTTCCG	823
hsa-miR-370*	AAGCCAGGTCACGTCTCTGCAGTTACAC	624
hsa-miR-412*	TGGTCGACCAGTTGGAAAGTAAT	578
hsa-miR-376c*	GTGGATATTCCTTCTATGTTTAT	568
hsa-miR-381*	AAGCGAGGTTGCCCTTTGTATATTC	567
hsa-miR-376b*	GTGGATATTCCTTCTATGTTTA	532

Expression levels of new miRNAs identified in SET2 cells ranged from 10 to 72,670 (mean 1471, median 63) and were significantly lower than those of known miRNAs (Two Sample t-test of mean equality p-value =6.521e-06) (Figure 38).

Nevertheless, 11 new miRNAs (14%) showed an expression level higher than the median value observed for known miRNAs. In particular, hsa-miR-1307*, hsa-miR-376a-2* and hsa-miR-382* resulted very highly expressed, at level even greater than 75% of known miRNAs.

Conserved TargetScan custom target predictions (See Methods) for 15 novel miRNAs with a read count of at least 500 are included in Table S 8. Specifically, conserved and not-conserved target sites were predicted using TargetScan and filtered according to the context score. Only conserved target sites associated to top 25% scores and non-conserved sites included in top 5% scores were reported.

5.6.4. Sister miRNA expression prevalence

Considering known and new miRNAs expressed in SET2 cells as a whole, we found that both miRNA and miRNA* were expressed concurrently in 260 hairpins, corresponding to about one half of those with at least one miRNA expressed (Table 11). miRNA and




Figure 38. SET2 expression levels distributions for known and novel miRNAs shown as boxplot with log₁₀ scale.

miRNA* of the same hairpin, called a sister miRNA pair, have different sequences, thus targeting different sets of coding RNAs and contributing uniquely, but possibly in a coordinate way, to transcriptional regulation. When increasing thresholds of read count were applied in order to consider a miRNA as being “expressed”, the fraction of hairpins producing concurrently miRNA and miRNA* decreased (Table 11).

Table 11. Number of expressed miRNAs respective to number of known miRNAs, per hairpin (A). Percentages of hairpins associated to concurrently expressed miRNA/miRNA* pairs, according to different thresholds on expression level (B).

A

# known miRNAs	Hairpins	# of expressed miRNAs					
		2		1		0	
		#	%	#	%	#	%
2	478	189	39.54	102	21.3	187	39.1
1	943	71	7.53	175	18.6	697	73.9
Hairpins	1421	260	18.30	277	19.5	884	62.2

B

Expression of at least	Hairpins with at least one miRNA expressed	Hairpins with two miRNAs expressed	% of expressed hairpins with two miRNAs
10	522	250	47.9
10 ²	331	175	52.9
10 ³	229	94	41.0
10 ⁴	125	15	12.0

Nevertheless, the fraction of hairpins producing a meaningful quantity of both miRNAs remained considerable at all thresholds.

No strand prevalence in expressed miRNAs was observed (Figure 39). Out of 277 hairpins expressing only one miRNA, 47% and 53% expressed only the 5' or the 3' miRNA (130 and 147), respectively. Regarding 260 hairpins expressing both sister miRNAs, the highly expressed miRNA was the 5' or 3' form in 135 and 125 of them, respectively. A considerable fraction of concurrently expressed miRNA pairs were found to be expressed at comparable level: 66 (25%) and 38 (14%) of concurrently expressed pairs were associated to an absolute $\log_2(\text{ratio})$ of expression values not higher than 2 and 1, respectively.




Figure 39. Prevalence of 5' and 3' miRNAs expression. A) Scatterplot showing 5' and 3' miRNAs expression, both for the sister pairs including two known miRNAs and for those including one new miRNA. B) Distribution of \log_2 ratio of 5' and 3' miRNAs expression values.

5.6.5. miRNA-offset RNAs (moRNAs) identification in known hairpin precursors

ERE was found also outside known and novel miRNAs. These were classified as 5' moRNAs, 3' moRNAs and expressed loops (Figure 40). In particular, 58 moRNAs expressed from 56 hairpins, at moderate to high level (mean 127, median 52) was identified.

A considerable prevalence of 5' moRNAs was observed: 95% of moRNAs derived from the 5' arm of the hairpin precursor (n=55 versus 5 for the 3' moRNAs). The average expression level of 5' moRNAs (129) was higher than 3' moRNAs (89) but the difference was not statistically significant (t-test p-value = 0.5804).

Expressed miRNA length ranged from 16 to 27 nt, with an average of 21, at variance with moRNA sequences that were less variable in length, ranging from 18 to 25 nt, average of 20.2.

It is worth noticed that, among the 55 5' moRNAs, 8 were included in the "classic" hairpin precursor sequence while only one belonged to the region of 30 nt flanking the hairpin, whereas 46 (84%) were partially overlapping the hairpin 5' border. This may indicate that moRNA sequence spanned the canonical Drosha cutting site and supports a role for non-canonical Drosha cleavage in moRNAs biogenesis.




Figure 40. Two miRNAs and two moRNAs may be produced by transcription and processing of a single miRNA locus. The plots show expression levels of miRNAs, moRNAs and loops from 15 hairpins corresponding to most expressed moRNAs

6. Discussion and Conclusions

In this thesis I illustrated results obtained combining different type of data and bioinformatic analyses to investigate different aspect of miRNA. An integrative genomic and systems biology approach based on computational prediction of miRNA targets in combination with experimentally-determined miRNAs and genes expression measures is more effective for the identification of biologically relevant miRNA-target relationships. Integrating miRNA and gene expression data we are able to identify miRNA target gene most reliable among the vast number of computational prediction available on-line providing an important contribution aimed at characterizing the role of specific miRNAs in different neoplasms. Moreover the reconstruction of transcriptional and post-transcriptional regulatory networks became a crucial step to understand mechanism of all biological systems. We exploited method deriving from social network theory to analyze these regulatory networks to hamper our capacity of extracting *de-novo* knowledge from biological networks. To delve into some miRNA aspects, post-transcriptional regulation in miRNA biogenesis, namely the strand selection theory, and the relation between intragenic miRNAs and their host gene, we used sequence, genomic and expression information in different biological context in 5 large dataset. And lastly the deep sequencing data analysis help us to portray a general picture of short RNAs expressed in SET2 cells, a JAK2V617F mutated cell line, where known and novel miRNA expressions was quantified and a new class of short RNAs, moRNAs, was discovered.

6.1. Identification of microRNA expression patterns and definition of a transcriptional and post-transcriptional regulatory network in distinct molecular groups of multiple myeloma

The integrative analysis of the different types of genomic data (i.e., miRNA and mRNA expression levels and genome-wide CN profiles) allowed the definition of distinct patterns of miRNA deregulation and the prediction of the miRNA/mRNA regulatory networks in molecular subtypes of MM.

Particularly, results highlighted that specific patterns of miRNA expression may differentiate MMs with distinct and well-known genetic alterations. Specific signatures were found to be associated with t(4;14) or translocated MAF genes and, to a lesser

extent, with t(11;14) and TC2 group (expressing moderate levels of CCND1 in the absence of IGH translocation).

Most of the 26 miRNAs significantly discriminating the TC groups have previously been found to be involved in solid and hematologic tumors. The most extensively investigated are miR-155, miR-221 and miR-222, and the let-7 family. MiR-155 is involved in many biologic processes, including hematopoiesis, inflammation, and immunity, and its deregulation has been found to be associated with certain types of solid and hematologic tumors, in which it is predominantly overexpressed and acts as an oncomiR (Esquela-Kerscher and Slack, 2006). Notably, miR-155 has been very recently found deregulated in Waldenström macroglobulinemia (WM), suggesting a role in the proliferation and growth of WM cells acting on signaling cascades, including MAPK/ERK, PI3/AKT, and nuclear factor- κ B pathways (Roccaro et al., 2009). In addition, miR-155 knockdown leads to significant increase of WM cells in G1 phase and to the down-regulation of cyclin-dependent kinases and cyclins D and the simultaneous up-regulation of p53 expression, suggesting a critical role in the regulation of cell-cycle proteins responsible for G1 arrest (Roccaro et al., 2009). MiR-221 and miR-222 have also been found to be up-modulated in many tumors and described to target the C-KIT, p27, and p57 genes (Lotterman et al., 2008; Visone and Croce, 2009). Finally, many human let-7 genes, which are known to target RAS genes and oncogenes involved in the cell cycle, such as HMGA2, MYC, CDK6, and CDC25, (Medina and Slack, 2008) map to regions frequently deleted in human tumors, indicating that they may function as tumor suppressors. The most striking finding was the very specific expression of 3 miRNAs (miR-99b, let-7e, and miR-125a-5p), encoded in a conserved genomic cluster, in the t(4;14) cases. They are coordinately up-regulated during metamorphosis in *Drosophila*, where they are cotranscribed as a single polycistronic transcript (Sempere et al., 2003; Sokol et al., 2008). Although their involvement has been suggested in various tumors, to our knowledge, this is the first evidence of their coordinated deregulation in cancer.

The differential miRNA expression associated with distinct genetic subgroups is a novel finding in MM. Of note, it has already been reported in other hematologic malignancies, such as acute myeloid leukemia (Jongen-Lavrencic et al., 2008) and chronic lymphocytic leukemia. As regards this latter neoplasia, in which the role of miRNA has been extensively investigated, (Calin and Croce, 2009) the presence of miRNA signatures associated with the major specific genetic lesions (trisomy 12 and 13q14, 11q23, and 17p13 deletions) has been reported very recently (Visone et al., 2009). Interestingly, as found in our study, the discriminating miRNAs were not localized in the chromosomal regions specific for the corresponding cytogenetic abnormalities. Overall, the identification of specific miRNA patterns may help not only to distinguish distinct MM genetic subgroups known to show differences in term of response to therapy and survival, but also to provide a better understanding of their pathogenesis.

The computational prediction of miRNA targets currently presents several significant challenges because all of the most widely used tools (miRanda, TargetScan, PicTar, PITA, and RNAhybrid) are characterized by a significant proportion of false-positive interactions (Didiano and Hobert, 2008; Grimson et al., 2007b) (Curtale et al., 2010) that are partly because posttranscriptional regulation is context-dependent. On the basis of increasing experimental evidence supporting the hypothesis that miRNAs can act through target degradation, it has been proposed that target predictions could be integrated with miRNA and gene expression profiles to select functional miRNA/mRNA relationships. This can be done by adopting a variational Bayesian model and software, (Huang et al., 2007b; Huang et al., 2007c) or simply using a nonheuristic method based on miRNA/mRNA anticorrelation. We applied the latter to our dataset, which allowed the reconstruction of a general miRNA/mRNA regulatory network that represents the putative functional regulatory effects (as supported by expression data) of all of these miRNAs on their targets in MM.

On the basis of the target genes identified here, several the miRNAs differentially expressed in IGH translocated cases may play important roles in the biology of MM PCLs. With regard to the t(4;14) miRNA signature, 5 miRNAs target CBFA2T2, a nuclear repressor homologous to ETO that binds to the AML1-ETO complex and may play a role in hematopoietic differentiation (Fracchiolla et al., 1998; Lindberg et al., 2005). Furthermore, let-7e targets PTPRE, a positive regulator of osteoclast function (Chiusaroli et al., 2004) and a selective inhibitor of IL-6- and IL-10-induced JAK-STAT signaling (Tanuma et al., 2001). Interestingly, the expression of the tumor suppressor gene PDCD4 (programmed cell death 4) (Lankat-Buttgereit and Goke, 2009), a supported target of miR-221 based on our analysis, has recently been found to depend on the levels of MMSET, which is deregulated by the t(4;14) (Brito et al., 2009). ING4, a tumor suppressor frequently mutated or down-regulated in human cancers, which was recently described to exert an inhibitory effect on MM-induced angiogenesis (Colla et al., 2007; Kim, 2005a), is a supported target of miR-365. Concerning the TC5 signature, miR-133a targets DM vs TF1, a putative tumor suppressor that activates the ARF-p53 pathway, leading to cell growth arrest or apoptosis; notably, it maps at 7q21, often deleted in human malignancies (Inoue et al., 2007). Finally, among the miRNAs up-regulated in t(11;14), miR-361-3p and miR-30e* target PPP2R4, an activator subunit of PP2A, which plays an important role in the survival and growth of MM cells because it dephosphorylates the GP130 subunit of the IL-6 receptor, thus preventing its degradation and allowing the activation of IL-6 signaling (Kang et al., 1996; Mitsuhashi et al., 2005). All this findings strongly suggest that understanding the molecular biology of myeloma requires considering the miRNome in the context of the genomic and transcriptomic features of malignant PCLs. Based on this integrated approach, our data may provide an

important contribution to future investigations aimed at characterizing the role of specific miRNAs in MM pathogenesis.

Furthermore, reconstructing regulatory network from expression data is a crucial step to understand the mechanisms underlying biological systems. However, the high number of genes and interactions still represents a challenging issue for the extraction of relevant targets and relationships from such large systems. A standard approach is searching targets among the most connected genes (hubs) or among sub groups of genes known to be relevant in the analyzed phenotype. The goal of this type of analysis is to identify previously unknown relationships that can be the object of a subsequent experimental validation. An alternative approach is studying the network characteristics to identify groups of genes organized in sub-networks, which may suggest novel interactions and shed light on regulatory modules involving these genes or their common targets. Although effective, both strategies rely on prior knowledge to select the genes of interest, thus hampering the capacity of extracting de-novo knowledge from the network. A way to overcome this limitation could be adapting techniques commonly used in the analysis of communication and infrastructure networks. In these fields, a key analysis is the resilience of the network to external disturbances and to malfunctioning. Network robustness strongly relies on the network structure and, in particular, on the existence of paths between the nodes. When nodes or links are removed, the lengths of these paths can increase and some nodes will become disconnected. It is therefore interesting to find the critical component of the network, i.e. the nodes or edges that are really important for the functioning of the network. In Latora and Marchiori, the authors proposed a method to evaluate the importance of a network element (that can be a node or an edge) by considering the drop in the network performance caused by its deactivation (Latora and Marchiori, 2005). The performance of the perturbed network is compared with the original one. Iturria-Medina and colleagues applied a similar approach to investigate the human brain anatomical network (Iturria-Medina et al., 2008). Different criteria can be used to measure the performance, such as efficiency or mean flow rate of information. Efficiency measures how efficiently the nodes of the network exchange information. Applying this concept to regulatory network, critical nodes and edges are critical genes and critical regulatory interaction, respectively. Usually the most important nodes are considered the most connected ones (hubs), but this is not always the case. In genetic networks a gene can be connected to many genes simply because is a transcription factor that normally controls many targets or a gene that is controlled by many other genes. For instance, in the analysis of the B cell networks, the largest hub with more than 300 interactions was a poorly characterized gene, BYSL. Instead, a much more interesting gene was MYC that, with only 56 neighbors, ranked 410th in terms of connectivity. MYC, a well-known proto-oncogene, had neighbors that were themselves genetic hubs (including BYSL), such that MYC could modulate a substantial percentage of all genes in

the cell through a relatively small number of neighbors (Basso et al., 2005b). Recently, some approaches exploited the topological features of large gene regulatory networks to identify individual components that are biologically relevant or to elucidate the role of each particular element in regulation. Patapov and co-workers introduced the pair-wise disconnectivity index to quantitatively evaluate the topological significance of each element (i.e., nodes and edges) in the context of all other elements of the regulatory network (Potapov et al., 2008). The application of this approach to the analysis of the TLR4 signal transduction network allowed identifying a number of key signaling and transcription regulators among the nodes top-ranking in terms of disconnectivity index. Differently, Emmert-Streib and Dehmer used the concept of functional robustness, originally introduced by Li et al. (Li et al., 2004), to study the functional robustness of the transcriptional regulatory network in yeast (Emmert-Streib and Dehmer, 2009). The definition of an information theoretic measure to estimate the influence of single node perturbations on the global network topology allowed identifying nodes which are fragile with respect to single node knockouts and revealed significant differences between fragile nodes and hubs. Interestingly, the set of fragile nodes was statistically enriched in essential genes, i.e. in genes required to sustain vital yeast. Here, the critical analysis of network components has been applied to inspect the transcriptional and posttranscriptional regulatory networks reconstructed from mRNA and miRNA expression data of multiple myeloma samples. The transcriptional and post-transcriptional networks were reconstructed using ARACNe and the Pearson correlation coefficient of the expression vectors of miRNA target genes, respectively. Both networks showed a scale free structure, i.e. a type of structure reported with evidence in lower organisms, but still argument of debate in eukaryotes. The connectivity plots of Figure 14 strengthen the hypothesis that the structure of human interaction networks has a scale free nature with a saturation effect also reported for other scale-free networks, when the maximum connectivity range is below 1000 (Albert, 2005; Almaas, 2007; Barabasi and Albert, 1999; Basso et al., 2005a). Both networks are also slightly assortative, meaning that they tend to have an aristocratic behavior where nodes with high degree tend to connect with nodes with similar degree. This suggests a hierarchical control mechanism, as also reported in (Basso et al., 2005a). The analysis of critical components revealed that genes with a limited number of connections could be critical for the structure of the network and that hubs are not necessarily critical nodes. Indeed, about one half of most connected nodes in each considered network were not included in the corresponding list of most critical nodes and genes like BLNK, characterized by a low node degree, were instead critical. These non-hub critical nodes would have been disregarded as putative regulatory targets due to their limited number of connections although they may provide clues to the detection of key regulatory circuits. Finally, the integration of the transcriptional and post-transcriptional levels allowed identifying critical genes for both

types of regulatory interactions and dissecting direct critical relationships at transcriptional level from interaction that are instead indirect since mediated by post-transcriptional regulation.

6.2. miRNAs modulation in colon cancer and metastasis development and its impact on regulatory networks and pathways

The impact of miRNA in colorectal cancer (CRC) development and progression has been clearly demonstrated in the recent years, and for several miRNAs tumor-suppressor or tumor promoter roles have been proposed. Furthermore, different miRNA signatures have been found informative for tumor prognosis and clinical outcome in various cohorts of patients.

In this study, we carried out a genome-wide integrative analysis of miRNA and genes expression profiles in CRC samples, comprehensive of normal colon mucosa, primary tumor and liver metastasis, in order to identify differentially expressed miRNAs and their anti-correlated targets, defining modulated post-transcriptional regulatory networks. The ultimate aims were to discover specific miRNA-gene relationships significantly supported by expression data and associated with tumor progression, and to gain new insights into the cellular pathways affected by identified miRNAs.

Our results suggested that miRNA and gene expression profiles had different capability to discriminate different sample classes. The fairly good separation of normal samples from tumor and metastases that was obtained according to both miRNA and gene profiles, confirmed the quality of tissue enrichment procedure implemented in the study. On the other hand, expression profiles of miRNAs resulted to be more informative than those of genes to distinguish primary tumors from metastases. Interestingly, by considering per-patient match of different tissue samples, we showed that tumor and metastatic samples obtained from the same patient have a not negligible tendency to cluster together. This finding indicates that, on the basis of gene expression characteristics, a metastasis is more similar to the matched tumor than to the metastases of other patients. Differently, our results seem to suggest that the variability of miRNAs expression profiles observed after metastasis development process, is more extensively shared between different patients.

For the identification of miRNAs and genes differentially expressed in different tissue types (DEM and DEG, respectively), we adopted stringent criteria. We implemented two strategies for the identification of DEM modulated between sample classes: considering the whole set of samples and by using per-patient matching information, but using a smaller group of patients. We observed that the second approach seem to be less powerful, since it discover set of DEMs largely represented in those already found by the first one. This may be partially due to the reduced number of patients for which all tissue

types were available. Besides, the T vs N contrast identified about six times more DEM than the M vs T comparison, confirming above raised observations.

A global reduction of miRNA expression levels has been reported as a general trait of human cancer (Lu et al., 2005), and the experimental repression of miRNA biogenesis in cancer cell lines has been shown capable to promote cell proliferation and invasion (Martello et al., 2010). These observations led to the hypothesis that cancer cells may use down regulation of miRNA to foster invasive and metastatic behaviors. However, in contrast with these findings are studies on clinical samples showing that in solid tumors the most common miRNA event is gain of expression, whereas loss of expression is a more limited event and more tissue specific (Volinia et al., 2006). Partially in agreement with this last report, we did not observe a preferential down-regulation of miRNAs in our set of samples, since a similar number of up- and down-regulated miRNAs (29 and 33, respectively) was obtained when an all tumors (paired and unpaired samples) were contrasted vs all normal tissues. Also, among the robust group of miRNAs resulting modulated in the NT contrast according to both paired and unpaired samples comparisons, up- and down-regulated miRNAs are equally represented.

The number of dysregulated miRNAs was basically maintained from tumor to metastasis transition. A more general tendency towards the down-regulation was instead demonstrated in gene expression data, as 100 up-regulated and 355 down-regulated genes were observed when tumor vs normal comparison was carried out, while 29 and 9 genes were up- and down-regulated, respectively, in the tumor vs metastasis transition. Clearly, it is difficult to exactly establish how much gene expression down-regulation is a direct effect of miRNAs modulation and how much it may be due instead to different forces, working at other regulatory levels. Nevertheless, our data confirm that miRNA dysregulation is essential at all stages of tumorigenesis, since it largely occurs in primary tumor as well as in metastasis. Furthermore, once present, the specific miRNA pattern is almost steadily maintained even in advanced primary tumors and in their distant metastases.

The list of miRNAs differentially expressed between tumor and normal mucosa (both in paired and unpaired comparisons) includes miRNAs that have been previously described as members of a miRNA "signature" common to different types of solid tumors (Negrini et al., 2009). Many of them have been also implicated in molecular and biological processes that drive tumorigenesis in CRC. Relevant examples are miR-143, miR-145, miR-125b and miR-21, which are associated with cell growth and survival; the miR-17-92 cluster, miR-20 and miR-100, which are involved in uncontrolled cellular proliferation; the miR-183 cluster and miR-31, which are implicated in cell migration; and miR-150, which has been very recently identified as a potential biomarker of prognosis and therapeutic outcome in CRC (for the details about up- or down-regulation of these miRNAs see Table). Interestingly miR-139-5p, the most down-regulated in the T

vs N comparison, has been very recently identified as a member of a signature predictive of the tumor status in stage II CRC (Chang et al., 2011b); moreover, miR-224, the most up-regulated together with miR-183 in the same comparison, was identified for its ability to distinguish CRC with a proficient or a deficient DNA mismatch repair (Oberg et al., 2011). For some of these miRNA the tumor-promoting or tumor-suppressing functions in CRC as well as in other tumors have been previously suggested. However, in the light of the large number of mRNA regulated by each miRNA, it is very likely that two or more genes from different molecular pathways may be altered in their expression, and considering the tissue specificity of the miRNA activity, a strict classification of cancer-associated miRNAs into onco- or tumor-suppressor miRNAs might be an oversimplification.

When primary tumor and metastatic samples were compared, a limited number of differentially expressed miRNAs comprising 5 over and 6 under expressed miRNAs was obtained in unpaired comparison; while only 5 over expressed miRNA were obtained in paired comparison. Common to both paired and unpaired comparison were miR-210, whose over expression in solid tumors has been associated with hypoxia, cell survival and invasion, miR-100 that has been considered a regulator of ATM/mTOR pathway, and miR-122, that it was shown being a contamination from residual liver tissue.

Notably, two other miRNAs, miR-100 and miR-139-5p, were characterized by an inversion of their down modulation in the tumor toward metastasis transition (in paired and unpaired group, respectively) even if their expression level in the metastatic samples was still lower in comparison with normal tissue.

The identification of a limited number of miRNAs differentially expressed between tumor and metastases may be explained in two different ways. On one hand, as a consequence of cancer progression a malignant tumor contains multiple cell populations with heterogeneous behaviors, and clones with the ability to invade and develop metastases might be present in the primary lesion. Thus, miRNAs associated with metastasis may already be expressed in early tumors, which implies that clones with metastatic potential are present from the beginning in the primary lesion. Alternatively, primary tumors that we had used were of advanced stage and then of high metastatic potential, thus dysregulated miRNAs associated with primary tumor were not further modified during the transition from primary tumor to metastatic lesion.

In the second part of the study, we carried out the integrative analysis of miRNA and genes expression profiles to reconstruct post-transcriptional regulatory networks. Post-transcriptional regulatory networks unveil a significant layer of interconnection among different miRNAs and genes during the transition from normal to tumor stage

Clearly, the point is understanding how much miRNA expression variation through the main steps of disease progression impacts on gene expression modulation, and ultimately on cell behavior. We exploited miRNAs and genes matched expression profiles to

identify a very reduced set of miRNA-gene targeting relationships, which are most likely to take place in the considered cells. miRNA activity is part of complex regulatory networks and gene expression profiles are the result of different forces, working at multiple regulatory levels. Proteomics studies (Baek et al., 2008), showed that most miRNA targets with significantly reduced protein levels also experienced detectable reduction in mRNA levels, indicating that changes in mRNA expression are reasonable indicators for microRNA regulation. Using a stringent significance criterion ($FDR < 0.01$) and controlling for multiple testing, we were able to identify a set of 3,078 miRNA-target relations, involving 117 (39%) out of 309 selected miRNAs. Afterwards, we considered the results of this enrichment analysis in the light of information about differentially expressed miRNAs and genes in the T vs N and M vs T comparisons. The study of the regulatory network in tumor development is particularly relevant: it involves the subset of miRNAs differentially expressed in the T vs N comparison, showing a sizeable fold-change and resulting to be associated to at least one supported target gene. The T vs N network we identified includes two components (unconnected subnetworks), involving respectively 6 up-regulated and 17 down-regulated miRNAs together with their putative target genes, part of which are significantly differentially expressed in the same contrast. The biological meaning of the smaller component (Figure 22) pertaining to the 6 miRNAs up-modulated in the T vs N contrast is witnessed by the large proportion of significantly modulated genes among the set of supported target genes represented in the network. This observation outlines that the pure number of up- or down-regulated miRNAs may be scarcely relevant to predict the impact of miRNA regulation on cell behavior, for which gene expression is a proxy.

Some genes are shared targets of different miRNAs. For instance, the PDCD4 gene, a tumor suppressor gene, appears to be the target of three different miRNAs, miR-21, miR-182 and miR-183 (these last are members of the same family), up-regulated in the primary tumor compared with normal counterpart, and resulted significantly down-regulated in the same comparison.

The interplay between the sub-networks modulated by miR-21 and miR-182 deserves some comments. miR-21 is an oncomiR whose role in "licensing" and supporting the neoplastic process since the earliest step of tumorigenesis is well known in different solid tumors; its overexpression, indeed, has been detected in pre-neoplastic lesions of colon mucosa and in advanced adenocarcinomas (Chang et al., 2011a). The connection between miR-21 and miR-182 is particularly intriguing in view of the role of miR-182 in the cytoskeleton reorganization, a process that favors the epithelial-to-mesenchymal transition and fosters cell proliferation and invasion. Among the miR-182 predicted targets, ENTPD5 resulted differentially down-regulated in our analysis. The gene product is a member of the family of ectonucleoside triphosphate diphosphohydrolase (E-NTPDases) enzymes that hydrolyze extracellular tri- and diphosphonucleosides, are components of

cellular purinergic signaling and involved in energy metabolism (Stella et al., 2010). Recently, Mikula et al. showed that both ENTPD5 mRNA and protein levels progressively decrease during the transition from normal colon mucosa, through adenoma, to adenocarcinoma (Mikula et al., 2010). This finding is in line with our results, which additionally indicate miR-182 as a possible regulator of ENTPD5 expression. Overall, our results go beyond the idea of up- or down-regulated miRNA signatures affecting a given cell behavior. Instead, they suggest a complex interplay between up- and down-regulated miRNAs: the admixture thereof is a specific signature of tumor development (or progression), whose modulation (up- or down-) impact in different ways to genes belonging to the same pathway. Final biological output obviously depends on miRNA and gene quality, on direction of modulation, as well as on the pathway structure (i.e. the role of gene products and their direct relationships in the pathway).

6.3. microRNA expression in HTLV-1 infection and adult T-cell leukemia/lymphoma

Using microRNA-arrays, we identified 21 downregulated microRNAs and 6 upregulated microRNAs in ATLL samples with respect to resting CD4⁺ T-cells.

First of all an unsupervised cluster analysis was performed on selected microRNA expression profiles, to eliminate miRNA with very weak signals. The hierarchical cluster analysis showed high heterogeneity among the ATLL patients, although all samples except PT 1 were more similar to resting CD4⁺ cells than to their stimulated counterparts. The resting CD4⁺ controls well clustered together, while the stimulated counterparts differed considerably from each other.

Differential expression analysis on microRNA data highlighted a preponderance of downregulated microRNA expression in tumor cells versus their normal counterparts in agreement with early profiling studies of broad panel of human tumors (Lu et al., 2005). Indeed the two classes statistical analysis performed on ATLL versus resting CD4⁺ miRNAs evidenced 21 down-regulated and 6 up-regulated miRNAs. In particular, functional data in the context of HTLV-1 are already published for miR-130b (Yeung et al., 2008). The predicted promoter region of miR-130b contains potential binding sites for NF- κ B, and is responsive to Tax (Yeung et al., 2008). miR-130b as well as miR-93 (upregulated in ATLL samples examined by Yeung et al.) were found to provide a survival advantage to ATLL cell lines through downregulation of TP53INP1 (tumor protein 53-induced nuclear protein 1) (Yeung et al., 2008), a protein that contributes to cell cycle-arrest- and apoptotic signals transmitted by p53 and p73 in response to DNA damage and other stress conditions (Pouyet and Carrier, 2010; Savkovic et al., 2004).

miR-146b-5p is identical to miR-146a except for 2 differing nucleotides near their 3' ends. Downregulation of miR-146b-5p in ATLL samples is therefore interesting in light of the documented increase in levels of miR-146a in HTLV-1-infected cells (Pichler et al., 2008; Tomita et al., 2009). miR-146a was initially distinguished by its upregulation in myeloid cells exposed to the innate immune stimulus lipopolysaccharide; this induction occurs through the NK-kB pathway and has a role in fine-tuning the innate immune response (Zhao et al., 2011). In CD4⁺ T-cells, miR-146a is induced upon TCR stimulation (Cobb et al., 2006; Curtale et al., 2010), where it contributes to attenuation of the IL-2 signal and protects the cells from AICD (activation-induced cell death) (Curtale et al., 2010; Taganov et al., 2006). Induction of miR-146a in HTLV-1-infected cells is also NF-kB-mediated through Tax, and confers a survival advantage to these cells (Tomita et al., 2009). Increased expression of miR-146a is also observed in EBV-infected B-cells during latency III, the viral growth program that drives B-cell proliferation (Cameron et al., 2008b). These properties, along with the fact that several solid tumors display upregulation of miR-146a/b (Li et al., 2010; Wang et al., 2011), suggest that they could contribute to the transformation process associated with HTLV-1. On the other hand, studies in breast cancer cells (Bhaumik et al., 2008; Hurst et al., 2009) and glioma cells (Xia et al., 2009) indicate that miR-146a and 146b interfere with metastasis and invasion, therefore suggesting tumor suppressor function for these microRNAs in some cell contexts. miR-146a and miR-146b map to chromosomes 5q33 and 10q24, respectively, and their genomic regions differ in terms of promoter elements, length and intron-exon content (Taganov et al., 2006). Determination of the mechanism responsible for downregulation of miR-146b-5p in ATLL cells may therefore add to the understanding of alterations in transcription factors and RNA processing pathways that contribute to the transformation process.

The sequence of miR-125a-5p is very similar to miR-125b, one of 5 microRNAs that target the HIV-1 3'UTR (along with miR-150, miR-28, miR-223 and miR-382) and influence the ability of the virus to productively infect CD4⁺ T-cells, monocytes and macrophages (Huang et al., 2007a; Wang et al., 2009b).

Interesting among 6 miRNA upregulated in the ATLL-resting CD4⁺ comparison is miR-34a known to be upregulated by p53 in response to genotoxic and oncogenic stress and targets genes affecting cell proliferation and survival, resulting in growth arrest, senescence and apoptosis; miR-34a downregulation in several solid tumors suggests its function as a tumor suppressor (Hermeking, 2010). However, miR-34a is upregulated in Epstein-Barr virus-transformed B-cells (Mrazek et al., 2007) during latency type III (Cameron et al., 2008a) and in hepatitis B virus-associated hepatocellular carcinoma (Mizuguchi et al., 2011), and might exert diverse effects depending on the cell context (Dutta et al., 2007). Among hematological cancers miR-34a has been studied most extensively in chronic lymphocytic leukemia (CLL). miR-34a levels vary among CLL cases and can exceed those

found in normal CD19⁺ B-cells (Asslaber et al., 2010), but are consistently lower in tumors bearing mutated or otherwise inactivated p53 (Asslaber et al., 2010; Mraz et al., 2009). This is of interest, as ATLL cells generally harbor functionally inactive p53 (Wang et al., 2009a; Yamada and Kamihira, 2005), implying involvement of alternative pathways driving miR-34a expression. This is supported by studies of human papillomavirus-infected keratinocytes, which show initial downregulation of miR-34a due to interaction of E6 with p53, followed by restoration of miR-34a expression despite continued p53 inactivation (Wang et al., 2009a).

The post-transcriptional regulatory network, involving miRNA differentially expressed in ATLL versus resting CD4⁺ cells and their putative target mRNAs, was reconstructed. Network observation suggests that down-regulated miR-192, miR-212 and miR-31 seem to act in a cooperative way in the cAMP signaling by determining the upregulation of several forms of Adenylate cyclase. Previous studies of miR-34a demonstrated that it targets mRNAs coding for genes affecting cell proliferation and survival, including Cyclins D1 and E2, Bcl-2, CDK4 and CDK6, c-Myc and N-Myc, E2F3, Met, and SIRT1. In turn, downregulation of SIRT1 enhances p53 activity (Hermeking, 2010; Yamakuchi and Lowenstein, 2009). Among the potential microRNA targets revealed for miR-34a in our analysis, STAT4 is of particular interest. STAT4 is a transcription factor that plays an important role in mediating proinflammatory immune responses (Kaplan, 2005). Studies of STAT4-deficient mice demonstrated its importance for biologic responses to IL-12, including production of IFN-gamma (Watford et al., 2004).

Moreover, in some enriched GO term “regulation of biological quality”, “primary metabolic process” and “developmental process” we found several members of the RAS superfamily of small GTPase, RAB14, RAB23, RHOQ (Ras homolog gene family, member Q), and RAC1, predicted to be targets of several miRNA in the network (miR-31, miR-30b, miR-142-5p). Several RAS proteins have been associated with cancer cell migration and invasiveness.

Furthermore, the involvement of many miRNA supported target genes in critical biological circuits leading to ATLL was also reinforced from the enrichment in KEGG pathway in “pathway in cancer”, “Wnt-signaling pathway” and “cell cycle”.

6.4. MAGIA, a web-based tool for miRNA and Genes Integrated Analysis

The integrative analysis of target prediction, miRNA and gene expression profiles is not straightforward for most experimental researchers, not only for problems regarding miRNA and targets annotations, but also for the many-to-many nature of predicted relationships to be considered and the extensive time requirements of computations.

However, there is an increasing amount of experimental studies aiming at gaining molecular understanding of biological processes or diseases from the computation and the visualization of high-throughput systems biology analyses results. Available tools are not adequate to the rapidly increasing amount of matched miRNA–gene profiles, the analysis of which could gain a remarkable advantage from target predictions and miRNA–gene expression profiles integration. MAGIA (MiRNA And Genes Integrated Analysis) tries to fill these gaps allowing the combination of target predictions for either matched or unmatched expression miRNA–gene profiles. Using different relatedness measures and integration methods, MAGIA refines target predictions and reconstructs miRNA–gene bipartite networks. In this context, MAGIA is a useful, timely and easy-to-use web tool that will facilitate users in the investigation of the post-transcriptional regulatory networks and in the discovery of biologically relevant regulatory circuits.

6.5. Impact of host genes and strand selection on miRNA and miRNA* expression

Post-transcriptional regulation in miRNA biogenesis, namely strand selection, and expression relationships between intragenic miRNAs and host genes was investigated exploiting sequence, genomic and expression information.

Our observations were based on a comprehensive collection of miRNAs and genes/transcripts whose annotation and localization was integrated with expression profiles computed from five large microarray-based datasets, regarding different biological contexts and including both normal and tumor/disease samples. At least 8 different tissues types are represented (breast, prostate, liver, ovary, testes, lung, colon and brain) plus different T- and B-lineage blood cells. The high number of samples and the broad coverage of cell types would guarantee both significance and fair generality of the obtained results.

The first evidence emerging from our analysis regards the expression behavior of pairs of sister mature miRNAs produced from the same hairpin. In the classic model of miRNA biogenesis, the duplex of mature miRNAs is produced by Dicer processing of the hairpin precursor. Then, a following strand selection step determines which mature miRNA is the degraded “passenger” strand and which is the major and stable form that will act as guide for the mature miRISC complex in the post-transcriptional silencing of target genes. It is worth notice that the two mature miRNAs have different sets of target genes and may differently contribute to the regulation of cell activities. The analysis of expression profiles showed that, considering different samples, representing different tissue types under various conditions, the strand selection is highly regulated. In fact, we observed miRNA pairs in which the same miRNA is the most expressed in the majority of

considered samples, as well as miRNA pairs expressed at comparable level in almost all considered samples. Nevertheless, the large majority of miRNA pairs show a not deterministic strand selection bias, which may be highly regulated since it shows tissue-/cell-/condition-specific modulation. This is confirmed by the fact that unsupervised analysis, using for samples classification only information about the direction and the strength of the strand selection bias, is able to distinguish different tissues, and sometimes also different conditions (as normal and malignant cells). Moreover, when considering a minimum expression threshold, only a minority of pairs were expressed alternatively in all considered cell types, whereas the majority were concurrently expressed in some cell types and alternatively in others. A significant fraction of concurrently expressed pairs showed highly comparable levels, suggesting that both the major and the minor forms may contribute to post-transcriptional gene silencing, possibly in a coordinate way. Also considering separately alternatively and concurrently expressed pairs, the regulated nature of the strand selection is evident. All these results highlighted once again the complexity of miRNA biogenesis regulation that is also emerging from sequencing data analysis, continuously adding novel layers to miRNAs biogenesis pathways and enriching possibilities for their regulation.

The second aim of the study was to clarify to what extent intragenic miRNAs were co-expressed with the corresponding host genes. An intragenic miRNAs and host genes related behavior has been taken for proven by different Authors and used as a strong assumption for the design of computational methods for miRNA targets identification (Moreau et al., 2003) or to go further and explore the possible role of intragenic miRNAs in supporting the regulatory activity of host genes products (Mi et al., 2007). We considered four expression datasets including expression profiles in various cell types (brain in normal and with Alzheimer disease conditions, normal prostate and prostate cancer, normal blood cells and different blood cell diseases) and clearly showed, that the large majority of intragenic miRNAs do not share similar expression profiles with their host genes. Only 10% of miRNA and host gene pairs appear significantly co-expressed. This may be partially explained by the fact that not all miRNAs located in introns of protein coding genes are under the transcriptional control of coding gene promoter(s). In fact, Corcoran and colleagues (2009) (Corcoran et al., 2009) experimentally identified mammalian miRNA Polymerase II promoters by chromatin immunoprecipitation. They discovered that the nearest ChIP-chip peak for a number of intragenic miRNAs overlaps the host gene's TSS but that reportedly one quarter of intragenic miRNAs may be transcribed from their own promoters and thus showing different expression behavior and modulation than the protein-coding gene transcript(s). This result, as well our findings and considerations, encourage much more detailed studies about transcriptional regulation of miRNAs expression.

Moreover, host genes expression profiles were proposed as possible proxies for the intragenic miRNA expression profile, when the latter is unavailable, to identify most probable miRNA target genes. So we conducted two integrated analysis of target prediction and expression profiles, one using real miRNA and gene expression profiles, and the second using host genes expression profiles as proxy for miRNAs, and gene expression profiles. The comparative evaluation of the two methods was based on an independent true solution, represented by a set of validated regulatory interactions. This allowed to measure and compare the effectiveness of the two methods in finding validated regulatory interactions, among the subset of predicted miRNA-target relations supported by negative correlations of expression profiles. Our results support the usefulness of the integrated analysis conducted on real miRNAs expression profiles, when stringency is kept reasonably high. Moreover, as expected from previous observations about intragenic miRNAs and host genes scarce co-expression, we experienced that the use of host genes expression as a proxy for miRNA profiles for the integrated analysis seems not significantly enrich in validated relations.

We can conclude that the large majority of miRNA pairs show a not deterministic strand selection bias, which may be highly regulated, since it presents tissue-/cell-/condition-specific modulation reinforcing the importance of the strand selection regulation, adding the role of such layer of miRNA biogenesis in miRNA-based control of cell activities. Furthermore, our results showed that most host genes and intragenic miRNAs are scarcely co-expressed. In specific cases, they might be co/expressed but mainly in a cell/tissue-specific way. This actually does not rule out the importance of already documented cooperation of specific intragenic miRNAs and host genes products, but proves that the expression information of corresponding host genes can hardly be used as estimator for actual expression of the co-transcribed miRNA and encourage more detailed studies of transcriptional regulation of miRNAs expression.

6.6. Characterization and discovery of novel miRNAs and moRNAs in JAK2V617F mutated SET2 cell

By exploiting deep sequencing data the fraction of short RNAs expressed in SET2 cells, a JAK2V617F mutated cell line was characterized and analyzed in integration with different levels of genomic information and metadata concerning known hairpin loci.

We focused on known miRNA loci by considering 1,421 known hairpin precursors and 1,731 known mature miRNAs, including hundreds of new miRNAs discovered by massive sequencing approaches.

The expression of known mature miRNAs from sequencing data has been estimated with a method able to correct for multiple mapping issues. Reads multiple mapping might arise

from variable reasons largely attributable to miRNA loci redundancy and similarity, to the existence of miRNA families, as well to reads-to-reference sequence mapping choices. The problem of mapping quality was considerably overlooked by different studies that recently exploited RNA-seq for miRNAs and isomiRs discovery. It has been shown (Papadopoulos et al., 2009a) that short reads are prone to map to multiple genomic loci with an equal number of mismatches (or even without mismatches), in particular among multicopy miRNA precursors (identical mature miRNAs may be produced by different hairpins, transcribed from different loci) and miRNA families. Other studies considered only reads with unique mapping (Petrocca et al., 2008), although a too restrictive mapping settings may affect quantitative estimation of multicopy miRNAs. Basically, we implemented a “multiple-mapping corrected read count” to quantify correctly expression levels relatively to both hairpin and mature miRNAs, also including multilocus miRNAs and miRNA families.

Another main finding of the study regards mature miRNA sequence variation. We showed that mature miRNAs were no longer represented by a unique sequence, i.e. the one annotated in miRBase, rather they were found as mixtures of sequence variants, called isomiRs, that derive mainly from non-canonical processing of hairpin precursors. Two third of miRNAs expressed in SET2 cells were found associated to different sequences. Data showed that 60% of miRNAs are associated to 2-4 isomiRs, that differ from the most expressed isomiR only for 5' and 3' sequence length, but align exactly to the hairpin precursor. This might imply that most isomiRs arise as a consequence of alternative processing of miRNA precursors. Interestingly, the sequence variability of isomiRs regards prevalently the 3' region of mature miRNAs, but 8% of isomiRs differ from the “classic” miRNA sequence in the 5' region, possibly impacting on target recognition and/or regulatory activity and strength. Future evaluations of isomiR quality and proportion in different cell types will help to clarify if and how much this miRNA biogenesis feature is cell- and context-specifically regulated.

In the second part of the study, we exploited the discovery power of RNA-seq to identify a consistent number of novel short RNAs expressed from miRNA loci in SET2 cells. It is worth notice that RNA discovery results were produced using only read aligning exactly to hairpin loci in order to minimize artifacts. At variance with other studies, we mapped sequence reads to extended hairpin loci, i.e. the hairpin precursor genomic regions plus 30 nucleotides upstream and downstream. This allowed us to uncover novel short RNAs derived from extended hairpin loci transcription and canonical or non-canonical processing. More specifically, we discovered 78 novel miRNAs expressed from known hairpin precursors. These are all new miRNA*, 11 of which are expressed in SET2 cells over the median value observed for the group of detected known miRNAs.

These data confirm recent findings about the importance of miRNA* (Kuchenbauer et al., 2011). Considering known and new miRNAs together, we took into account expression

behavior of pairs of miRNAs derived from 5 and 3' strands of the same hairpin (miRNA/miRNA*, so called "sister miRNAs"). Sister miRNAs have different sequences and target different sets of coding RNAs. We showed that for about one half of hairpins both sister miRNAs are expressed concurrently; very likely, both contribute to target repression. Moreover, slightly less than one quarter of concurrently detected sister miRNA pairs were expressed at the same or comparable level. No strand prevalence was observed. These results further support theories about the not deterministic nature of strand selection bias, that appears to be regulated in cell-, tissue- and condition-specific way. Also, our findings are compatible with the two-steps cleavage of hairpin RNA by Dicer(Burroughs et al., 2011); bidirectional binding of processed dsRNAs by Dicer may indeed result in directional presentation of double strand miRNA duplex to Argonaute influencing the strand selection bias.

Very interestingly, we found short expressed RNAs derived from regions of extended hairpins outside known and new miRNAs. These are members of a novel class of miRNA-related RNAs, called micro-RNA offset RNAs (moRNAs)(Fernandez-Valverde et al., 2010) recently identified by massive short RNAseq. In the present study 58 moRNAs expressed from 56 hairpins at moderate to high level were identified. In particular hsa-5'-moR-103a-2, hsa-5'-moR-106b, hsa-5'-moR-19b-1 and hsa-5'-moR-16-1 were highly expressed in SET2 cells. It was also of interest that 5 of the 16 most expressed moRNAs were associated with the 17-92 (miR-19b-1, miR-20a, miR-92a, miR-19a) and the 106-25 (miR-106b) cluster, as discussed above for miRNAs. Of note, some of the highly expressed moRNAs were unique and did not perfectly overlap the most expressed miRNAs from the same cluster, suggesting that activation of the cluster might result in global up- regulation of the genes but also in a non-balanced ratio between miRNAs and moRNAs.

Evidence regarding possible functions of moRNAs is still fragmentary(Fernandez-Valverde et al., 2010); one hypothesis claims that moRNAs might guide RISC to complementary target mRNAs as miRNAs do(Guo et al., 2011). Nevertheless, the fact that moRNAs are nuclear enriched may support the alternative hypothesis that moRNAs intervene specifically in nuclear processes as other nuclear short and long RNAs do. Therefore, moRNAs can be viewed as a new class of regulators whose qualitative and/or expression abnormalities might impact on human diseases. In this view, the discovery of expressed moRNAs in SET2 cells is intriguing.

In summary, we have extensively characterized the profile of short RNAs expressed in SET2 cells, a model used for mechanistic and drug sensitivity studies in the field of MPNs. This information could be useful for further characterization of the cell model and future studies involving primary MPN cells. It will be key to understand how the interplay of known and new miRNAs, isomiRs, and moRNAs contribute to the abnormal regulation of cell proliferation that characterizes MPN cells and whether and how novel

drugs affect this complex system of regulators. Taken together, our results regarding isomiRs and moRNA expression fit well in the “RNA in pieces” phenomenon(Berezikov et al., 2011b): many transcripts undergo post-transcriptional cleavage to release specific, functionally independent, fragments expanding the spectrum of regulatory RNAs produced by the human genome and from single loci.

Reference List

- Albert, R. (2005). Scale-free networks in cell biology. *J. Cell. Sci.* *118*, 4947-4957.
- Albert, R., Albert, I., and Nakarado, G.L. (2004). Structural vulnerability of the North American power grid. *Phys. Rev. E. Stat. Nonlin Soft Matter Phys.* *69*, 025103.
- Alexiou, P., Maragkakis, M., Papadopoulos, G.L., Reczko, M., and Hatzigeorgiou, A.G. (2009). Lost in translation: an assessment and perspective for computational microRNA target identification *Bioinformatics* *25*, 3049-3055.
- Almaas, E. (2007). Biological impacts and context of network theory. *J. Exp. Biol.* *210*, 1548-1558.
- Ando, Y., Maida, Y., Morinaga, A., Burroughs, A.M., Kimura, R., Chiba, J., Suzuki, H., Masutomi, K., and Hayashizaki, Y. (2011). Two-step cleavage of hairpin RNA with 5' overhangs by human DICER *BMC Mol. Biol.* *12*, 6.
- Asslaber, D., Pinon, J.D., Seyfried, I., Desch, P., Stocher, M., Tinhofer, I., Egle, A., Merkel, O., and Greil, R. (2010). microRNA-34a expression correlates with MDM2 SNP309 polymorphism and treatment-free survival in chronic lymphocytic leukemia *Blood* *115*, 4191-4197.
- Axtell, M.J., Westholm, J.O., and Lai, E.C. (2011). Vive la difference: biogenesis and evolution of microRNAs in plants and animals. *Genome Biol.* *12*, 221.
- Baek, D., Villen, J., Shin, C., Camargo, F.D., Gygi, S.P., and Bartel, D.P. (2008). The impact of microRNAs on protein output *Nature* *455*, 64-71.
- Bagga, S., Bracht, J., Hunter, S., Massirer, K., Holtz, J., Eachus, R., and Pasquinelli, A.E. (2005). Regulation by let-7 and lin-4 miRNAs results in target mRNA degradation *Cell* *122*, 553-563.
- Barabasi, A.L., and Albert, R. (1999). Emergence of scaling in random networks. *Science* *286*, 509-512.
- Bashir, T., and Pagano, M. (2003). Aberrant ubiquitin-mediated proteolysis of cell cycle regulatory proteins and oncogenesis *Adv. Cancer Res.* *88*, 101-144.

- Basso, K., Margolin, A.A., Stolovitzky, G., Klein, U., Dalla-Favera, R., and Califano, A. (2005a). Reverse engineering of regulatory networks in human B cells *Nat. Genet.* *37*, 382-390.
- Basso, K., Margolin, A.A., Stolovitzky, G., Klein, U., Dalla-Favera, R., and Califano, A. (2005b). Reverse engineering of regulatory networks in human B cells. *Nat. Genet.* *37*, 382-390.
- Berezikov, E., Robine, N., Samsonova, A., Westholm, J.O., Naqvi, A., Hung, J.H., Okamura, K., Dai, Q., Bortolamiol-Becet, D., Martin, R., *et al.* (2011a). Deep annotation of *Drosophila melanogaster* microRNAs yields insights into their processing, modification, and emergence *Genome Res.* *21*, 203-215.
- Berezikov, E., Robine, N., Samsonova, A., Westholm, J.O., Naqvi, A., Hung, J.H., Okamura, K., Dai, Q., Bortolamiol-Becet, D., Martin, R., *et al.* (2011b). Deep annotation of *Drosophila melanogaster* microRNAs yields insights into their processing, modification, and emergence *Genome Res.* *21*, 203-215.
- Betel, D., Koppal, A., Agius, P., Sander, C., and Leslie, C. (2010). Comprehensive modeling of microRNA targets predicts functional non-conserved and non-canonical sites *Genome Biol.* *11*, R90.
- Bhaumik, D., Scott, G.K., Schokrpur, S., Patil, C.K., Campisi, J., and Benz, C.C. (2008). Expression of microRNA-146 suppresses NF-kappaB activity with reduction of metastatic potential in breast cancer cells. *Oncogene* *27*, 5643-5647.
- Biasiolo, M., Forcato, M., Possamai, L., Ferrari, F., Agnelli, L., Lionetti, M., Todoerti, K., Neri, A., Marchiori, M., Bortoluzzi, S., and Bicciato, S. (2010). Critical analysis of transcriptional and post-transcriptional regulatory networks in multiple myeloma. *Pac. Symp. Biocomput.* 397-408.
- Biasiolo, M., Sales, G., Lionetti, M., Agnelli, L., Todoerti, K., Bisognin, A., Coppe, A., Romualdi, C., Neri, A., and Bortoluzzi, S. (2011). Impact of Host Genes and Strand Selection on miRNA and miRNA* Expression *PLoS One* *6*, e23854.
- Bortoluzzi, S., Biasiolo, M., and Bisognin, A. (2011). microRNA-offset RNAs (moRNAs): by-product spectators or functional players? *Trends in Molecular Medicine*
- Bortoluzzi, S., Bisognin, A., Biasolo, M., Guglielmelli, P., Biamonte, F., Norfo, R., Manfredini, R., and Vannucchi, A.M. (2012). Characterisation and discovery of novel miRNAs and moRNAs in JAK2V617F mutated SET2 cells *Blood*
- Brito, J.L., Walker, B., Jenner, M., Dickens, N.J., Brown, N.J., Ross, F.M., Avramidou, A., Irving, J.A., Gonzalez, D., Davies, F.E., and Morgan, G.J. (2009). MMSET

deregulation affects cell cycle progression and adhesion regulons in t(4;14) myeloma plasma cells. *Haematologica* 94, 78-86.

Brosnan, C.A., and Voinnet, O. (2009). The long and the short of noncoding RNAs *Curr. Opin. Cell Biol.* 21, 416-425.

Bruchova, H., Merkerova, M., and Prchal, J.T. (2008). Aberrant expression of microRNA in polycythemia vera *Haematologica* 93, 1009-1016.

Bruchova, H., Yoon, D., Agarwal, A.M., Mendell, J., and Prchal, J.T. (2007). Regulated expression of microRNAs in normal and polycythemia vera erythropoiesis *Exp. Hematol.* 35, 1657-1667.

Burroughs, A.M., Ando, Y., de Hoon, M.J., Tomaru, Y., Suzuki, H., Hayashizaki, Y., and Daub, C.O. (2011). Deep-sequencing of human Argonaute-associated small RNAs provides insight into miRNA sorting and reveals Argonaute association with RNA fragments of diverse origin *Biol.* 8, 158-177.

Butte, A.J., and Kohane, I.S. (2000). Mutual information relevance networks: functional genomic clustering using pairwise entropy measurements *Pac. Symp. Biocomput.* 418-429.

Cai, Y., Yu, X., Hu, S., and Yu, J. (2009). A Brief Review on the Mechanisms of miRNA Regulation *Genomics, Proteomics & Bioinformatics* 7, 147 <last_page> 154.

Calin, G.A., and Croce, C.M. (2009). Chronic lymphocytic leukemia: interplay between noncoding RNAs and protein-coding genes *Blood* 114, 4761-4770.

Cameron, J.E., Fewell, C., Yin, Q., McBride, J., Wang, X., Lin, Z., and Flemington, E.K. (2008a). Epstein-Barr virus growth/latency III program alters cellular microRNA expression *Virology* 382, 257-266.

Cameron, J.E., Fewell, C., Yin, Q., McBride, J., Wang, X., Lin, Z., and Flemington, E.K. (2008b). Epstein-Barr virus growth/latency III program alters cellular microRNA expression *Virology* 382, 257-266.

Chang, K.H., Miller, N., Kheirleiseid, E.A., Ingoldsby, H., Hennessy, E., Curran, C.E., Curran, S., Smith, M.J., Regan, M., McAnena, O.J., and Kerin, M.J. (2011a). MicroRNA-21 and PDCD4 expression in colorectal cancer. *Eur. J. Surg. Oncol.* 37, 597-603.

Chang, K.H., Miller, N., Kheirleiseid, E.A., Lemetre, C., Ball, G.R., Smith, M.J., Regan, M., McAnena, O.J., and Kerin, M.J. (2011b). MicroRNA signature analysis in colorectal cancer: identification of expression profiles in stage II tumors associated with aggressive disease. *Int. J. Colorectal Dis.* 26, 1415-1422.

Cheng, C., Yan, K.K., Hwang, W., Qian, J., Bhardwaj, N., Rozowsky, J., Lu, Z.J., Niu, W., Alves, P., Kato, M., Snyder, M., and Gerstein, M. (2011). Construction and analysis of an integrated regulatory network derived from high-throughput sequencing data *PLoS Comput. Biol.* *7*, e1002190.

Chien, Y., and White, M.A. (2003). RAL GTPases are linchpin modulators of human tumour-cell proliferation and survival *EMBO Rep.* *4*, 800-806.

Chiusaroli, R., Knobler, H., Luxenburg, C., Sanjay, A., Granot-Attas, S., Tiran, Z., Miyazaki, T., Harmelin, A., Baron, R., and Elson, A. (2004). Tyrosine phosphatase epsilon is a positive regulator of osteoclast function in vitro and in vivo. *Mol. Biol. Cell* *15*, 234-244.

Chng, W.J., Kumar, S., Vanwier, S., Ahmann, G., Price-Troska, T., Henderson, K., Chung, T.H., Kim, S., Mulligan, G., Bryant, B., *et al.* (2007). Molecular dissection of hyperdiploid multiple myeloma by gene expression profiling *Cancer Res.* *67*, 2982-2989.

Cobb, B.S., Hertweck, A., Smith, J., O'Connor, E., Graf, D., Cook, T., Smale, S.T., Sakaguchi, S., Livesey, F.J., Fisher, A.G., and Merckenschlager, M. (2006). A role for Dicer in immune regulation *J. Exp. Med.* *203*, 2519-2527.

Colla, S., Tagliaferri, S., Morandi, F., Lunghi, P., Donofrio, G., Martorana, D., Mancini, C., Lazzaretti, M., Mazzera, L., Ravanetti, L., *et al.* (2007). The new tumor-suppressor gene inhibitor of growth family member 4 (ING4) regulates the production of proangiogenic molecules by myeloma cells and suppresses hypoxia-inducible factor-1 alpha (HIF-1alpha) activity: involvement in myeloma-induced angiogenesis. *Blood* *110*, 4464-4475.

Corcoran, D.L., Pandit, K.V., Gordon, B., Bhattacharjee, A., Kaminski, N., and Benos, P.V. (2009). Features of mammalian microRNA promoters emerge from polymerase II chromatin immunoprecipitation data *PLoS One* *4*, e5279.

Crucitti, P., Latora, V., and Marchiori, M. (2004). Model for cascading failures in complex networks. *Phys. Rev. E. Stat. Nonlin Soft Matter Phys.* *69*, 045104.

Crucitti, P., Latora, V., Marchiori, M., and Rapisarda, A. (2003). Efficiency of scale-free networks: error and attack tolerance. *Physica A* *320*, 622-642.

Curtale, G., Citarella, F., Carissimi, C., Goldoni, M., Carucci, N., Fulci, V., Franceschini, D., Meloni, F., Barnaba, V., and Macino, G. (2010). An emerging player in the adaptive immune response: microRNA-146a is a modulator of IL-2 expression and activation-induced cell death in T lymphocytes *Blood* *115*, 265-273.

- De Smet, R., and Marchal, K. (2010). Advantages and limitations of current network inference methods *Nat. Rev. Microbiol.* *8*, 717-729.
- Didiano, D., and Hobert, O. (2008). Molecular architecture of a miRNA-regulated 3' UTR. *RNA* *14*, 1297-1317.
- Dorogovtsev, S.N., and Mendes, J.F.F. (2003). *Evolution of networks: from biological nets to the Internet and WWW* (Oxford: Oxford University Press).
- Dutta, K.K., Zhong, Y., Liu, Y.T., Yamada, T., Akatsuka, S., Hu, Q., Yoshihara, M., Ohara, H., Takehashi, M., Shinohara, T., *et al.* (2007). Association of microRNA-34a overexpression with proliferation is cell type-dependent *Cancer. Sci.* *98*, 1845-1852.
- Eisen, M.B., Spellman, P.T., Brown, P.O., and Botstein, D. (1998). Cluster analysis and display of genome-wide expression patterns. *Proc. Natl. Acad. Sci. U. S. A.* *95*, 14863-14868.
- Emmert-Streib, F., and Dehmer, M. (2009). Information processing in the transcriptional regulatory network of yeast: functional robustness. *BMC Syst. Biol.* *3*, 35.
- Enright, A.J., John, B., Gaul, U., Tuschl, T., Sander, C., and Marks, D.S. (2003a). MicroRNA targets in *Drosophila*. *Genome Biol.* *5*, R1.
- Enright, A.J., John, B., Gaul, U., Tuschl, T., Sander, C., and Marks, D.S. (2003b). MicroRNA targets in *Drosophila* *Genome Biol.* *5*, R1.
- Erson, A.E., and Petty, E.M. (2008). MicroRNAs in development and disease *Clin. Genet.* *74*, 296-306.
- Esquela-Kerscher, A., and Slack, F.J. (2006). Oncomirs - microRNAs with a role in cancer *Nat. Rev. Cancer.* *6*, 259-269.
- Faith, J.J., Hayete, B., Thaden, J.T., Mogno, I., Wierzbowski, J., Cottarel, G., Kasif, S., Collins, J.J., and Gardner, T.S. (2007). Large-scale mapping and validation of *Escherichia coli* transcriptional regulation from a compendium of expression profiles *PLoS Biol.* *5*, e8.
- Fasold, M., Langenberger, D., Binder, H., Stadler, P.F., and Hoffmann, S. (2011). DARIO: a ncRNA detection and analysis tool for next-generation sequencing experiments *Nucleic Acids Res.* *39*, W112-7.
- Fernandez-Valverde, S.L., Taft, R.J., and Mattick, J.S. (2010). Dynamic isomiR regulation in *Drosophila* development *RNA* *16*, 1881-1888.

Ferrari, F., Bortoluzzi, S., Coppe, A., Sirota, A., Safran, M., Shmoish, M., Ferrari, S., Lancet, D., Danieli, G.A., and Bicciato, S. (2007). Novel definition files for human GeneChips based on GeneAnnot BMC Bioinformatics 8, 446.

Filipowicz, W., and Grosshans, H. (2011). The liver-specific microRNA miR-122: biology and therapeutic potential Prog. Drug Res. 67, 221-238.

Fracchiolla, N.S., Colombo, G., Finelli, P., Maiolo, A.T., and Neri, A. (1998). EHT, a new member of the MTG8/ETO gene family, maps on 20q11 region and is deleted in acute myeloid leukemias. Blood 92, 3481-3484.

Friedman, R.C., Farh, K.K., Burge, C.B., and Bartel, D.P. (2009). Most mammalian mRNAs are conserved targets of microRNAs Genome Res. 19, 92-105.

Fulci, V., Colombo, T., Chiaretti, S., Messina, M., Citarella, F., Tavolaro, S., Guarini, A., Foa, R., and Macino, G. (2009). Characterization of B- and T-lineage acute lymphoblastic leukemia by integrated analysis of MicroRNA and mRNA expression profiles. Genes Chromosomes Cancer 48, 1069-1082.

Garzon, R., Pichiorri, F., Palumbo, T., Visentini, M., Aqeilan, R., Cimmino, A., Wang, H., Sun, H., Volinia, S., Alder, H., *et al.* (2007). MicroRNA gene expression during retinoic acid-induced differentiation of human acute promyelocytic leukemia Oncogene 26, 4148-4157.

Gennarino, V.A., Sardiello, M., Avellino, R., Meola, N., Maselli, V., Anand, S., Cuttillo, L., Ballabio, A., and Banfi, S. (2009). MicroRNA target prediction by expression analysis of host genes. Genome Res. 19, 481-490.

Golan, D., Levy, C., Friedman, B., and Shomron, N. (2010). Biased hosting of intronic microRNA genes. Bioinformatics 26, 992-995.

Goncalves, D.U., Proietti, F.A., Ribas, J.G., Araujo, M.G., Pinheiro, S.R., Guedes, A.C., and Carneiro-Proietti, A.B. (2010). Epidemiology, treatment, and prevention of human T-cell leukemia virus type 1-associated diseases Clin. Microbiol. Rev. 23, 577-589.

Grimson, A., Farh, K.K., Johnston, W.K., Garrett-Engele, P., Lim, L.P., and Bartel, D.P. (2007a). MicroRNA targeting specificity in mammals: determinants beyond seed pairing Mol. Cell 27, 91-105.

Grimson, A., Farh, K.K., Johnston, W.K., Garrett-Engele, P., Lim, L.P., and Bartel, D.P. (2007b). MicroRNA targeting specificity in mammals: determinants beyond seed pairing. Mol. Cell 27, 91-105.

- Guan, D.G., Liao, J.Y., Qu, Z.H., Zhang, Y., and Qu, L.H. (2011). mirExplorer: Detecting microRNAs from genome and next generation sequencing data using the AdaBoost method with transition probability matrix and combined features. *RNA Biol.* *8*,
- Guglielmelli, P., Tozzi, L., Bogani, C., Iacobucci, I., Ponziani, V., Martinelli, G., Bosi, A., Vannucchi, A.M., and AGIMM (AIRC-Gruppo Italiano Malattie Mieloproliferative) Investigators. (2011). Overexpression of microRNA-16-2 contributes to the abnormal erythropoiesis in polycythemia vera *Blood* *117*, 6923-6927.
- Guglielmelli, P., Tozzi, L., Pancrazzi, A., Bogani, C., Antonioli, E., Ponziani, V., Poli, G., Zini, R., Ferrari, S., Manfredini, R., *et al.* (2007). MicroRNA expression profile in granulocytes from primary myelofibrosis patients *Exp. Hematol.* *35*, 1708-1718.
- Guo, L., Liang, T., and Lu, Z. (2011). A comprehensive study of multiple mapping and feature selection for correction strategy in the analysis of small RNAs from SOLiD sequencing *BioSystems* *104*, 87-93.
- Hackenberg, M., Sturm, M., Langenberger, D., Falcon-Perez, J.M., and Aransay, A.M. (2009). miRanalyzer: a microRNA detection and analysis tool for next-generation sequencing experiments *Nucleic Acids Res.* *37*, W68-76.
- Hahne, J.C., Kummer, S., Heukamp, L.C., Fuchs, T., Gun, M., Langer, B., Von Ruecker, A., and Wernert, N. (2009). Regulation of protein tyrosine kinases in tumour cells by the transcription factor Ets-1 *Int. J. Oncol.* *35*, 989-996.
- Hecker, M., Lambeck, S., Toepfer, S., van Someren, E., and Guthke, R. (2009). Gene regulatory network inference: data integration in dynamic models-a review *BioSystems* *96*, 86-103.
- Hermeking, H. (2010). The miR-34 family in cancer and apoptosis *Cell Death Differ.* *17*, 193-199.
- Holme, P., Kim, B.J., Yoon, C.N., and Han, S.K. (2002). Attack vulnerability of complex networks *Phys. Rev. E. Stat. Nonlin Soft Matter Phys.* *65*, 056109.
- Hrstka, R., Coates, P.J., and Vojtesek, B. (2009). Polymorphisms in p53 and the p53 pathway: roles in cancer susceptibility and response to treatment *J. Cell. Mol. Med.* *13*, 440-453.
- Hu, Z., Shu, Y., Chen, Y., Chen, J., Dong, J., Liu, Y., Pan, S., Xu, L., Xu, J., Wang, Y., *et al.* (2010). Genetic Polymorphisms in the pre-MicroRNA Flanking Region and Non-Small-Cell Lung Cancer Survival *Am. J. Respir. Crit. Care Med.*

- Huang da, W., Sherman, B.T., and Lempicki, R.A. (2009). Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources *Nat. Protoc.* *4*, 44-57.
- Huang, J., Wang, F., Argyris, E., Chen, K., Liang, Z., Tian, H., Huang, W., Squires, K., Verlinghieri, G., and Zhang, H. (2007a). Cellular microRNAs contribute to HIV-1 latency in resting primary CD4+ T lymphocytes *Nat. Med.* *13*, 1241-1247.
- Huang, J.C., Babak, T., Corson, T.W., Chua, G., Khan, S., Gallie, B.L., Hughes, T.R., Blencowe, B.J., Frey, B.J., and Morris, Q.D. (2007b). Using expression profiling data to identify human microRNA targets *Nat. Methods* *4*, 1045-1049.
- Huang, J.C., Morris, Q.D., and Frey, B.J. (2007c). Bayesian inference of MicroRNA targets from sequence and expression data *J. Comput. Biol.* *14*, 550-563.
- Huang, X., Le, Q.T., and Giaccia, A.J. (2010). MiR-210--micromanager of the hypoxia pathway *Trends Mol. Med.* *16*, 230-237.
- Hurst, D.R., Edmonds, M.D., Scott, G.K., Benz, C.C., Vaidya, K.S., and Welch, D.R. (2009). Breast cancer metastasis suppressor 1 up-regulates miR-146, which suppresses breast cancer metastasis. *Cancer Res.* *69*, 1279-1283.
- Inoue, K., Mallakin, A., and Frazier, D.P. (2007). Dmp1 and tumor suppression. *Oncogene* *26*, 4329-4335.
- Iturria-Medina, Y., Sotero, R.C., Canales-Rodriguez, E.J., Aleman-Gomez, Y., and Melie-Garcia, L. (2008). Studying the human brain anatomical network via diffusion-weighted MRI and Graph Theory. *Neuroimage* *40*, 1064-1076.
- Jazdzewski, K., Liyanarachchi, S., Swierniak, M., Pachucki, J., Ringel, M.D., Jarzab, B., and de la Chapelle, A. (2009). Polymorphic mature microRNAs from passenger strand of pre-miR-146a contribute to thyroid cancer *Proc. Natl. Acad. Sci. U. S. A.* *106*, 1502-1505.
- Jeffries, C.D., Fried, H.M., and Perkins, D.O. (2010). Additional layers of gene regulatory complexity from recently discovered microRNA mechanisms *Int. J. Biochem. Cell Biol.* *42*, 1236-1242.
- Jeong, H., Mason, S.P., Barabasi, A.L., and Oltvai, Z.N. (2001). Lethality and centrality in protein networks *Nature* *411*, 41-42.
- Jeong, H., Tombor, B., Albert, R., Oltvai, Z.N., and Barabasi, A.L. (2000). The large-scale organization of metabolic networks *Nature* *407*, 651-654.

- Jiang, Q., Wang, Y., Hao, Y., Juan, L., Teng, M., Zhang, X., Li, M., Wang, G., and Liu, Y. (2009). miR2Disease: a manually curated database for microRNA deregulation in human disease *Nucleic Acids Res.* *37*, D98-104.
- Jin, W., Grant, J.R., Stothard, P., Moore, S.S., and Guan, L.L. (2009). Characterization of bovine miRNAs by sequencing and bioinformatics analysis. *BMC Mol. Biol.* *10*, 90.
- John, B., Enright, A.J., Aravin, A., Tuschl, T., Sander, C., and Marks, D.S. (2004). Human MicroRNA targets *PLoS Biol.* *2*, e363.
- Jongen-Lavrencic, M., Sun, S.M., Dijkstra, M.K., Valk, P.J., and Lowenberg, B. (2008). MicroRNA expression profiling in relation to the genetic heterogeneity of acute myeloid leukemia *Blood* *111*, 5078-5085.
- Kang, H.S., Lee, B.S., Yang, Y., Park, C.W., Ha, H.J., Pyun, K.H., and Choi, I. (1996). Roles of protein phosphatase 1 and 2A in an IL-6-mediated autocrine growth loop of human myeloma cells. *Cell. Immunol.* *168*, 174-183.
- Kaplan, M.H. (2005). STAT4: a critical regulator of inflammation in vivo *Immunol. Res.* *31*, 231-242.
- Kertesz, M., Iovino, N., Unnerstall, U., Gaul, U., and Segal, E. (2007). The role of site accessibility in microRNA target recognition *Nat. Genet.* *39*, 1278-1284.
- Kim, S. (2005a). HuntIN4 new tumor suppressors. *Cell. Cycle* *4*, 516-517.
- Kim, V.N. (2005b). MicroRNA biogenesis: coordinated cropping and dicing. *Nat. Rev. Mol. Cell Biol.* *6*, 376-385.
- Kim, V.N., Han, J., and Siomi, M.C. (2009). Biogenesis of small RNAs in animals *Nat. Rev. Mol. Cell Biol.* *10*, 126-139.
- Kozomara, A., and Griffiths-Jones, S. (2011). miRBase: integrating microRNA annotation and deep-sequencing data *Nucleic Acids Res.* *39*, D152-7.
- Kraskov, A., Stogbauer, H., and Grassberger, P. (2004). Estimating mutual information *Phys. Rev. E. Stat. Nonlin Soft Matter Phys.* *69*, 066138.
- Kuchenbauer, F., Mah, S.M., Heuser, M., McPherson, A., Ruschmann, J., Rouhi, A., Berg, T., Bullinger, L., Argiropoulos, B., Morin, R.D., *et al.* (2011). Comprehensive analysis of mammalian miRNA* species and their role in myeloid cells *Blood* *118*, 3350-3358.

- Kuhn, D.E., Martin, M.M., Feldman, D.S., Terry, A.V., Jr, Nuovo, G.J., and Elton, T.S. (2008). Experimental validation of miRNA targets. *Methods* *44*, 47-54.
- Langenberger, D., Bermudez-Santana, C., Hertel, J., Hoffmann, S., Khaitovich, P., and Stadler, P.F. (2009). Evidence for human microRNA-offset RNAs in small RNA sequencing data *Bioinformatics* *25*, 2298-2301.
- Lankat-Buttgereit, B., and Goke, R. (2009). The tumour suppressor Pcd4: recent advances in the elucidation of function and regulation. *Biol. Cell.* *101*, 309-317.
- Latora, V., and Marchiori, M. (2005). Vulnerability and protection of infrastructure networks. *Phys. Rev. E. Stat. Nonlin Soft Matter Phys.* *71*, 015103.
- Latora, V., and Marchiori, M. (2001). Efficient behavior of small-world networks *Phys. Rev. Lett.* *87*, 198701.
- Lee, R.C., Feinbaum, R.L., and Ambros, V. (1993). The *C. elegans* heterochronic gene *lin-4* encodes small RNAs with antisense complementarity to *lin-14* *Cell* *75*, 843-854.
- Lewis, B.P., Burge, C.B., and Bartel, D.P. (2005). Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets *Cell* *120*, 15-20.
- Lewis, B.P., Shih, I.H., Jones-Rhoades, M.W., Bartel, D.P., and Burge, C.B. (2003). Prediction of mammalian microRNA targets *Cell* *115*, 787-798.
- Lhakhang, T.W., and Chaudhry, M.A. (2011). Current approaches to micro-RNA analysis and target gene prediction. *J. Appl. Genet.*
- Li, F., Long, T., Lu, Y., Ouyang, Q., and Tang, C. (2004). The yeast cell-cycle network is robustly designed. *Proc. Natl. Acad. Sci. U. S. A.* *101*, 4781-4786.
- Li, L., Chen, X.P., and Li, Y.J. (2010). MicroRNA-146a and human disease *Scand. J. Immunol.* *71*, 227-231.
- Li, M., Marin-Muller, C., Bharadwaj, U., Chow, K.H., Yao, Q., and Chen, C. (2009). MicroRNAs: control and loss of control in human physiology and disease *World J. Surg.* *33*, 667-684.
- Liang, S., Fuhrman, S., and Somogyi, R. (1998). Reveal, a general reverse engineering algorithm for inference of genetic network architectures *Pac. Symp. Biocomput.* 18-29.

- Lim, L.P., Lau, N.C., Garrett-Engle, P., Grimson, A., Schelter, J.M., Castle, J., Bartel, D.P., Linsley, P.S., and Johnson, J.M. (2005). Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs *Nature* *433*, 769-773.
- Lim, L.P., Lau, N.C., Weinstein, E.G., Abdelhakim, A., Yekta, S., Rhoades, M.W., Burge, C.B., and Bartel, D.P. (2003). The microRNAs of *Caenorhabditis elegans* *Genes Dev.* *17*, 991-1008.
- Lindberg, S.R., Olsson, A., Persson, A.M., and Olsson, I. (2005). The Leukemia-associated ETO homologues are differently expressed during hematopoietic differentiation. *Exp. Hematol.* *33*, 189-198.
- Lionetti, M., Biasiolo, M., Agnelli, L., Todoerti, K., Mosca, L., Fabris, S., Sales, G., Delilieri, G.L., Biciato, S., Lombardi, L., Bortoluzzi, S., and Neri, A. (2009). Identification of microRNA expression patterns and definition of a microRNA/mRNA regulatory network in distinct molecular groups of multiple myeloma. *Blood* *114*, e20-6.
- Lotterman, C.D., Kent, O.A., and Mendell, J.T. (2008). Functional integration of microRNAs into oncogenic and tumor suppressor pathways *Cell. Cycle* *7*, 2493-2499.
- Lu, J., Getz, G., Miska, E.A., Alvarez-Saavedra, E., Lamb, J., Peck, D., Sweet-Cordero, A., Ebert, B.L., Mak, R.H., Ferrando, A.A., *et al.* (2005). MicroRNA expression profiles classify human cancers *Nature* *435*, 834-838.
- Luo, W., Friedman, M.S., Shedden, K., Hankenson, K.D., and Woolf, P.J. (2009). GAGE: generally applicable gene set enrichment for pathway analysis *BMC Bioinformatics* *10*, 161.
- Maglott, D., Ostell, J., Pruitt, K.D., and Tatusova, T. (2005). Entrez Gene: gene-centered information at NCBI *Nucleic Acids Res.* *33*, D54-8.
- Martello, G., Rosato, A., Ferrari, F., Manfrin, A., Cordenonsi, M., Dupont, S., Enzo, E., Guzzardo, V., Rondina, M., Spruce, T., *et al.* (2010). A MicroRNA targeting dicer for metastasis control *Cell* *141*, 1195-1207.
- Maslov, S., and Sneppen, K. (2002). Specificity and stability in topology of protein networks *Science* *296*, 910-913.
- Mayr, C., and Bartel, D.P. (2009). Widespread shortening of 3'UTRs by alternative cleavage and polyadenylation activates oncogenes in cancer cells *Cell* *138*, 673-684.
- Medina, P.P., and Slack, F.J. (2008). microRNAs and cancer: an overview *Cell. Cycle* *7*, 2485-2492.

- Meiri, E., Levy, A., Benjamin, H., Ben-David, M., Cohen, L., Dov, A., Dromi, N., Elyakim, E., Yerushalmi, N., Zion, O., Lithwick-Yanai, G., and Sitbon, E. (2010). Discovery of microRNAs and other small RNAs in solid tumors *Nucleic Acids Res.* *38*, 6234-6246.
- Merkerova, M., Belickova, M., and Bruchova, H. (2008). Differential expression of microRNAs in hematopoietic cell lineages *Eur. J. Haematol.* *81*, 304-310.
- Mi, S., Lu, J., Sun, M., Li, Z., Zhang, H., Neilly, M.B., Wang, Y., Qian, Z., Jin, J., Zhang, Y., *et al.* (2007). MicroRNA expression signatures accurately discriminate acute lymphoblastic leukemia from acute myeloid leukemia *Proc. Natl. Acad. Sci. U. S. A.* *104*, 19971-19976.
- Mikula, M., Rubel, T., Karczmarski, J., Goryca, K., Dadlez, M., and Ostrowski, J. (2010). Integrating proteomic and transcriptomic high-throughput surveys for search of new biomarkers of colon tumors. *Funct. Integr. Genomics*
- Milo, R., Shen-Orr, S., Itzkovitz, S., Kashtan, N., Chklovskii, D., and Alon, U. (2002). Network motifs: simple building blocks of complex networks *Science* *298*, 824-827.
- Mitsuhashi, S., Shima, H., Tanuma, N., Sasa, S., Onoe, K., Ubukata, M., and Kikuchi, K. (2005). Protein phosphatase type 2A, PP2A, is involved in degradation of gp130. *Mol. Cell. Biochem.* *269*, 183-187.
- Mizuguchi, Y., Mishima, T., Yokomuro, S., Arima, Y., Kawahigashi, Y., Shigehara, K., Kanda, T., Yoshida, H., Uchida, E., Tajiri, T., and Takizawa, T. (2011). Sequencing and bioinformatics-based analyses of the microRNA transcriptome in hepatitis B-related hepatocellular carcinoma *PLoS One* *6*, e15304.
- Moreau, Y., Aerts, S., De Moor, B., De Strooper, B., and Dabrowski, M. (2003). Comparison and meta-analysis of microarray data: from the bench to the computer desk *Trends Genet.* *19*, 570-577.
- Motter, A.E., and Lai, Y.C. (2002). Cascade-based attacks on complex networks. *Phys. Rev. E. Stat. Nonlin Soft Matter Phys.* *66*, 065102.
- Mraz, M., Pospisilova, S., Malinova, K., Slapak, I., and Mayer, J. (2009). MicroRNAs in chronic lymphocytic leukemia pathogenesis and disease subtypes *Leuk. Lymphoma* *50*, 506-509.
- Mrazek, J., Kreutmayer, S.B., Grasser, F.A., Polacek, N., and Huttenhofer, A. (2007). Subtractive hybridization identifies novel differentially expressed ncRNA species in EBV-infected human B cells *Nucleic Acids Res.* *35*, e73.

- Nakayama, J., Yamamoto, M., Hayashi, K., Satoh, H., Bundo, K., Kubo, M., Goitsuka, R., Farrar, M.A., and Kitamura, D. (2009). BLNK suppresses pre-B-cell leukemogenesis through inhibition of JAK3 *Blood* 113, 1483-1492.
- Navon, R., Wang, H., Steinfeld, I., Tsalenko, A., Ben-Dor, A., and Yakhini, Z. (2009). Novel rank-based statistical methods reveal microRNAs with differential expression in multiple cancer types. *PLoS One* 4, e8003.
- Negrini, M., Nicoloso, M.S., and Calin, G.A. (2009). MicroRNAs and cancer--new paradigms in molecular oncology. *Curr. Opin. Cell Biol.* 21, 470-479.
- Nunez-Iglesias, J., Liu, C.C., Morgan, T.E., Finch, C.E., and Zhou, X.J. (2010). Joint genome-wide profiling of miRNA and mRNA expression in Alzheimer's disease cortex reveals altered miRNA regulation *PLoS One* 5, e8898.
- Oberg, A.L., French, A.J., Sarver, A.L., Subramanian, S., Morlan, B.W., Riska, S.M., Borralho, P.M., Cunningham, J.M., Boardman, L.A., Wang, L., *et al.* (2011). miRNA expression in colon polyps provides evidence for a multihit model of colon cancer *PLoS One* 6, e20465.
- Olena, A.F., and Patton, J.G. (2010). Genomic organization of microRNAs *J. Cell. Physiol.* 222, 540-545.
- Olive, V., Jiang, I., and He, L. (2010). mir-17-92, a cluster of miRNAs in the midst of the cancer network. *Int. J. Biochem. Cell Biol.* 42, 1348-1354.
- Papadopoulos, G.L., Alexiou, P., Maragkakis, M., Reczko, M., and Hatzigeorgiou, A.G. (2009a). DIANA-mirPath: Integrating human and mouse microRNAs in pathways *Bioinformatics* 25, 1991-1993.
- Papadopoulos, G.L., Reczko, M., Simossis, V.A., Sethupathy, P., and Hatzigeorgiou, A.G. (2009b). The database of experimentally supported targets: a functional update of TarBase *Nucleic Acids Res.* 37, D155-8.
- Parkinson, H., Kapushesky, M., Kolesnikov, N., Rustici, G., Shojatalab, M., Abeygunawardena, N., Berube, H., Dylag, M., Emam, I., Farne, A., *et al.* (2009). ArrayExpress update--from an archive of functional genomics experiments to the atlas of gene expression *Nucleic Acids Res.* 37, D868-72.
- Peifer, M., and Polakis, P. (2000). Wnt signaling in oncogenesis and embryogenesis--a look outside the nucleus *Science* 287, 1606-1609.

- Petrocca, F., Vecchione, A., and Croce, C.M. (2008). Emerging role of miR-106b-25/miR-17-92 clusters in the control of transforming growth factor beta signaling *Cancer Res.* *68*, 8191-8194.
- Pichler, K., Schneider, G., and Grassmann, R. (2008). MicroRNA miR-146a and further oncogenesis-related cellular microRNAs are dysregulated in HTLV-1-transformed T lymphocytes *Retrovirology* *5*, 100.
- Pise-Masison, C.A., Radonovich, M., Dohoney, K., Morris, J.C., O'Mahony, D., Lee, M.J., Trepel, J., Waldmann, T.A., Janik, J.E., and Brady, J.N. (2009). Gene expression profiling of ATL patients: compilation of disease-related genes and evidence for TCF4 involvement in BIRC5 gene expression and cell viability *Blood* *113*, 4016-4026.
- Plikus, M.V., Zhang, Z., and Chuong, C.M. (2006). PubFocus: semantic MEDLINE/PubMed citations analytics through integration of controlled biomedical dictionaries and ranking algorithm *BMC Bioinformatics* *7*, 424.
- Ponting, C.P., and Belgard, T.G. (2010). Transcribed dark matter: meaning or myth? *Hum. Mol. Genet.* *19*, R162-8.
- Potapov, A.P., Goemann, B., and Wingender, E. (2008). The pairwise disconnectivity index as a new metric for the topological analysis of regulatory networks. *BMC Bioinformatics* *9*, 227.
- Pouyet, L., and Carrier, A. (2010). Mutant mouse models of oxidative stress. *Transgenic Res.* *19*, 155-164.
- Qiang, Y.W., Endo, Y., Rubin, J.S., and Rudikoff, S. (2003). Wnt signaling in B-cell neoplasia *Oncogene* *22*, 1536-1545.
- Rebholz-Schuhmann, D., Kirsch, H., Arregui, M., Gaudan, S., Riethoven, M., and Stoehr, P. (2007). EBIMed--text crunching to gather facts for proteins from Medline *Bioinformatics* *23*, e237-44.
- Ro, S., Park, C., Young, D., Sanders, K.M., and Yan, W. (2007). Tissue-dependent paired expression of miRNAs *Nucleic Acids Res.* *35*, 5944-5953.
- Roccaro, A.M., Sacco, A., Chen, C., Runnels, J., Leleu, X., Azab, F., Azab, A.K., Jia, X., Ngo, H.T., Melhem, M.R., *et al.* (2009). microRNA expression in the biology, prognosis, and therapy of Waldenstrom macroglobulinemia *Blood* *113*, 4391-4402.
- Saggiaro, D., Silic-Benussi, M., Biasiotto, R., D'Agostino, D.M., and Ciminale, V. (2009). Control of cell death pathways by HTLV-1 proteins *Front. Biosci.* *14*, 3338-3351.

- Sales, G., Coppe, A., Bisognin, A., Biasiolo, M., Bortoluzzi, S., and Romualdi, C. (2010). MAGIA, a web-based tool for miRNA and Genes Integrated Analysis. *Nucleic Acids Res. 38 Suppl*, W352-9.
- Savkovic, V., Gaiser, S., Iovanna, J.L., and Bodeker, H. (2004). The stress response of the exocrine pancreas. *Dig. Dis. 22*, 239-246.
- Schmeier, S., Schaefer, U., Essack, M., and Bajic, V.B. (2011). Network analysis of microRNAs and their regulation in human ovarian cancer *BMC Syst. Biol. 5*, 183.
- Sempere, L.F., Sokol, N.S., Dubrovsky, E.B., Berger, E.M., and Ambros, V. (2003). Temporal regulation of microRNA expression in *Drosophila melanogaster* mediated by hormonal signals and broad-Complex gene activity *Dev. Biol. 259*, 9-18.
- Sethupathy, P., Megraw, M., and Hatzigeorgiou, A.G. (2006). A guide through present computational approaches for the identification of mammalian microRNA targets. *Nat. Methods 3*, 881-886.
- Sharan, R., and Ideker, T. (2006). Modeling cellular machinery through biological network comparison *Nat. Biotechnol. 24*, 427-433.
- Shi, W., Hendrix, D., Levine, M., and Haley, B. (2009). A distinct class of small RNAs arises from pre-miRNA-proximal regions in a simple chordate *Nat. Struct. Mol. Biol. 16*, 183-189.
- Shruti, K., Shrey, K., and Vibha, R. (2011). Micro RNAs: tiny sequences with enormous potential. *Biochem. Biophys. Res. Commun. 407*, 445-449.
- Smyth, G.K. (2004). Linear models and empirical bayes methods for assessing differential expression in microarray experiments *Stat. Appl. Genet. Mol. Biol. 3*, Article3.
- Sokol, N.S., Xu, P., Jan, Y.N., and Ambros, V. (2008). *Drosophila* let-7 microRNA is required for remodeling of the neuromusculature during metamorphosis *Genes Dev. 22*, 1591-1596.
- Stella, J., Bavaresco, L., Braganhol, E., Rockenbach, L., Farias, P.F., Wink, M.R., Azambuja, A.A., Barrios, C.H., Morrone, F.B., and Oliveira Battastini, A.M. (2010). Differential ectonucleotidase expression in human bladder cancer cell lines. *Urol. Oncol. 28*, 260-267.
- Steuer, R., Kurths, J., Daub, C.O., Weise, J., and Selbig, J. (2002). The mutual information: detecting and evaluating dependencies between variables *Bioinformatics 18 Suppl 2*, S231-40.

- Strogatz, S.H. (2001). Exploring complex networks *Nature* *410*, 268-276.
- Taft, R.J., Simons, C., Nahkuri, S., Oey, H., Korbie, D.J., Mercer, T.R., Holst, J., Ritchie, W., Wong, J.J., Rasko, J.E., *et al.* (2010). Nuclear-localized tiny RNAs are associated with transcription initiation and splice sites in metazoans *Nat. Struct. Mol. Biol.* *17*, 1030-1034.
- Taganov, K.D., Boldin, M.P., Chang, K.J., and Baltimore, D. (2006). NF-kappaB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses *Proc. Natl. Acad. Sci. U. S. A.* *103*, 12481-12486.
- Tanuma, N., Shima, H., Nakamura, K., and Kikuchi, K. (2001). Protein tyrosine phosphatase epsilonC selectively inhibits interleukin-6- and interleukin- 10-induced JAK-STAT signaling. *Blood* *98*, 3030-3034.
- Taylor, B.S., Schultz, N., Hieronymus, H., Gopalan, A., Xiao, Y., Carver, B.S., Arora, V.K., Kaushik, P., Cerami, E., Reva, B., *et al.* (2010). Integrative genomic profiling of human prostate cancer *Cancer. Cell.* *18*, 11-22.
- Tomita, M., Tanaka, Y., and Mori, N. (2009). MicroRNA miR-146a is induced by HTLV-1 tax and increases the growth of HTLV-1-infected T-cells. *Int. J. Cancer*
- Tusher, V.G., Tibshirani, R., and Chu, G. (2001). Significance analysis of microarrays applied to the ionizing radiation response *Proc. Natl. Acad. Sci. U. S. A.* *98*, 5116-5121.
- Umbach, J.L., and Cullen, B.R. (2010). In-depth analysis of Kaposi's sarcoma-associated herpesvirus microRNA expression provides insights into the mammalian microRNA-processing machinery *J. Virol.* *84*, 695-703.
- Umbach, J.L., Strelow, L.I., Wong, S.W., and Cullen, B.R. (2010). Analysis of rhesus rhadinovirus microRNAs expressed in virus-induced tumors from infected rhesus macaques *Virology* *405*, 592-599.
- Vannucchi, A.M., Guglielmelli, P., Rambaldi, A., Bogani, C., and Barbui, T. (2009). Epigenetic therapy in myeloproliferative neoplasms: evidence and perspectives *J. Cell. Mol. Med.* *13*, 1437-1450.
- Vazquez, A., Dobrin, R., Sergi, D., Eckmann, J.P., Oltvai, Z.N., and Barabasi, A.L. (2004). The topological relationship between the large-scale attributes and local interaction patterns of complex networks *Proc. Natl. Acad. Sci. U. S. A.* *101*, 17940-17945.
- Visone, R., and Croce, C.M. (2009). MiRNAs and cancer *Am. J. Pathol.* *174*, 1131-1138.

- Visone, R., Rassenti, L.Z., Veronese, A., Taccioli, C., Costinean, S., Aguda, B.D., Volinia, S., Ferracin, M., Palatini, J., Balatti, V., *et al.* (2009). Karyotype-specific microRNA signature in chronic lymphocytic leukemia *Blood* *114*, 3872-3879.
- Volinia, S., Calin, G.A., Liu, C.G., Ambs, S., Cimmino, A., Petrocca, F., Visone, R., Iorio, M., Roldo, C., Ferracin, M., *et al.* (2006). A microRNA expression signature of human solid tumors defines cancer gene targets *Proc. Natl. Acad. Sci. U. S. A.* *103*, 2257-2261.
- Wagner, A., and Fell, D.A. (2001). The small world inside large metabolic networks *Proc. Biol. Sci.* *268*, 1803-1810.
- Wang, G., Kwan, B.C., Lai, F.M., Chow, K.M., Li, P.K., and Szeto, C.C. (2011). Elevated levels of miR-146a and miR-155 in kidney biopsy and urine from patients with IgA nephropathy. *Dis. Markers* *30*, 171-179.
- Wang, X., Wang, H.K., McCoy, J.P., Banerjee, N.S., Rader, J.S., Broker, T.R., Meyers, C., Chow, L.T., and Zheng, Z.M. (2009a). Oncogenic HPV infection interrupts the expression of tumor-suppressive miR-34a through viral oncoprotein E6 RNA *15*, 637-647.
- Wang, X., Ye, L., Hou, W., Zhou, Y., Wang, Y.J., Metzger, D.S., and Ho, W.Z. (2009b). Cellular microRNA expression correlates with susceptibility of monocytes/macrophages to HIV-1 infection *Blood* *113*, 671-674.
- Wang, Z. (2010). MicroRNA: A matter of life or death *World J. Biol. Chem.* *1*, 41-54.
- Wasserman S., F.K. (1994). *Social Networks Analysis*. Cambridge
- Watford, W.T., Hissong, B.D., Bream, J.H., Kanno, Y., Muul, L., and O'Shea, J.J. (2004). Signaling by IL-12 and IL-23 and the immunoregulatory roles of STAT4 *Immunol. Rev.* *202*, 139-156.
- Westholm, J.O., and Lai, E.C. (2011). Mirtrons: microRNA biogenesis via splicing. *Biochimie*
- Wightman, B., Ha, I., and Ruvkun, G. (1993). Posttranscriptional regulation of the heterochronic gene *lin-14* by *lin-4* mediates temporal pattern formation in *C. elegans* *Cell* *75*, 855-862.
- Winter, J., Jung, S., Keller, S., Gregory, R.I., and Diederichs, S. (2009a). Many roads to maturity: microRNA biogenesis pathways and their regulation. *Nat. Cell Biol.* *11*, 228-234.

- Winter, J., Jung, S., Keller, S., Gregory, R.I., and Diederichs, S. (2009b). Many roads to maturity: microRNA biogenesis pathways and their regulation *Nat. Cell Biol.* *11*, 228-234.
- Witkos, T.M., Koscianska, E., and Krzyzosiak, W.J. (2011). Practical Aspects of microRNA Target Prediction. *Curr. Mol. Med.* *11*, 93-109.
- Wu, L., and Belasco, J.G. (2008). Let me count the ways: mechanisms of gene regulation by miRNAs and siRNAs *Mol. Cell* *29*, 1-7.
- Xia, H., Qi, Y., Ng, S.S., Chen, X., Li, D., Chen, S., Ge, R., Jiang, S., Li, G., Chen, Y., *et al.* (2009). microRNA-146b inhibits glioma cell migration and invasion by targeting MMPs. *Brain Res.* *1269*, 158-165.
- Xiao, F., Zuo, Z., Cai, G., Kang, S., Gao, X., and Li, T. (2009a). miRecords: an integrated resource for microRNA-target interactions *Nucleic Acids Res.* *37*, D105-10.
- Xiao, F., Zuo, Z., Cai, G., Kang, S., Gao, X., and Li, T. (2009b). miRecords: an integrated resource for microRNA-target interactions *Nucleic Acids Res.* *37*, D105-10.
- Xin, F., Li, M., Balch, C., Thomson, M., Fan, M., Liu, Y., Hammond, S.M., Kim, S., and Nephew, K.P. (2009). Computational analysis of microRNA profiles and their target genes suggests significant involvement in breast cancer antiestrogen resistance *Bioinformatics* *25*, 430-434.
- Yamada, Y., and Kamihira, S. (2005). Inactivation of tumor suppressor genes and the progression of adult T-cell leukemia-lymphoma *Leuk. Lymphoma* *46*, 1553-1559.
- Yamakuchi, M., and Lowenstein, C.J. (2009). MiR-34, SIRT1 and p53: the feedback loop *Cell. Cycle* *8*, 712-715.
- Yeung, M.L., Yasunaga, J., Bennasser, Y., Duseti, N., Harris, D., Ahmad, N., Matsuoka, M., and Jeang, K.T. (2008). Roles for microRNAs, miR-93 and miR-130b, and tumor protein 53-induced nuclear protein 1 tumor suppressor in cell growth dysregulation by human T-cell lymphotropic virus 1. *Cancer Res.* *68*, 8976-8985.
- Zhang, C. (2008). MicroRNomics: a newly emerging approach for disease biology *Physiol. Genomics* *33*, 139-147.
- Zhao, H., Kalota, A., Jin, S., and Gewirtz, A.M. (2009). The c-myc proto-oncogene and microRNA-15a comprise an active autoregulatory feedback loop in human hematopoietic cells *Blood* *113*, 505-516.

Zhao, J.L., Rao, D.S., Boldin, M.P., Taganov, K.D., O'Connell, R.M., and Baltimore, D. (2011). NF-kappaB dysregulation in microRNA-146a-deficient mice drives the development of myeloid malignancies *Proc. Natl. Acad. Sci. U. S. A.* *108*, 9184-9189.

Supplementary material

Table S 1. Demographic, clinic and biomolecular data concerning the 40 MM/PCL patients investigated for miRNA expression by microarray analysis.

Sample name	Sex	Age at diagnosis (years)	Stage*	Monoclonal component	TC§	HD⊕	del(13)•	del(17p)•	+1q•
MM-212	F	55	IIIA	Nd	1	-	-	-	-
MM-246	M	nd	nd	Nd	1	-	-	-	-
MM-015	M	70	II A	Gk	1	-	+	-	-
MM-037	F	51	II A	Gk + Ak	1	-	+	-	-
MM-052	F	39	IA	Gl + Al	1	-	+	-	+
MM-115	F	53	IIIA	K	1	-	+	-	+
MM-032	M	56	IIIB	Gl	1	+	-	-	-
MM-179	M	50	IIIA	Gl	1	+	-	+	-
MM-026	F	73	IIIB	K	1	nd	-	-	-
MM-131	M	69	IA	Gk	2	+	-	-	-
MM-043	F	73	IA	Gk + Gl	2	-	-	-	+
MM-030	M	69	IIIA	Gl	2	+	-	-	-
MM-034	M	72	IA	Gk	2	+	-	-	-
MM-039	M	49	IIA	Gl	2	+	-	-	-
MM-049	M	63	IIIB	K	2	+	-	-	-
MM-143	M	56	IIA	Gk	2	+	-	-	-
MM-243	F	68	nd	Nd	2	+	-	-	+
MM-038	F	67	IIA	K	2	+	+	-	-
MM-035	M	74	IA	Gk	2	nd	-	-	-
MM-229	M	75	IIA	Gk	3	-	-	-	-
MM-036	M	66	IIA	Gk	3	-	+	-	+
MM-177	M	73	IIIA	Gk	3	-	+	-	+
MM-016	M	66	IIIB	Gk	3	+	-	-	+
MM-239	F	72	nd	A	3	+	+	-	-
MM-027	M	61	IA	Gk	3	+	+	-	+
MM-040	F	77	IIIB	Gl	3	+	+	-	+
MM-253	F	46	nd	L	3	+	+	-	+
MM-050	M	71	IA	Al	3	Nd	-	-	Nd
MM-087	F	85	IIIA	Gl	4	-	+	-	+
MM-104	F	63	IIIA	Al	4	-	+	-	+
MM-123	M	56	IIIA	Gk	4	-	+	-	+
MM-206	F	73	IA	Gk	4	-	+	-	-⊗
MM-067	F	74	IIIA	Gk	4	-	+	+	+
MM-042	M	54	IIIA	Al	4	+	+	-	+
MM-074	M	69	IIIA	Ak	4	+	+	-	+
MM-025	F	64	IA	Gl	5	-	+	-	+
MM-069	M	66	IIA	Gk	5	-	+	-	+
MM-154	F	71	IIA	G	5	-	+	-	+

PCL-011	M	76	PCL	Gk	5	-	+	+	+
PCL-006	M	55	PCL	Gk	5	Nd	-	+	Nd

*The Durie clinical staging system was adopted. §The TC (translocation/cyclin D expression) group according to Hideshima classification is indicated. ⊕HD = presence of the hyperdiploid status on the basis of FISH evaluation criteria. •del(13), del(17), 1q gain/amplification were determined by FISH and/or microarray genome-wide analysis. ⊗ FISH revealed multiple copies of the *BCL9* locus (1q21.1), and two copies of the *ARF9* locus (1q42.13), so the patient was not considered in the supervised analysis regarding 1q gain.

Table S 2. List of supported target genes of miRNAs up-regulated in TC5 Cases (A) and TC1 cases (B).

A				B			
GeneID	Gene symbol	GeneID	Gene symbol	GeneID	Gene symbol	GeneID	Gene symbol
21	ABCA3	23107	MRPS27	10057	ABCC5	26156	RSL1D1
32	ACACB	26292	MYCBP	11057	ABHD2	9092	SART1
177	AGER	4624	MYH6	57406	ABHD6	26135	SERBP1
79796	ALG9	8775	NAPA	31	ACACA	10147	SFRS14
57538	ALPK3	79829	NAT11	8728	ADAM19	51092	SIDT2
271	AMPD2	26151	NAT9	219	ALDH1B1	65010	SLC26A6
22881	ANKRD6	26012	NELF	513	ATP5D	54946	SLC41A3
10307	APBB3	65083	NOL6	598	BCL2L1	4090	SMAD5
362	AQP5	55270	NUDT15	55643	BTBD2	27293	SMPDL3B
411	ARSB	4987	OPRL1	56946	C11orf30	9892	SNAP91
472	ATM	114884	OSBPL10	79622	C16orf33	6619	SNAPC3
489	ATP2A3	22953	P2RX2	203197	C9orf91	27131	SNX5
540	ATP7B	5058	PAK1	11007	CCDC85B	11063	SOX30
554	AVPR2	50855	PARD6A	55573	CDV3	6749	SSRP1
651	BMP3	5071	PARK2	1951	CELSR3	8677	STX10
8927	BSN	10336	PCGF3	11261	CHP	23102	TBC1D2B
7832	BTG2	58488	PCTP	81570	CLPB	6925	TCF4
54906	C10orf18	5153	PDE1B	1503	CTPS	10227	TETRA
79096	C11orf49	9409	PEX16	79901	CYBRD1	60436	TGIF2
25906	C11orf51	5217	PFN2	54205	CYCS	26517	TIMM13
29965	C16orf5	8503	PIK3R3	1613	DAPK3	9854	TMEM24
51279	C1RL	26034	PIP3-E	79016	DDA1	7126	T vs NFAIP1
51754	C9orf127	5310	PKD1	54555	DDX49	8764	T vs NFRSF14
79886	C9orf82	8681	PLA2G4B	10522	DEAF1	27348	TOR1B
11092	C9orf9	5338	PLD2	1718	DHCR24	9830	TRIM14
81617	CAB39L	23203	PMPCA	1717	DHCR7	5976	UPF1
857	CAV1	5454	POU3F2	8721	EDF1	10975	UQCR
54862	CC2D1A	8541	PPFIA3	8178	ELL	27089	UQCRQ
9720	CCDC144A	5536	PPP5C	256364	EML3	81605	URM1
892	CCNC	5562	PRKAA1	23404	EXOSC2	7756	ZNF207
1235	CCR6	5742	PTGS1	56915	EXOSC5	54811	ZNF562
912	CD1D	5778	PTPN7	2313	FLI1	51042	ZNF593
1003	CDH5	5787	PTPRB	55101	FLJ10241		
1029	CDKN2A	9727	RAB11FIP3	23171	GPD1L		
1138	CHRNA5	9649	RALGPS1	2821	GPI		

23529	CLCF1	29098	RANGRF	131601	GPR175	
1184	CLCN5	10633	RASL10A	9380	GRHPR	
1186	CLCN7	11228	RASSF8	2962	GTF2F1	
55118	CRTAC1	5962	RDX	3108	HLA-DMA	
1408	CRY2	9827	RGP1	3159	HMGA1	
54205	CYCS	6007	RHD	3382	ICA1	
27065	D4S234E	89941	RHOT2	7866	IFRD2	
9988	DM vs TF1	9912	RICH2	3633	INPP5B	
57171	DOLPP1	9853	RUSC2	64768	IPPK	
8444	DYRK3	284904	SEC14L4	3669	ISG20	
1871	E2F3	25956	SEC31B	23383	KIAA0892	
1889	ECE1	79048	SECISBP2	23095	KIF1B	
1947	EFNB1	10500	SEMA6C	26468	LHX6	
51386	EIF3EIP	23064	SETX	4012	LNPEP	
2043	EPHA4	25970	SH2B1	11253	MAN1B1	
54869	EPS8L1	57823	SLAMF7	4242	MFNG	
9715	FAM131B	4891	SLC11A2	6945	MLX	
79981	FRMD1	57468	SLC12A5	130916	MvsTERFD2	
9758	FRMPD4	54977	SLC25A38	10608	MXD4	
26515	FXC1	65010	SLC26A6	4686	NCBP1	
9513	FXR2	66035	SLC2A11	51517	NCKIPSD	
64223	GBL	1317	SLC31A1	56926	NCLN	
2648	GCN5L2	55234	SMU1	374291	NDUFS7	
10755	GIPC1	11262	SP140	26012	NELF	
57720	GPR107	56928	SPPL2B	26155	NOC2L	
9380	GRHPR	90864	SPSB3	55651	NOLA2	
2948	GSTM4	6714	SRC	4957	ODF2	
2954	GSTZ1	58477	SRPRB	5032	P2RY11	
2995	GYPC	6483	ST3GAL2	56652	PEO1	
51409	HEMK1	55576	STAB2	5830	PEX5	
3207	HOXA11	8614	STC2	10471	PFDN6	
8809	IL18R1	8675	STX16	51588	PIAS4	
64806	IL25	25830	SULT4A1	8503	PIK3R3	
26512	INTS6	9900	SV2A	58473	PLEKHB1	
3673	ITGA2	8189	SYMPK	64425	POLR1E	
3748	KCNC3	55633	TBC1D22B	5434	POLR2E	
23201	KIAA0280	7074	TIAM1	5441	POLR2L	
84726	KIAA0515	283232	TMEM80	10622	POLR3G	
9776	KIAA0652	7274	TTPA	56342	PPAN	
23251	KIAA1024	57348	TTYH1	60490	PPCDC	
55243	KIRREL	51271	UBAP1	5524	PPP2R4	
26249	KLHL3	29855	UBN1	27339	PRPF19	
10536	LEPREL2	81605	URM1	8934	RAB7L1	
51149	LOC51149	7433	VIPR1	5962	RDX	
4017	LOXL2	51352	WIT1	57109	REXO4	
4034	LRCH4	64328	XPO4	55312	RFK	
23162	MAPK8IP3	51364	ZMYND10	9025	RNF8	
7867	MAPKAPK3	7692	ZNF133	6158	RPL28	
53615	MBD3	10472	ZNF238	6227	RPS21	
23263	MCF2L	10127	ZNF263	6228	RPS23	
6837	MED22	55311	ZNF444	6198	RPS6KB1	

4248	MGAT3	26048	ZNF500	6203	RPS9	
------	-------	-------	--------	------	------	--

Table S 3. miRNA differentially expressed in different contrast, according to unpaired test.

T vs N DEM			M vs N DEM		
miRNAs	FoldChange	q-value	miRNAs	FoldChange	q-value
hsa-miR-139-5p	-3.272177914	0	hsa-miR-215	-3.929340947	0
hsa-miR-215	-2.988818352	0	hsa-miR-497	-3.0947646	0
hsa-miR-99a	-2.383513412	0	hsa-miR-195	-3.03721844	0
hsa-miR-143*	-2.366759526	0	hsa-miR-10b	-2.817199413	0
hsa-miR-497	-2.34419323	0	hsa-miR-143*	-2.74101808	0
hsa-miR-100	-2.324930718	0	hsa-miR-139-5p	-2.438803085	0
hsa-miR-138	-2.238032916	0	hsa-miR-138	-2.395860799	0
hsa-miR-195	-2.107741275	0	hsa-miR-422a	-2.32174352	0
hsa-miR-150	-2.069699018	0	hsa-miR-375	-2.279264002	0
hsa-miR-145	-1.91804478	0	hsa-miR-145	-2.086918938	0
hsa-miR-378	-1.850939299	0	hsa-miR-133a	-2.078677786	0
hsa-miR-422a	-1.81814864	0	hsa-miR-143	-2.067109714	0
hsa-miR-375	-1.793533624	0	hsa-miR-378*	-2.012477446	0
hsa-miR-30a	-1.793453612	0	hsa-miR-378	-2.005904658	0
hsa-miR-378*	-1.790182405	0	hsa-miR-30a	-1.758636411	0
hsa-miR-133a	-1.773823053	0	hsa-miR-150	-1.741173237	0
hsa-miR-125b	-1.77084525	0	hsa-miR-130a	-1.526273828	0
hsa-miR-10b	-1.713863042	0	hsa-miR-194*	-1.510021172	0
hsa-miR-194*	-1.632313259	0	hsa-miR-28-3p	-1.440290149	0
hsa-miR-143	-1.57945413	0	hsa-miR-140-3p	-1.365613614	0
hsa-miR-342-5p	-1.526441766	0	hsa-miR-342-5p	-1.317922801	0
hsa-miR-140-3p	-1.334735965	0	hsa-miR-27b	-1.166394486	0
hsa-miR-28-3p	-1.299378565	0	hsa-miR-28-5p	-1.134539748	0
hsa-miR-342-3p	-1.295561642	0	hsa-miR-192*	-1.122937275	0
hsa-miR-149	-1.294815379	0	hsa-miR-574-3p	-1.101312861	0
hsa-miR-574-3p	-1.251981975	0	hsa-miR-30e	-1.067718574	0
hsa-miR-30a*	-1.206077017	0	hsa-miR-29c	-1.059051697	0
hsa-miR-127-3p	-1.163578041	0	hsa-miR-342-3p	-1.058066906	0
hsa-miR-130a	-1.116957708	0	hsa-miR-147b	-1.050725923	0
hsa-miR-152	-1.116820485	0	hsa-miR-199b-3p	-1.021067375	0
hsa-miR-487b	-1.075980581	0	hsa-miR-152	-1.020728547	0
hsa-miR-379	-1.031769391	0	hsa-miR-30a*	-1.010530732	0
hsa-miR-125a-5p	-1.025384903	0	hsa-miR-25*	1.002975554	0
hsa-miR-421	1.000284994	0	hsa-miR-17*	1.028867701	0.55
hsa-miR-424*	1.003380509	0	hsa-miR-106b*	1.071120871	0
hsa-miR-429	1.007465396	0	hsa-miR-18a*	1.072760582	0
hsa-miR-21*	1.026996086	0	hsa-miR-20a	1.075735491	0
hsa-miR-106a	1.042630924	0	hsa-miR-92a-1*	1.094289701	0
hsa-miR-17	1.091146105	0	hsa-miR-188-5p	1.098647694	0
hsa-miR-1290	1.093749518	0	hsa-miR-19a	1.106163101	0
hsa-miR-20a	1.111479331	0	hsa-miR-210	1.111334098	0
hsa-miR-25	1.122075965	0	hsa-miR-20b	1.117501533	0
hsa-miR-17*	1.13475031	0	hsa-miR-106a	1.132522457	0

hsa-miR-25*	1.149337691	0	hsa-miR-17	1.236828699	0
hsa-miR-552	1.208369576	0	hsa-miR-1275	1.250592958	0
hsa-miR-19a	1.221854517	0	hsa-miR-203	1.261763799	0
hsa-miR-92a-1*	1.227938987	0	hsa-miR-483-5p	1.359232784	0
hsa-miR-181d	1.282578776	0	hsa-miR-552	1.391223984	0
hsa-miR-29b-1*	1.328202727	0	hsa-miR-421	1.42187077	0
hsa-miR-203	1.389987787	0	hsa-miR-886-5p	1.463191451	0
hsa-miR-886-5p	1.46179031	0	hsa-miR-1308	1.593441466	0
hsa-miR-20b	1.468807073	0	hsa-miR-885-5p	1.625067821	0
hsa-miR-1246	1.775916675	0	hsa-miR-181d	1.657513172	0
hsa-miR-1308	1.857166271	0	hsa-miR-424*	1.689271681	0
hsa-miR-31	1.877829229	0.51	hsa-miR-224	1.747108666	0
hsa-miR-18b	1.909565741	0	hsa-miR-1290	1.998961285	0
hsa-miR-21	1.913670952	0	hsa-miR-18b	2.026686411	0
hsa-miR-18a	1.93394207	0	hsa-miR-18a	2.065786605	0
hsa-miR-503	1.950664843	0	hsa-miR-1246	2.384683531	0
hsa-miR-224	2.058520635	0	hsa-miR-182	2.388952962	0
hsa-miR-182	2.187797216	0	hsa-miR-503	2.616172225	0
hsa-miR-183	2.53733318	0	hsa-miR-183	2.693341196	0
			hsa-miR-122	8.312462259	0

M vs T DEM

miRNAs	FoldChange	q-value
hsa-miR-146a	-1.379160258	0
hsa-miR-708	-1.292819562	0
hsa-miR-15a	-1.212038005	0
hsa-miR-196a	-1.166896704	0
hsa-miR-10b	-1.103336371	0
hsa-miR-15b	-1.068075875	0
hsa-miR-210	1.114739685	0
hsa-miR-99a	1.483966648	0
hsa-miR-885-5p	1.506612383	0
hsa-miR-100	1.753641519	0
hsa-miR-122	7.943847008	0

Table S 4. miRNA differentially expressed in different contrast, according to paired test.

T vs N			M vs N		
miRNAs	Fold Change	q-value	miRNAs	Fold Change	q-value
hsa-miR-139-5p	-3.843098125	0	hsa-miR-215	-4.0958715	0
hsa-miR-497	-3.09369775	0	hsa-miR-195	-3.200875	0
hsa-miR-138	-2.7540045	0	hsa-miR-497	-3.154721875	0
hsa-miR-150	-2.743002375	0	hsa-miR-139-5p	-2.717419125	0
hsa-miR-195	-2.73133675	0	hsa-miR-10b	-2.615537125	0
hsa-miR-375	-2.59429075	0	hsa-miR-133a	-2.569697875	0
hsa-miR-99a	-2.577299125	0	hsa-miR-375	-2.40409025	0
hsa-miR-133a	-2.322061088	0	hsa-miR-138	-2.402280625	0
hsa-miR-30a	-2.217122625	0	hsa-miR-422a	-2.323093	0
hsa-miR-145	-2.09149625	0	hsa-miR-143	-2.1387105	0
hsa-miR-342-5p	-1.919002875	0	hsa-miR-145	-2.11873625	0
hsa-miR-378	-1.917125125	0	hsa-miR-30a	-2.046916625	0
hsa-miR-194*	-1.8245275	0	hsa-miR-130a	-1.8769065	0
hsa-miR-143	-1.70583375	0	hsa-miR-378*	-1.819690375	0
hsa-miR-140-3p	-1.665123125	0	hsa-miR-378	-1.791166375	0
hsa-miR-342-3p	-1.5621085	0	hsa-miR-381	-1.312789	0
hsa-miR-30a*	-1.55852025	0	hsa-miR-140-3p	-1.261712125	0
hsa-miR-422a	-1.505709875	0	hsa-miR-342-5p	-1.180007875	0
hsa-miR-768-3p	-1.450829	0	hsa-miR-20a	1.004735125	0
hsa-miR-28-3p	-1.342629625	0	hsa-miR-93	1.043093625	0
hsa-miR-574-3p	-1.284033875	0	hsa-miR-210	1.0654855	0
hsa-miR-381	-1.1066095	0	hsa-miR-18a*	1.0906075	0
hsa-miR-768-5p	-1.095674125	0	hsa-miR-106a	1.11549275	0
hsa-miR-20a	1.115748875	0	hsa-miR-27a*	1.147799375	0
hsa-miR-106a	1.20225525	0	hsa-miR-92a-1*	1.198501875	0
hsa-miR-17	1.29234875	0	hsa-miR-17	1.238445	0
hsa-miR-20b	1.41034325	0	hsa-miR-29b-1*	1.473451375	0
hsa-miR-106b*	1.460387125	0	hsa-miR-885-5p	1.487745625	0
hsa-miR-421	1.63622425	0	hsa-miR-106b*	1.77119125	0
hsa-miR-1308	2.2919085	0	hsa-miR-181d	2.02541625	0
hsa-miR-183	2.5195705	0	hsa-miR-1246	2.284496125	0
hsa-miR-224	2.590309875	0	hsa-miR-18b	2.287867	0
hsa-miR-18a	2.830789875	0	hsa-miR-183	2.604235875	0
hsa-miR-18b	2.862260875	0	hsa-miR-18a	2.615767875	0
			hsa-miR-552	2.622208375	0
			hsa-miR-503	3.0354695	0
			hsa-miR-182	3.0650235	0
			hsa-miR-122	9.42885325	0

M vs T		
miRNAs	FoldChange	q-value
hsa-miR-139-5p	1.125679	0
hsa-miR-210	1.597213875	0
hsa-miR-150	1.67365425	0
hsa-miR-100	2.444512125	0
hsa-miR-122	9.23824025	0

Table S 5. KEGG pathways significantly modulated in T-N and in T-M contrasts. For each contrast, significantly modulated pathways were identified considering expression profiles of all genes being supported targets of DEMs and considering only the subset of genes being supported targets of DEMs and differentially expressed in the same contrast. In bold, genes in common for DEM and DEM.DEG.

KEGG ID	Pathway	T-N DEM and supported target genes				T-N DEM and supported target T-N DEG			
		miRNA	Sign	genes	sign	miRNA	sign	genes	sign
4110	Cell cycle	hsa-miR-182	up	CDKN2B	down	hsa-miR-195	down	CDC25B	up
		hsa-miR-100	down	ATR	up		hsa-miR-145	down	MYC
		hsa-miR-497	down	CCND1	up			PRKDC	up
		hsa-miR-195	down	CCNB1	up				
		hsa-miR-30a	down	BUB1	up				
		hsa-miR-145	down	CDC25A	up				
		hsa-miR-125b	down	CDC25B	up				
		hsa-miR-139-5p	down	CDC25C	up				
		hsa-miR-378	down	E2F3	up				
		hsa-miR-378*	down	MCM2	up				
		hsa-miR-422a	down	MYC	up				
				PRKDC	up				
				YWHAG	up				
		CDC23	up						
		DBF4	up						
		ORC6L	up						
		ANAPC7	up						
		ANAPC1	up						

4115	p53 signaling pathway	hsa-miR-182 up FAS down hsa-miR-183 up ATR up hsa-miR-30a down CCND1 up hsa-miR-195 down CCNB1 up hsa-miR-497 down BID up hsa-miR-145 down SERPINE up hsa-miR-194* down 1 up hsa-miR-378* down RRM2 up hsa-miR-125b down SHISA5 up hsa-miR-139-5p down GTSE1	
450	Selenoamino acid metabolism	hsa-miR-183 up PAPSS2 down hsa-miR-182 up AHCYL2 down hsa-miR-145 down MARS up hsa-miR-138 down MARS2 up hsa-miR-30a down WBSCR2 2 up	hsa-miR-183 up PAPSS2 down hsa-miR-182 up AHCYL2 down
970	Aminoacyl-tRNA biosynthesis	hsa-miR-145 down AARS up hsa-miR-150 down IARS up hsa-miR-195 down KARS up hsa-miR-497 down MARS up hsa-miR-138 down TARS2 up hsa-miR-30a down MARS2 up	
5222	Small cell lung cancer	hsa-miR-21 up PIK3R1 down hsa-miR-182 up CDKN2B down hsa-miR-497 down CCDN1 up hsa-miR-195 down CKS1B up hsa-miR-150 down COL4A1 up hsa-miR-194* down E2F3 up hsa-miR-30a down MYC up hsa-miR-125b down RELA up hsa-miR-139-5p down ITGA2 up hsa-miR-145 down hsa-miR-378* down	

630	Glyoxylate and dicarboxylate metabolism	hsa-miR-378 down hsa-miR-145 down hsa-miR-30a down hsa-miR-138 down	M vs up THFD1 up M vs up THFD1L AFMID						
4114	Oocyte meiosis	hsa-miR-30a down hsa-miR-195 down hsa-miR-145 down hsa-miR-497 down hsa-miR-378* down hsa-miR-125b down hsa-miR-139-5p down hsa-miR-182 up hsa-miR-18a up	BUB1 up CCNB1 up CDC25C up PPP2R1A up YWHAG up CDC23 up ANAPC7 up ANAPC1 up ITPR1 down PRKACB down						
100	Steroid biosynthesis	hsa-miR-139-5p down hsa-miR-145 down	DHCR7 up NSDHL up HS17B7 up						
670	One carbon pool by folate	hsa-miR-10b down hsa-miR-30a down hsa-miR-138 down	GART up M vs up THFD1 up M vs THFD1L						
5219	Bladder cancer	hsa-miR-497 down hsa-miR-30a down hsa-miR-125b down hsa-miR-195 down hsa-miR-145 down hsa-miR-138 down hsa-miR-182 up	CCND1 up E2F3 up MYC up VEGFA up RPS6KA5 down						
4310	Wnt signaling pathway			hsa-miR-145 down hsa-miR-497 down hsa-miR-195 down hsa-miR-143* up hsa-miR-182 down MYC up AXIN2 up RUVBL1 up PRKACB down					
5210	Colorectal cancer			hsa-miR-1246 up hsa-miR-182 up hsa-miR-145 down hsa-miR-497 down hsa-miR-195 down PDGFR up A down MYC down AXIN2					
750	Vitamin B6 metabolism			hsa-miR-195 down hsa-miR-497 down hsa-miR-145 down hsa-miR-30a down PSAT1 up up up down					
5213	Endometrial cancer			hsa-miR-145 down hsa-miR-497 down hsa-miR-195 down MYC up AXIN2 up					
KEGG ID	Pathway	T-N DEM and supported target genes				T-N DEM and supported target T-N DEG			
		miRNA	Sign	gene	sign	miRNA	sign	gene	sign
230	Purine metabolism	hsa-miR-10b down hsa-miR-122 up	GART up PDE1C down						

280	Valine, leucine and isoleucine degradation	hsa-miR-10b	Down	MCCC2	up
670	One carbon pool by folate	hsa-miR-10b	Down	GART	up

Figure S 1. Inverse correlation between c-Myc and miR-145 expression. Quantitative RT-PCR was carried out for **A.** c-Myc target gene and **B.** miR-145 in 78 samples of N, T and M samples used for gene profiling. Quantification was normalized to the expression of DACT1 and miR-200c respectively. Data are shown as the mean \pm standard deviation (SD) of the mean of three experiments performed in triplicate. ****** $P < 0.01$ vs N. nRQ: normalized Relative Quantity.




Table S 6. Biological process GO Terms significantly enriched in supported target gene from miRNA differently expressed in ATLL versus resting CD4+.

Symbol			GOBPID	Pvalue	Count	Term
HSD3B1 SRD5A1 HSD17B6			GO:0006702	2,09E+09	3	androgen biosynthetic process
CDC23 CCND1 PPP6C CDC7 CUL3 RB1	CDK2AP1 KPNA2 CDC6 APBB2 GAS1		GO:0051329	8,10E+09	11	interphase of mitotic cell cycle
INCENP MYH9 RASA1 ROCK2 CCND1 CCNF CDC6 NEDD9 NEK3 RB1	TACC1 WEE1 SMC1A CDC7 CDC23 ARHGEF2 PDS5B PELO MIS12		GO:0051301	0,0002	19	cell division
MAP1B MAP4	ARHGEF2 MID1IP1		GO:0007026	0,0006	4	negative regulation of microtubule depolymerization
SOAT1 DHCR24	PSEN1 ACHE		GO:0042982	0,0006	4	amyloid precursor protein metabolic
KPNA2 CDC23 CCND1 PPP6C CDC7 CUL3 RB1 CDK2AP1	MYH9 SMC1A PDS5B CCNF CDC6 INCENP NEDD9 NEK3	WEE1 ARHGEF2 MIS12 SEH1L SPO11 ADCY3 APBB2 GAS1	GO:0022403	0,0007	24	cell cycle phase
AQP2	AVPR1A		GO:0009415	0,0008	2	response to water
AQP2	AVPR1A		GO:0042631	0,0008	2	cellular response to water deprivation
APBB2 GAS1	RB1 CDC7		GO:0033261	0,001	4	regulation of S phase
AGT LEPR	ADAM vs TS1		GO:0001542	0,001	3	ovulation from ovarian follicle
APBB2 GAS1	RB1		GO:0045749	0,001	3	negative regulation of S phase of mitotic cell cycle

NDRG4 SGMS1 AGT IGFBP5 HTRA1 WISP1 PAPPA2	APBB2 ING1 ENPP1 RB1 NDRG3 ADIPOR2 SLC1A2	NEDD9 COL4A4 FGA GAS1 GLI3 MST vs N BMP8A	GO:0040007	0,001	21	Growth
ST8SIA4 MAN1A2	ST8SIA3		GO:0006491	0,002	3	N-glycan processing
APBB2 ING1 ENPP1 RB1	NDRG3 ADIPOR2 AGT IGFBP5	HTRA1 WISP1 PAPPA2	GO:0001558	0,002	11	regulation of cell growth
ALDH9A1 GAD1 ACHE KCND2 NDRG4 SGMS1 AGT IGFBP5 HTRA1 WISP1 PAPPA2 AVPR1A BCL10 AQP2 PLAU PRDX3 DIO2 HSD3B1 SRD5A1 HSD17B6	RHAG CCL23 TFRC CLCN3 ATP6V1H LPAR1 OPRL1 SYT1 RAB14 F9 FLI1 AKR1D1 MYH9 RASA1 RHOQ CPN2 MCL1 ABCA12 PLP1 PCSK2	FGA APBB2 ING1 ENPP1 RB1 NDRG3 ADIPOR2 ARPC5 ATP2C1 PSEN1 COL4A4 NR5A2 SLC2A4 SOAT1 LIPG USH2A SEH1L RDX KCNE1 SLC22A5	GO:0065008	0,002	47	regulation of biological quality

KPNA1	SMUG1	ROCK2	ARHGEF2				
KPNA2	SETX	OXSR1	MID1IP1				
ACHE	ALKBH1	C7orf16	OPRL1				
NASP	SIRT7	STK39	GNAI3				
TK2	PAPOLB	PPP2R2A	GRM3				
T vs	RTF1	PPP6C	CHRM5				
NFAIP1	TTF2	PTPN7	C1orf25				
CDC7	ATF1	PTPN9	OSBP2				
SUPT16H	RUNX1T1	M vs TMR2	LEPR				
CDC6	DLX4	ART3	NOVA1				
RB1	EN2	ST8SIA4	ITPA				
RFX5	ETV1	B3GALNT1	ENPP1				
SUPT4H1	EZH2	ST8SIA3	NNAT				
ST18	FLI1	ST6GALN	LIPG				
LPAR1	NR5A2	AC5	ALDH9A1				
MET	IRF4	MAN1A2	AGT				
UBE2D1	MITF	CASP7	ATP5G3				
UBE2N	NAB1	F9	ATP6V0A2				
TRIP12	NFATC4	MMP3	ATP6V1H				
KIAA0317	ZNF192	MMP16	PLCB1				
WWP2	LIMD1	MMP19	GLI3				
HECW1	PREB	NSF	CPN2				
FBXW2	IRF9	PCSK2	IGFBP5				
UBR7	CARHSP1	PLAU	DYRK1A				
TBL1XR1	YBX2	HTRA1	SRC				
CRNKL1	ZNF117	XPNPEP1	CLK4				
SF3A1	ZNF701	ADAM vs	C14orf147	GO:0044238	0,002097	232	primary metabolic process
CSTF1	ZNF695	TS1	ITIH5		948		
CSTF2	ZNF557	DPP3	RASA1				
SFRS2	MYCN	WDR7	ARPC5				
SMC1A	MYF6	PAPPA2	PSMD5				
DIO2	SP4	MYH9	BCL10				
PTGIS	TCF12	PSEN1	PLP1				
ITGB8	TIAL1	UBE2K	PPP2R5C				
PRKAR1A	MED20	UBE2G1	APBB2				
CCND1	FTSJ1	CUL3	CT vs				
SELE	MAX	CDC23	NND2				
FKBP15	MBD1	ARIH2	SALL1				
DNAJB5	GTF2E1	FBXL7	SOX11				
UBE2D3	TAF7L	GOT2	ZBTB24				
AKR1B1	IVNS1ABP	GAD1	MLXIP				
GBE1	A2BP1	ACADL	ASXL2				
MGAT1	PTBP2	STS	CNOT6				
NAGA	MRPL19	SOAT1	MED28				
SLC2A4	MRPL15	SRD5A1	LBH				
POFUT2	PELO	AKR1D1	VGLL3				
PC	MRP63	HSD17B6	RAB23				
METTL4	DARS2	ACAA2	BCOR				
ADCY3	USP6	ADIPOR2	ESRRG				
ADCY6	TTLL4	SGMS1	NFYB				
ADCY7	ERBB4	SCD	MST vs N				
RHOQ	FLT3	PIP5K1A	PCBD1				
DHODH	GMFB	DHCR24	MYF5				
UMPS	NEK3	HMGCS1	MYO6				

DHODH	UMPS	GO:0006222	0,002	2	UMP biosynthetic process		
DHODH	UMPS	GO:0009173	0,002	2	pyrimidine ribonucleoside monophosphate metabolic process		
SMC1A PDS5B CDC23	SEH1L INCENP	PSEN1 MIS12	GO:0007059	0,002	7	chromosome segregation	
NDRG4 SGMS1 AGT IGFBP5 HTRA1	WISP1 PAPPA2 APBB2 ING1	ENPP1 RB1 NDRG3 ADIPOR2	GO:0008361	0,002	13	regulation of cell size	
SUPT16H TTF2 MAP1B	MAP4 ARHGEF2	MID1IP1 RDX	GO:0034623	0,003	7	cellular macromolecular complex disassembly	
SUPT16H TTF2 MAP1B	MAP4 ARHGEF2 MID1IP1	LIPG LAMC1 RDX	GO:0022411	0,003	9	cellular component disassembly	
ARHGEF2 MYH9 MYF5 BMP8A LEPR MMP19 ROBO4 ADAM vs TS1 AGT RASA1 IGFBP5 GLI3 SALL1 ZFAND5 PRKAR1A MCL1 MYF6 DCX MET NASP BCL10 CCNF KCNE1 ACHE PVRL2 BAG1 DHCR24	YWHAZ CIAPIN1 COL4A3 TIA1 TIAL1 NOD1 CT vs NND2 DLX4 ELAVL1 EN2 MITF NNAT PLXNA2 PRM1 SOX11 TCF12 TMEFF1 NUMB LIMD1 ARIH2 OLFM1 DKK2 TAF7L PPP1R9A OLFML3 NDRG4 SEMA6D	LBH NR5A2 RAC1 T vs NFAIP1 FLI1 KRT6A DYRK1A ERBB4 GMFB MOBP PCSK2 SLC1A2 ST8SIA4 LGI1 RAPGEF5 RAB23 GAS1 C7orf16 SLC5A3 LAMC1 NFATC4 BCOR MST vs N SGCD SRD5A1 MFN1 RHOO	STS FGF7 KRT34 LAMC2 POU2F3 ATP2C1 CUL3 PPP3R1 PLP1 SOAT1 MAP1B FLT3 PRDX3 NDRG3 PAPPA2 ENPP1 CCND1 SRC COL4A4 FGA IRF4 SGMS1 RB1 RUNX1T1 TEK USH2A SLC2A4	GO:0032502	0,004	109	developmental process

DHCR24 HMGCS1 PRKAA2 ACAA2 AKR1D1	HSD3B1 SRD5A1 HSD17B6 STS	LEPR SOAT1 AGT OSBP2	GO:0008202	0,004	13	steroid metabolic process
ADCY3 ADCY6 ADCY7 RHOQ DHODH UMPS ATP8A1	ATP2C1 ATP8B4 OPRL1 GNAI3 GRM3 CHRM5	ITPA ENPP1 ATP5G3 ATP6V0A2 ATP6V1H SMUG1	GO:0006753	0,004	19	nucleoside phosphate metabolic process
MAP1B MAP4	ARHGEF2 MID1IP1		GO:0031110	0,004	4	regulation of microtubule polymerization or depolymerization
ADCY3 ADCY6 ADCY7 RHOQ ATP8A1	ATP2C1 ATP8B4 OPRL1 GNAI3 GRM3	CHRM5 ATP5G3 ATP6V0A2 ATP6V1H ENPP1	GO:0006163	0,004	15	purine nucleotide metabolic process

Table S 7. Expression values and sequences for 78 new mature miRNAs expressed in SET2 cells.

New miRNA	Sequence	Expression
hsa-miR-1307*	CTCGACCGGACCTCGACCGGCTCGT	72670
hsa-miR-376a-2*	GGTAGATTTTCTTCTATGGTTA	14296
hsa-miR-382*	CGAATCATTACGGACAACACTTTTT	8296
hsa-miR-539*	AATCATACAAGGACAATTTCTTTTTGA	3332
hsa-miR-181b-1*	CTCACTGAACAATGAATGCAACT	1542
hsa-miR-561*	ATCAAGGATCTTAACTTTGCC	1315
hsa-let-7c*	CTGTACAACCTTCTAGCTTTCCT	1195
hsa-miR-652*	ACAACCCTAGGAGAGGGTGCCATTCA	982
hsa-miR-301a*	GCTCTGACTTTATTGCACTACT	880
hsa-miR-487a*	GTGGTTATCCCTGCTGTGTTCCG	823
hsa-miR-370*	AAGCCAGGTCACGTCTCTGCAGTTACAC	624
hsa-miR-412*	TGGTCGACCAGTTGGAAAGTAAT	578
hsa-miR-376c*	GTGGATATTCCTTCTATGTTTAT	568
hsa-miR-381*	AAGCGAGGTTGCCCTTTGTATATTC	567
hsa-miR-376b*	GTGGATATTCCTTCTATGTTTA	532
hsa-miR-487b*	AGTGGTTATCCCTGTCCTGTTCCGT	491
hsa-miR-1277*	TATATATATATGTACGTATGT	422
hsa-miR-101-2*	TCGGTTATCATGGTACCGATGCTGT	386
hsa-miR-942*	CACATGGCCGAAACAGAGAAGTTA	373
hsa-miR-1185-1*	ATATACAGGGGGAGACTCTTATT	355
hsa-miR-503*	GGGGTATTGTTCCGCTGCCAGG	335

hsa-miR-210*	AGCCCCTGCCACCGCACACTGC	325
hsa-miR-543*	GAAGTTGCCCGTGTTCCTCGCT	305
hsa-miR-152*	CAGGTTCTGTGATACACTCCGACTC	301
hsa-miR-1304*	CATCTCACTGTAGCCTCGAACCCT	296
hsa-miR-659*	CAGGACCTCCCTGAACCAAGGAAGA	251
hsa-miR-889*	GAATGGCTGTCCGTAGTATGGTC	213
hsa-miR-128-1*	CGGGGCCGTAGCACTGTCTGAGA	201
hsa-miR-410*	AGTTGTCTGTGATGAGTTCG	185
hsa-miR-107*	AGCTTCTTTACAGTGTTCCTTGT	175
hsa-miR-495*	GAAGTTGCCCATGTTATTTTCG	158
hsa-miR-758*	ATGGTTGACCAGAGACACACG	143
hsa-miR-181b-2*	ACTCACTGATCAATGAATGCAAA	124
hsa-miR-212*	ACCTTGGCTCTAGACTGCTTACTG	110
hsa-miR-1185-2*	ATATACAGGGGGAGACTCTCAT	96
hsa-miR-544*	TCTTGTTAAAAAGCAGATTCT	87
hsa-miR-134*	CTGTGGGCCACCTAGTCACCAA	80
hsa-miR-874*	CGGCCCCACGCACCAGGGTAAGA	68
hsa-miR-513c*	TAAATTTACCTTTCTGAGAAGA	65
hsa-miR-1255a*	AACTATCTCTTTGCTCATCCTTG	61
hsa-miR-301b*	GCTCTGACGAGGTTGCACTACT	59
hsa-miR-450a-2*	ATTGGGGACATTTGCATTCAT	55
hsa-miR-98*	CTATACACTTACTACTTTCC	52
hsa-miR-656*	AGTTGCCTGTGAGGTGTCA	49
hsa-miR-433*	TACGGTGAGCCTGTCATTATTC	42
hsa-miR-660*	ACCTCCTGTGTGCATGGATTACA	42
hsa-miR-4424*	GTCCATTTCAAGTTAACTCTGT	41
hsa-miR-496*	GGTTGTCCATGGTGTGTTTCATT	38
hsa-miR-548j*	CAAAAAGTGCATTACTTTTGCA	38

Table S 8. List of conserved predicted target genes for new miRNAs with read count over 500. Conserved target sites were predicted using TargetScan and filtered according to the context score. Conserved predictions associated to top 25% scores were reported below.

miRNA	Symbol	#Conserved Syte	miRNA	Symbol	#Conserved Syte
hsa-let-7c*	ABCC5	1	hsa-miR-181b-1*	STXBP5L	1
hsa-let-7c*	ACVR1B	1	hsa-miR-181b-1*	TAB2	1
hsa-let-7c*	ACVR2A	1	hsa-miR-181b-1*	TAF5	1
hsa-let-7c*	ADAM19	1	hsa-miR-181b-1*	TAOK3	1
hsa-let-7c*	ADAMTSL1	2	hsa-miR-181b-1*	TASP1	1
hsa-let-7c*	ADAMTSL3	1	hsa-miR-181b-1*	TBC1D9	1
hsa-let-7c*	ADCY6	1	hsa-miR-181b-1*	TFRC	1
hsa-let-7c*	ADNP	1	hsa-miR-181b-1*	TIPARP	1
hsa-let-7c*	AKAP1	1	hsa-miR-181b-1*	TM9SF3	1
hsa-let-7c*	ANKRD12	1	hsa-miR-181b-1*	TMEM26	1

hsa-let-7c*	APC	1	hsa-miR-181b-1*	TRA2A	1
hsa-let-7c*	ARHGAP29	1	hsa-miR-181b-1*	TRIM55	1
hsa-let-7c*	ARID1B	1	hsa-miR-181b-1*	TSC1	1
hsa-let-7c*	ARID4B	2	hsa-miR-181b-1*	TSN	1
hsa-let-7c*	ARIH2	1	hsa-miR-181b-1*	TTC33	1
hsa-let-7c*	ARNT	1	hsa-miR-181b-1*	UBA6	1
hsa-let-7c*	ASAP1	1	hsa-miR-181b-1*	UBE3C	1
hsa-let-7c*	ASCL1	2	hsa-miR-181b-1*	UBQLN2	1
hsa-let-7c*	ATP1B1	1	hsa-miR-181b-1*	USP50	1
hsa-let-7c*	ATP2B4	1	hsa-miR-181b-1*	VSNL1	1
hsa-let-7c*	AUTS2	1	hsa-miR-181b-1*	YWHAG	2
hsa-let-7c*	AXIN1	1	hsa-miR-181b-1*	ZNF804A	1
hsa-let-7c*	B4GALT5	1	hsa-miR-301a*	AP2B1	1
hsa-let-7c*	BBC3	1	hsa-miR-301a*	BMP2	1
hsa-let-7c*	BCL11A	1	hsa-miR-301a*	BNC2	1
hsa-let-7c*	BCL7A	1	hsa-miR-301a*	CCNT2	1
hsa-let-7c*	BMI1	1	hsa-miR-301a*	CDC23	1
hsa-let-7c*	BNC2	1	hsa-miR-301a*	CHD9	1
hsa-let-7c*	BRD4	1	hsa-miR-301a*	CUL3	1
hsa-let-7c*	BTBD7	1	hsa-miR-301a*	DDX3Y	1
hsa-let-7c*	BTG1	1	hsa-miR-301a*	EGR1	1
hsa-let-7c*	C10orf140	1	hsa-miR-301a*	EIF2S2	1
hsa-let-7c*	C14orf43	1	hsa-miR-301a*	ELOVL6	1
hsa-let-7c*	C5orf53	1	hsa-miR-301a*	FAM46A	1
hsa-let-7c*	C7orf42	1	hsa-miR-301a*	FOXJ2	1
hsa-let-7c*	CACNA2D2	1	hsa-miR-301a*	GABPA	1
hsa-let-7c*	CALM2	1	hsa-miR-301a*	GPR3	1
hsa-let-7c*	CD9	1	hsa-miR-301a*	HNF1B	2
hsa-let-7c*	CDC27	1	hsa-miR-301a*	KIAA1737	1
hsa-let-7c*	CDC42SE2	1	hsa-miR-301a*	KIAA2022	1
hsa-let-7c*	CDH11	1	hsa-miR-301a*	KLF12	1
hsa-let-7c*	CDKN1C	1	hsa-miR-301a*	MAP2K4	1
hsa-let-7c*	CDYL	1	hsa-miR-301a*	NFYB	1
hsa-let-7c*	CELF5	1	hsa-miR-301a*	NR2C2	1
hsa-let-7c*	CITED2	2	hsa-miR-301a*	NTM	1
hsa-let-7c*	CLK1	1	hsa-miR-301a*	NUAK1	1
hsa-let-7c*	CLK2	1	hsa-miR-301a*	OLFM3	1
hsa-let-7c*	CLK4	1	hsa-miR-301a*	PACRG	1
hsa-let-7c*	COL13A1	1	hsa-miR-301a*	PITPNB	1
hsa-let-7c*	COLEC12	1	hsa-miR-301a*	PKIA	1
hsa-let-7c*	CREB5	1	hsa-miR-301a*	RAB12	1
hsa-let-7c*	CRMP1	1	hsa-miR-301a*	RAB1A	1
hsa-let-7c*	CSMD2	1	hsa-miR-301a*	RRAS2	1
hsa-let-7c*	CUL3	1	hsa-miR-301a*	SERBP1	1
hsa-let-7c*	CYFIP2	1	hsa-miR-301a*	SGMS1	1
hsa-let-7c*	DACH1	1	hsa-miR-301a*	SHOC2	1
hsa-let-7c*	DEK	1	hsa-miR-301a*	SLC44A1	1
hsa-let-7c*	DKK1	1	hsa-miR-301a*	SSR3	1

hsa-let-7c*	DLX6	1	hsa-miR-301a*	TMEM189	1
hsa-let-7c*	DMD	1	hsa-miR-301a*	TRAF3	1
hsa-let-7c*	DNAJA2	2	hsa-miR-301a*	UNC13B	1
hsa-let-7c*	DNAJC8	1	hsa-miR-301a*	VEZF1	1
hsa-let-7c*	DOCK4	1	hsa-miR-301a*	ZFX	1
hsa-let-7c*	DSCAML1	1	hsa-miR-370*	ACVR2A	1
hsa-let-7c*	DYRK4	1	hsa-miR-370*	BCL11A	1
hsa-let-7c*	E2F3	1	hsa-miR-370*	BCL2L11	1
hsa-let-7c*	E2F4	1	hsa-miR-370*	C11orf87	1
hsa-let-7c*	EIF4B	1	hsa-miR-370*	CADM2	1
hsa-let-7c*	ELL	1	hsa-miR-370*	CCDC6	1
hsa-let-7c*	ELMO1	1	hsa-miR-370*	CEACAM1	1
hsa-let-7c*	ELOVL5	1	hsa-miR-370*	CEBPG	1
hsa-let-7c*	EP300	1	hsa-miR-370*	EIF2S1	1
hsa-let-7c*	ERBB2IP	1	hsa-miR-370*	FAM110B	1
hsa-let-7c*	FAM108C1	1	hsa-miR-370*	FAM193A	1
hsa-let-7c*	FAM160B1	1	hsa-miR-370*	FAM98A	1
hsa-let-7c*	FAM49B	1	hsa-miR-370*	FBXL7	1
hsa-let-7c*	FAM60A	1	hsa-miR-370*	HIF1A	1
hsa-let-7c*	FAM76B	2	hsa-miR-370*	HNRNPA0	1
hsa-let-7c*	FBN2	1	hsa-miR-370*	MCAM	1
hsa-let-7c*	FBXL3	1	hsa-miR-370*	NEK9	1
hsa-let-7c*	FBXO21	1	hsa-miR-370*	ORMDL2	1
hsa-let-7c*	FBXO38	1	hsa-miR-370*	PAPD7	1
hsa-let-7c*	FBXW11	1	hsa-miR-370*	PPP2R5A	1
hsa-let-7c*	FERMT2	1	hsa-miR-370*	PRKAB1	1
hsa-let-7c*	FGF18	1	hsa-miR-370*	RAB3GAP2	1
hsa-let-7c*	FGF7	1	hsa-miR-370*	RBM9	1
hsa-let-7c*	FLI1	1	hsa-miR-370*	SH2D2A	1
hsa-let-7c*	FLRT2	1	hsa-miR-370*	SH2D4B	1
hsa-let-7c*	FOXF1	1	hsa-miR-370*	SORBS2	2
hsa-let-7c*	FOXO1	1	hsa-miR-370*	SPATS2L	1
hsa-let-7c*	FXR1	1	hsa-miR-370*	SRPR	1
hsa-let-7c*	FZD1	1	hsa-miR-370*	TCAP	1
hsa-let-7c*	GABBR2	1	hsa-miR-370*	YPEL2	1
hsa-let-7c*	GDF6	1	hsa-miR-370*	ZBTB44	1
hsa-let-7c*	GJC1	1	hsa-miR-370*	ZFC3H1	1
hsa-let-7c*	GNAI1	1	hsa-miR-376a-2*	ACVR1	1
hsa-let-7c*	GOLGA1	1	hsa-miR-376a-2*	C4orf40	1
hsa-let-7c*	GOPC	1	hsa-miR-376a-2*	C6orf195	1
hsa-let-7c*	GPM6A	2	hsa-miR-376a-2*	CAPRIN1	1
hsa-let-7c*	GPR126	1	hsa-miR-376a-2*	CAPZB	1
hsa-let-7c*	GRB10	1	hsa-miR-376a-2*	CD47	1
hsa-let-7c*	GRIA3	1	hsa-miR-376a-2*	CHD9	1
hsa-let-7c*	GRIN3A	1	hsa-miR-376a-2*	CHL1	1
hsa-let-7c*	GRPEL2	1	hsa-miR-376a-2*	CNRIP1	1
hsa-let-7c*	GTPBP2	1	hsa-miR-376a-2*	CSMD2	1
hsa-let-7c*	HAPLN1	1	hsa-miR-376a-2*	DAZAP1	1

hsa-let-7c*	HECTD2	2	hsa-miR-376a-2*	FAM60A	1
hsa-let-7c*	HERC1	1	hsa-miR-376a-2*	HDAC9	1
hsa-let-7c*	HERC4	1	hsa-miR-376a-2*	HOXA13	1
hsa-let-7c*	HIF1A	1	hsa-miR-376a-2*	HOXA9	1
hsa-let-7c*	HIVEP2	2	hsa-miR-376a-2*	HTR2C	1
hsa-let-7c*	HMGA2	1	hsa-miR-376a-2*	JAKMIP2	1
hsa-let-7c*	HMGCR	1	hsa-miR-376a-2*	KPNA4	1
hsa-let-7c*	HMGCS1	1	hsa-miR-376a-2*	LRRC4C	1
hsa-let-7c*	HMGNI	1	hsa-miR-376a-2*	MAF	1
hsa-let-7c*	HMGXB4	1	hsa-miR-376a-2*	MED14	1
hsa-let-7c*	HNRNPU	1	hsa-miR-376a-2*	NEGR1	1
hsa-let-7c*	HOXB2	1	hsa-miR-376a-2*	NRXN3	1
hsa-let-7c*	HOXB7	1	hsa-miR-376a-2*	OLA1	1
hsa-let-7c*	HOXC9	1	hsa-miR-376a-2*	PDS5B	1
hsa-let-7c*	INTS6	1	hsa-miR-376a-2*	PHYHIPL	1
hsa-let-7c*	IQSEC1	1	hsa-miR-376a-2*	PTBP2	1
hsa-let-7c*	IRF6	1	hsa-miR-376a-2*	PURB	1
hsa-let-7c*	IWS1	1	hsa-miR-376a-2*	SFRS9	1
hsa-let-7c*	JAZF1	1	hsa-miR-376a-2*	SMAD5	1
hsa-let-7c*	JMJD1C	1	hsa-miR-376a-2*	SP4	1
hsa-let-7c*	KAL1	1	hsa-miR-376a-2*	STAT6	1
hsa-let-7c*	KCNJ2	1	hsa-miR-376a-2*	USP38	1
hsa-let-7c*	KDM2B	2	hsa-miR-376a-2*	XRN1	1
hsa-let-7c*	KDM6A	1	hsa-miR-376a-2*	ZCCHC5	1
hsa-let-7c*	KIAA0247	1	hsa-miR-376b*	ARID2	1
hsa-let-7c*	KIAA0317	1	hsa-miR-376b*	ARID5B	1
hsa-let-7c*	KIAA1274	1	hsa-miR-376b*	ATP7A	1
hsa-let-7c*	KIAA1486	1	hsa-miR-376b*	BACH2	1
hsa-let-7c*	KIAA2026	1	hsa-miR-376b*	BNIP3L	1
hsa-let-7c*	KIF26A	1	hsa-miR-376b*	CHD9	1
hsa-let-7c*	KLF4	1	hsa-miR-376b*	ETV1	1
hsa-let-7c*	KLF9	2	hsa-miR-376b*	FAM19A2	1
hsa-let-7c*	KLHL14	1	hsa-miR-376b*	FZD8	1
hsa-let-7c*	KPNA4	1	hsa-miR-376b*	GRIA2	1
hsa-let-7c*	KRAS	1	hsa-miR-376b*	IGF2BP2	1
hsa-let-7c*	KRIT1	1	hsa-miR-376b*	IRF2BP2	1
hsa-let-7c*	KSR2	1	hsa-miR-376b*	JOSD1	1
hsa-let-7c*	L3MBTL3	1	hsa-miR-376b*	KY	1
hsa-let-7c*	LEPREL1	1	hsa-miR-376b*	MAGI2	1
hsa-let-7c*	LMNB2	1	hsa-miR-376b*	MBNL2	1
hsa-let-7c*	LRIG1	1	hsa-miR-376b*	MYST3	1
hsa-let-7c*	LRP1B	1	hsa-miR-376b*	NHLH2	1
hsa-let-7c*	LRP6	1	hsa-miR-376b*	NKRF	1
hsa-let-7c*	LZTS2	1	hsa-miR-376b*	NRN1	1
hsa-let-7c*	M6PR	1	hsa-miR-376b*	ODZ1	2
hsa-let-7c*	MAGI3	1	hsa-miR-376b*	PAX3	1
hsa-let-7c*	MAP4K3	1	hsa-miR-376b*	PPAP2B	1
hsa-let-7c*	MBD5	1	hsa-miR-376b*	RNF150	1

hsa-let-7c*	MECOM	1	hsa-miR-376b*	RNGTT	1
hsa-let-7c*	MED13	1	hsa-miR-376b*	RPGRIP1L	1
hsa-let-7c*	MED31	1	hsa-miR-376b*	RUNX1T1	1
hsa-let-7c*	MEF2C	2	hsa-miR-376b*	RYR2	1
hsa-let-7c*	MEGF11	1	hsa-miR-376b*	SALL1	1
hsa-let-7c*	MEMO1	1	hsa-miR-376b*	SECISBP2L	1
hsa-let-7c*	MGAT4A	1	hsa-miR-376b*	SLITRK1	1
hsa-let-7c*	MIER3	2	hsa-miR-376b*	SMPD3	1
hsa-let-7c*	MITF	1	hsa-miR-376b*	STMN1	1
hsa-let-7c*	MKL2	1	hsa-miR-376b*	THRB	1
hsa-let-7c*	MLL3	1	hsa-miR-376b*	ZBTB33	1
hsa-let-7c*	MLL4	1	hsa-miR-376b*	ZNF281	1
hsa-let-7c*	MLL5	1	hsa-miR-376c*	ARID2	1
hsa-let-7c*	MNT	1	hsa-miR-376c*	ARID5B	1
hsa-let-7c*	MRPL49	1	hsa-miR-376c*	ATP7A	1
hsa-let-7c*	MYCL1	1	hsa-miR-376c*	BACH2	1
hsa-let-7c*	MYT1L	1	hsa-miR-376c*	BNIP3L	1
hsa-let-7c*	NAA16	1	hsa-miR-376c*	CHD9	1
hsa-let-7c*	NAMPT	3	hsa-miR-376c*	ETV1	1
hsa-let-7c*	NAP1L4	1	hsa-miR-376c*	FAM19A2	1
hsa-let-7c*	NAV3	1	hsa-miR-376c*	FZD8	1
hsa-let-7c*	NCKAP5	1	hsa-miR-376c*	GRIA2	1
hsa-let-7c*	NEDD4L	1	hsa-miR-376c*	IGF2BP2	1
hsa-let-7c*	NEUROG1	1	hsa-miR-376c*	IRF2BP2	1
hsa-let-7c*	NFKBIA	1	hsa-miR-376c*	JOSD1	1
hsa-let-7c*	NKTR	1	hsa-miR-376c*	KY	1
hsa-let-7c*	NPC1	1	hsa-miR-376c*	MAGI2	1
hsa-let-7c*	NR2E1	1	hsa-miR-376c*	MBNL2	1
hsa-let-7c*	NUDT21	1	hsa-miR-376c*	MYST3	1
hsa-let-7c*	NUMB	1	hsa-miR-376c*	NHLH2	1
hsa-let-7c*	NUP153	1	hsa-miR-376c*	NKRF	1
hsa-let-7c*	NUP54	1	hsa-miR-376c*	NRN1	1
hsa-let-7c*	OSBPL8	1	hsa-miR-376c*	ODZ1	2
hsa-let-7c*	PAN3	1	hsa-miR-376c*	PAX3	1
hsa-let-7c*	PARD6B	1	hsa-miR-376c*	PPAP2B	1
hsa-let-7c*	PARVA	1	hsa-miR-376c*	RNF150	1
hsa-let-7c*	PATL1	1	hsa-miR-376c*	RNGTT	1
hsa-let-7c*	PCCA	1	hsa-miR-376c*	RPGRIP1L	1
hsa-let-7c*	PCDH7	1	hsa-miR-376c*	RUNX1T1	1
hsa-let-7c*	PDE4A	1	hsa-miR-376c*	RYR2	1
hsa-let-7c*	PDIA3	1	hsa-miR-376c*	SALL1	1
hsa-let-7c*	PGAP1	1	hsa-miR-376c*	SECISBP2L	1
hsa-let-7c*	PHC1	1	hsa-miR-376c*	SLITRK1	1
hsa-let-7c*	PHF2	2	hsa-miR-376c*	SMPD3	1
hsa-let-7c*	PHTF2	1	hsa-miR-376c*	STMN1	1
hsa-let-7c*	PIAS3	1	hsa-miR-376c*	THRB	1
hsa-let-7c*	PKIA	1	hsa-miR-376c*	ZBTB33	1
hsa-let-7c*	PKP4	1	hsa-miR-376c*	ZNF281	1

hsa-let-7c*	PLEKHA5	1	hsa-miR-381*	DDN	1
hsa-let-7c*	PLS3	1	hsa-miR-381*	PTPRU	1
hsa-let-7c*	PIIP5K1	1	hsa-miR-382*	AHCYL1	1
hsa-let-7c*	PPP1R12A	1	hsa-miR-382*	B4GALT5	1
hsa-let-7c*	PPP1R3B	1	hsa-miR-382*	BTRC	1
hsa-let-7c*	PPP1R8	1	hsa-miR-382*	C18orf34	1
hsa-let-7c*	PPP1R9A	1	hsa-miR-382*	CACNA1C	1
hsa-let-7c*	PPP2R5C	2	hsa-miR-382*	CFTR	1
hsa-let-7c*	PPP3CB	1	hsa-miR-382*	COL24A1	1
hsa-let-7c*	PPP3R1	1	hsa-miR-382*	CSMD3	1
hsa-let-7c*	PRDM10	1	hsa-miR-382*	EGR3	1
hsa-let-7c*	PRKCE	1	hsa-miR-382*	EIF4H	1
hsa-let-7c*	PRPF40A	1	hsa-miR-382*	ENAH	1
hsa-let-7c*	PSMG2	1	hsa-miR-382*	FZD4	1
hsa-let-7c*	PTMA	1	hsa-miR-382*	G3BP1	1
hsa-let-7c*	PTPRB	1	hsa-miR-382*	GJA1	1
hsa-let-7c*	PUM1	1	hsa-miR-382*	GPR85	1
hsa-let-7c*	PUS7	1	hsa-miR-382*	JAZF1	1
hsa-let-7c*	QSER1	1	hsa-miR-382*	LMO3	1
hsa-let-7c*	R3HDM1	1	hsa-miR-382*	MAPK6	1
hsa-let-7c*	RAB10	1	hsa-miR-382*	MEX3C	1
hsa-let-7c*	RAB40B	1	hsa-miR-382*	NFYB	1
hsa-let-7c*	RAPGEF2	1	hsa-miR-382*	NLGN1	1
hsa-let-7c*	RBM16	1	hsa-miR-382*	NOVA1	1
hsa-let-7c*	RBM23	1	hsa-miR-382*	NR3C1	1
hsa-let-7c*	RBM27	1	hsa-miR-382*	PARD6B	1
hsa-let-7c*	RBM5	1	hsa-miR-382*	PLAGL2	1
hsa-let-7c*	RCAN2	1	hsa-miR-382*	PRKD1	1
hsa-let-7c*	RDX	1	hsa-miR-382*	QKI	1
hsa-let-7c*	REV1	1	hsa-miR-382*	QSER1	1
hsa-let-7c*	RGS7BP	1	hsa-miR-382*	RC3H1	1
hsa-let-7c*	RLF	1	hsa-miR-382*	SFRS13A	1
hsa-let-7c*	RNF139	1	hsa-miR-382*	SNRK	1
hsa-let-7c*	RNF38	1	hsa-miR-382*	THRAP3	1
hsa-let-7c*	RNPS1	1	hsa-miR-382*	TRIM8	1
hsa-let-7c*	ROPN1	1	hsa-miR-382*	TRPS1	1
hsa-let-7c*	RP11-35N6.1	2	hsa-miR-382*	UBE2D2	1
hsa-let-7c*	RPL29	1	hsa-miR-382*	UBR3	1
hsa-let-7c*	RRP1B	1	hsa-miR-382*	YTHDF3	1
hsa-let-7c*	RUNX2	1	hsa-miR-382*	ZFC3H1	1
hsa-let-7c*	RXRA	1	hsa-miR-382*	ZNF10	1
hsa-let-7c*	SAPS3	2	hsa-miR-382*	ZNF281	1
hsa-let-7c*	SCAMP5	1	hsa-miR-412*	CCPG1	1
hsa-let-7c*	SCRIB	1	hsa-miR-412*	PCDH10	1
hsa-let-7c*	SCRN1	1	hsa-miR-487a*	AP3M1	1
hsa-let-7c*	SCYL1	1	hsa-miR-487a*	ATG2B	1
hsa-let-7c*	SEC11A	1	hsa-miR-487a*	CDC27	1
hsa-let-7c*	SEC24D	1	hsa-miR-487a*	CELF1	1

hsa-let-7c*	SEPT3	1	hsa-miR-487a*	CTNNA1	1
hsa-let-7c*	SEPT7	1	hsa-miR-487a*	CTNND2	1
hsa-let-7c*	SERPINE2	1	hsa-miR-487a*	DCX	1
hsa-let-7c*	SERTAD4	1	hsa-miR-487a*	DIXDC1	1
hsa-let-7c*	SF3B3	1	hsa-miR-487a*	GDF10	1
hsa-let-7c*	SLAIN2	1	hsa-miR-487a*	GRIA1	1
hsa-let-7c*	SLC25A26	1	hsa-miR-487a*	LAMC1	1
hsa-let-7c*	SLC35D1	1	hsa-miR-487a*	MAGT1	1
hsa-let-7c*	SLC39A10	1	hsa-miR-487a*	MECP2	1
hsa-let-7c*	SLC5A12	1	hsa-miR-487a*	NAP1L1	1
hsa-let-7c*	SLC6A6	1	hsa-miR-487a*	NUAK1	1
hsa-let-7c*	SMARCC1	1	hsa-miR-487a*	RSF1	1
hsa-let-7c*	SMC6	1	hsa-miR-487a*	SFRS2	1
hsa-let-7c*	SNRPB2	1	hsa-miR-487a*	SMARCA2	1
hsa-let-7c*	SNRPD1	1	hsa-miR-487a*	TPH2	1
hsa-let-7c*	SNX25	1	hsa-miR-487a*	UBE2D2	1
hsa-let-7c*	SORBS2	1	hsa-miR-487a*	UBTD2	1
hsa-let-7c*	SORCS3	1	hsa-miR-487a*	ZC3H7A	1
hsa-let-7c*	SOX2	1	hsa-miR-539*	ABTB2	1
hsa-let-7c*	SOX3	1	hsa-miR-539*	ANKS1B	1
hsa-let-7c*	SOX4	1	hsa-miR-539*	ARHGAP20	1
hsa-let-7c*	SOX8	1	hsa-miR-539*	ARHGAP26	1
hsa-let-7c*	SP1	1	hsa-miR-539*	ASAP2	1
hsa-let-7c*	SP8	1	hsa-miR-539*	ATP11C	1
hsa-let-7c*	SPAST	1	hsa-miR-539*	ATP8B1	1
hsa-let-7c*	SREBF1	1	hsa-miR-539*	BMI1	1
hsa-let-7c*	SS18L1	1	hsa-miR-539*	BOD1L	1
hsa-let-7c*	STAG1	1	hsa-miR-539*	C5orf41	1
hsa-let-7c*	STAT5A	1	hsa-miR-539*	C6orf106	1
hsa-let-7c*	STX16	1	hsa-miR-539*	CCNT2	1
hsa-let-7c*	STXBP5L	1	hsa-miR-539*	CHKA	1
hsa-let-7c*	SUFU	1	hsa-miR-539*	CNKSR3	1
hsa-let-7c*	SUMO3	1	hsa-miR-539*	CNR1	1
hsa-let-7c*	SUZ12	1	hsa-miR-539*	CREBZF	1
hsa-let-7c*	SWAP70	1	hsa-miR-539*	CSMD3	1
hsa-let-7c*	SYVN1	1	hsa-miR-539*	CUL4B	1
hsa-let-7c*	TAB3	1	hsa-miR-539*	DOCK4	1
hsa-let-7c*	TACSTD2	1	hsa-miR-539*	DYRK1A	1
hsa-let-7c*	TANC1	1	hsa-miR-539*	ENY2	1
hsa-let-7c*	TBC1D12	1	hsa-miR-539*	EVI5	1
hsa-let-7c*	TBX18	1	hsa-miR-539*	FSTL4	1
hsa-let-7c*	TCERG1L	1	hsa-miR-539*	GPM6A	1
hsa-let-7c*	TCF4	1	hsa-miR-539*	MAGI2	1
hsa-let-7c*	THBD	1	hsa-miR-539*	MEGF9	1
hsa-let-7c*	THBS1	1	hsa-miR-539*	NLK	1
hsa-let-7c*	TLK1	2	hsa-miR-539*	PDE4D	1
hsa-let-7c*	TMEM2	1	hsa-miR-539*	PDZD2	1
hsa-let-7c*	TNFRSF11B	1	hsa-miR-539*	PPP4R4	1

hsa-let-7c*	TOX	1	hsa-miR-539*	PRPF40A	1
hsa-let-7c*	TP63	1	hsa-miR-539*	PUM2	1
hsa-let-7c*	TRA2B	1	hsa-miR-539*	RC3H1	1
hsa-let-7c*	TRIM2	1	hsa-miR-539*	REPS2	1
hsa-let-7c*	TRRAP	1	hsa-miR-539*	RGS14	1
hsa-let-7c*	TSHZ1	1	hsa-miR-539*	RHOA	1
hsa-let-7c*	UBE2E2	1	hsa-miR-539*	RNF38	1
hsa-let-7c*	UBE2F	1	hsa-miR-539*	RNF44	1
hsa-let-7c*	UBE2G1	1	hsa-miR-539*	SEMA3C	1
hsa-let-7c*	UBE2T	1	hsa-miR-539*	SIRT1	1
hsa-let-7c*	UBQLN2	1	hsa-miR-539*	SMAD7	1
hsa-let-7c*	USMG5	1	hsa-miR-539*	SNRNP40	1
hsa-let-7c*	UST	1	hsa-miR-539*	SNX6	1
hsa-let-7c*	VANGL2	1	hsa-miR-539*	SOX9	1
hsa-let-7c*	VEZF1	1	hsa-miR-539*	SP3	1
hsa-let-7c*	WDR33	1	hsa-miR-539*	SPRED2	1
hsa-let-7c*	WWC1	1	hsa-miR-539*	STIM2	1
hsa-let-7c*	YPEL2	1	hsa-miR-539*	STYX	1
hsa-let-7c*	ZBTB33	1	hsa-miR-539*	TEAD1	1
hsa-let-7c*	ZBTB39	1	hsa-miR-539*	TMEM184B	1
hsa-let-7c*	ZCCHC14	1	hsa-miR-539*	TNPO1	1
hsa-let-7c*	ZDHHC21	1	hsa-miR-539*	TOP1	1
hsa-let-7c*	ZHX2	1	hsa-miR-539*	TRIB2	1
hsa-let-7c*	ZHX3	1	hsa-miR-539*	YPEL4	1
hsa-let-7c*	ZIC5	1	hsa-miR-539*	ZEB2	1
hsa-let-7c*	ZNF638	1	hsa-miR-539*	ZER1	1
hsa-let-7c*	ZNF704	1	hsa-miR-539*	ZNF217	1
hsa-let-7c*	ZNF831	1	hsa-miR-561*	ARHGAP5	1
hsa-let-7c*	ZNRF3	1	hsa-miR-561*	ASH1L	1
hsa-let-7c*	ZZEF1	1	hsa-miR-561*	BCL11B	1
hsa-miR-181b-1*	ABCD3	1	hsa-miR-561*	C9orf41	1
hsa-miR-181b-1*	ACVR1C	1	hsa-miR-561*	CCDC88A	1
hsa-miR-181b-1*	ADCY6	1	hsa-miR-561*	CLCN5	1
hsa-miR-181b-1*	AHCYL1	1	hsa-miR-561*	CNOT2	1
hsa-miR-181b-1*	AKAP2	1	hsa-miR-561*	DIP2B	1
hsa-miR-181b-1*	ARHGAP5	1	hsa-miR-561*	EIF3J	1
hsa-miR-181b-1*	ARID1A	1	hsa-miR-561*	ELOVL7	1
hsa-miR-181b-1*	ARID1B	1	hsa-miR-561*	FAM108B1	1
hsa-miR-181b-1*	ARMC1	1	hsa-miR-561*	FNTB	1
hsa-miR-181b-1*	ATRX	2	hsa-miR-561*	GALNT2	1
hsa-miR-181b-1*	ATXN7L1	1	hsa-miR-561*	GLO1	1
hsa-miR-181b-1*	BPTF	1	hsa-miR-561*	GOLT1A	1
hsa-miR-181b-1*	C10orf140	1	hsa-miR-561*	HIPK1	1
hsa-miR-181b-1*	C11orf75	1	hsa-miR-561*	HMGB1	1
hsa-miR-181b-1*	C20orf194	1	hsa-miR-561*	KCTD12	1
hsa-miR-181b-1*	C21orf34	1	hsa-miR-561*	KIAA0182	1
hsa-miR-181b-1*	CA10	1	hsa-miR-561*	KIT	1
hsa-miR-181b-1*	CDC27	1	hsa-miR-561*	LANCL3	1

hsa-miR-181b-1*	CDK8	1	hsa-miR-561*	MDGA2	1
hsa-miR-181b-1*	CEP135	1	hsa-miR-561*	MED1	1
hsa-miR-181b-1*	CKS2	1	hsa-miR-561*	MMP16	1
hsa-miR-181b-1*	CPSF6	1	hsa-miR-561*	NMNAT2	1
hsa-miR-181b-1*	CSDE1	1	hsa-miR-561*	NPAS4	1
hsa-miR-181b-1*	CYR61	1	hsa-miR-561*	NPEPPS	1
hsa-miR-181b-1*	DDX3X	2	hsa-miR-561*	ODZ1	1
hsa-miR-181b-1*	DDX3Y	2	hsa-miR-561*	PBRM1	1
hsa-miR-181b-1*	DNAJB7	1	hsa-miR-561*	PDE4DIP	1
hsa-miR-181b-1*	E2F5	1	hsa-miR-561*	PICALM	1
hsa-miR-181b-1*	EIF4E	1	hsa-miR-561*	PTPRB	1
hsa-miR-181b-1*	FAF2	1	hsa-miR-561*	RAC1	1
hsa-miR-181b-1*	FAM176A	1	hsa-miR-561*	RBM46	1
hsa-miR-181b-1*	FNDC3B	1	hsa-miR-561*	RDH10	1
hsa-miR-181b-1*	FOXP1	1	hsa-miR-561*	SDHC	1
hsa-miR-181b-1*	FUT9	1	hsa-miR-561*	SEC24A	1
hsa-miR-181b-1*	GAPVD1	1	hsa-miR-561*	SEPT7	1
hsa-miR-181b-1*	GPATCH2	1	hsa-miR-561*	SLC4A10	1
hsa-miR-181b-1*	GRIA3	1	hsa-miR-561*	SLC4A11	1
hsa-miR-181b-1*	HECW2	1	hsa-miR-561*	SMAD2	1
hsa-miR-181b-1*	HELZ	1	hsa-miR-561*	STK35	1
hsa-miR-181b-1*	HEPACAM2	1	hsa-miR-561*	SUZ12	1
hsa-miR-181b-1*	KLF9	1	hsa-miR-561*	TEAD1	1
hsa-miR-181b-1*	KPNA1	1	hsa-miR-561*	TRPC5	1
hsa-miR-181b-1*	LMAN1	1	hsa-miR-561*	TTN	1
hsa-miR-181b-1*	MAMDC2	1	hsa-miR-561*	WAPAL	1
hsa-miR-181b-1*	MAP1B	1	hsa-miR-561*	WDR26	1
hsa-miR-181b-1*	MAPRE1	1	hsa-miR-561*	WNT1	1
hsa-miR-181b-1*	MATR3	1	hsa-miR-561*	WWC3	1
hsa-miR-181b-1*	MEF2C	1	hsa-miR-561*	ZBTB47	1
hsa-miR-181b-1*	MEX3B	1	hsa-miR-561*	ZCCHC2	1
hsa-miR-181b-1*	MIER3	1	hsa-miR-561*	ZNF777	1
hsa-miR-181b-1*	MOBK1A	1	hsa-miR-561*	ZNF804A	1
hsa-miR-181b-1*	MYH10	1	hsa-miR-652*	C8orf34	1
hsa-miR-181b-1*	NAMPT	1	hsa-miR-652*	CELF2	1
hsa-miR-181b-1*	NAV3	1	hsa-miR-652*	CPEB2	1
hsa-miR-181b-1*	NHS	1	hsa-miR-652*	ERBB4	1
hsa-miR-181b-1*	NKAIN2	1	hsa-miR-652*	FNBP1L	1
hsa-miR-181b-1*	NMNAT2	1	hsa-miR-652*	KHDRBS2	1
hsa-miR-181b-1*	P4HA2	1	hsa-miR-652*	KIAA1409	1
hsa-miR-181b-1*	PALM2-				
hsa-miR-181b-1*	AKAP2	1	hsa-miR-652*	MACROD2	1
hsa-miR-181b-1*	PDE4D	1	hsa-miR-652*	MARCH4	1
hsa-miR-181b-1*	PDE4DIP	1	hsa-miR-652*	PAFAH1B1	1
hsa-miR-181b-1*	PHC3	1	hsa-miR-652*	PATZ1	1
hsa-miR-181b-1*	PLCXD3	1	hsa-miR-652*	PRKCA	1
hsa-miR-181b-1*	PRDM10	1	hsa-miR-652*	RCOR3	1
hsa-miR-181b-1*	PTP4A2	1	hsa-miR-652*	SNTB2	1

hsa-miR-181b-1*	PURA	1	hsa-miR-652*	TCF12	1
hsa-miR-181b-1*	RAP2C	1	hsa-miR-652*	TOP1	1
hsa-miR-181b-1*	RER1	1	hsa-miR-652*	TSPAN9	1
hsa-miR-181b-1*	RIMKLB	1	hsa-miR-652*	UBE2E2	1
hsa-miR-181b-1*	RSRC2	1	hsa-miR-652*	VEGFA	1
hsa-miR-181b-1*	SEC11A	1	hsa-miR-652*	YWHAG	1
hsa-miR-181b-1*	SH2B2	1	hsa-miR-652*	ZNF618	1
hsa-miR-181b-1*	SLC1A2	1			
hsa-miR-181b-1*	SLITRK3	1			
hsa-miR-181b-1*	SON	1			
hsa-miR-181b-1*	SPTBN1	1			